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GENERAL INTRODUCTION 
Patients with a chronic inflammatory demyelinating polyneuropathy (CIDP) may respond to 
treatment with corticosteroids and to plasmapheresis, which was demonstrated in controlled 
clinical studies.77'81 
In an uncontrolled study it was found that 13/17 CIDP patients had a rapid and clinical 
important impr?vement afte~ infusion ofF~esh Frozen Plasma qff'P)- A beneficial response was 
also seen after-mtravenous rmmunoglobulin (Mg) treatment. 
The aims of this study were: 
- to evaluate the clinical effectiveness of Mg in CIDP patients, 
- to define clinical and inrmunological factors associated with improvement after Mg in CIDP 
patients and 
- to investigate immunological mechanisms involved in the response to Mg treatment. 
History, clinical signs, symptoms, pathology, differential diagnosis and tre~tment of CIDP are 
described in chapter 1. 
In chapter 2, the results of a double-blind placebo-controlled crossover study on the 
effectiveness of IVIg treatment in 7 patients with CIDP are shown. 
Various clinical and laboratory factors were analyzed in relation to improvement after Mg in 
52 patients fulfilling the criteria of CIDP (Chapter 3). · 
The pathogenesis of the chronic inflammatory demyelinating polyneuropathy is unknown. There 
is evidence that immune-mediated mechanisms play a role, which is discussed in Chapter 4. 
To investigate a humoral immune-mediated mechanism of action of Mg, a mixed 
hemagglutination assay (MHT) was adapted from Vedeler et al?25 to detect anti-human 
peripheral nerve tissue antibodies (Chapter 5). ' 
To study the interaction of auto-antibodies with Mg, an in vitro model was necessary. An 
immunofluorescent assay (IFA) detecting circulating anti-neuroblastoma (NBL) cell line 
antibodies was developed. Different NBL cell lines from various species were tested for 
reactivity with patients's sera. The mouse-rat NBL 108cc15-IFA showed the highest specificity 
for the detection of antibodies in patients with an inflammatory demyelinating polyneuropathy 
(Chapter 6). 
This NBL 108cc15 cell line showed partial cross-reactivity with human peripheral nerve tissue. 
Furthermore it was shown that Mg could inhibit the interaction between serum from a CIDP 
patient with this cell line. (Chapter 7). 
1 
Susceptibility for immune-mediated diseases may be determined by immune response 
differences in relation to the major histocompatibility (MHC) antigens. Therefore, HLA 
antigens in 52 patients with CIDP were compared to healthy controls. Furthermore, the HLA 
antigens and the presence or absence of neural antibodies in these 52 CIDP patients were 
related to improvement after IVIg treatment (Chapter 8). 
The NBL 108cc15-IF A was used to study the interaction between patients' antibodies and IVIg. 
These experiments showed anti-idiotypic suppression of antibodies against neural tissue by IVIg 
(Chapter 9). 
2 
Chapter 1 
CHRONIC INFLAMMATORY 
DEMYELINATING POLYNEUROPATHY 
HISTORY 
Targowla was the first who clearly described a patient with recurrent neuritis; the report 
appeared in 1894.301 Since then several authors presented case reports on patients with a 
recurrent sensorimotor polyneuropathy. 
The first large study was presented by Austin16 in 1958, who made a careful description of the 
disease. Austin selected from the literature 30 cases with a recurrent, symmetrical 
polyneuropathy involving arms and legs and added 2 more cases. In these 32 patients no known 
cause of polyneuropathy, such as intoxication (lead, arsenic or thallium), diabetes mellitus, 
porphyria, obliterative vascular disease or malnutrition was found. 
According to Austin, a representative example of a recurrent polyneuropathy is a young adult 
who develops over many weeks or months, the progressive symptoms and signs of a 
symmetrical, chiefly distal and predominantly motor polyradiculoneuropathy involving arms and 
legs. Cranial nerves VII, VI, III, IX and X are occasionally involved and sphincters are almost 
always spared. There is usually no severe pain, infection, or systemic illness. The cerebrospinal 
fluid ( CSF) protein is usually elevated. Electrophysiologic studies demonstrate a mixture of 
nerve conduction block and partial denervation with severe motor unit loss. 
Generally, the patient gradually improves and often recovers completely. After months or years 
without symptoms, another bout of recurrence may occur. Each recurrence may be somewhat 
variable in severity, duration, and residual signs. 
In the group of 32 patients there was some male preponderance, the average age of onset was 
23 years. The peak of disability was slowly reached, on average after five months from onset. 
The duration of the recovery phase generally took longer than the duration of progression of 
muscle weakness. The mean number of bouts in these 32 patients was 3, with intervals of 4 
years. Four patients had a definite downhill course and died. 
Enlarged and firm peripheral nerves were reported in 11 of 17 cases. Nerve enlargement was 
either due to collagen and reticulin proliferation or to mucoid interstitial tissue. It was suggested 
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that patients with enlarged nerves because of interstitial edema are the ones particularly prone 
to respond to corticosteroids. 
In Austin's unique study, one patient with a spontaneously recurrent polyradiculoneuropathy had 
subsequently 20 recurrences depending on corticosteroid treatment during a study period of 5 
years. The patient had a consistent, reproducible and predictable pattern of response to ACTH, 
cortisone and prednisone which was controlled with intramuscular, intravenous and oral placebo 
treatment. 
These observations showed that recurrences will occur if the corticoid dosage is less than what 
may be considered as the steroid requirement of the patient at that time. To maintain a good 
and stable clinical condition, this patient needed up to 300 mg cortisone (-60 mg prednisone) 
per day. It was the impression that during the course of the disease the corticosteroid 
requirement increases, that later responses to treatment may be less rapid and that no cure 
could be achieved. Austin concluded that corticosteroids temporarily suppress the clinical and 
laboratory manifestations of active neuropathy: CSF protein decreases and enlarged nerves 
return to normal size. A remarkable feature mentioned by Austin was that fasciculations 
consistently returned during recovery periods. 
In 1967, Hinman and Magee130 and in 1968, Dyck et al.73 published reports on this disease. In 
1969, Thomas et al.303 reviewed the literature and found 14 acceptable' e:Xamples of recurrent 
acute symmetrical polyneuritis and added 2 more cases. They also de~cribed identical clinical 
· signs and symptoms in 3 patients with a progressive phase of at least 4-8 weeks and used the 
name "recurrent and chronic relapsing Guillain-Barre polyneuritis" which suggests that this 
might be a chronic recurrent form of the Guillain-Barre syndrome (GBS). 
A number of authors reported· their experience with the disorder under various names: 
Matthews et al.196 "relapsing corticosteroid-dependent pqlyneuritis", De Vivo and Engel64 
"steroid-responsive recurrent polyneuropathy", Dolman and Allen68 "relapsing hypertrophic 
neuritis". 
In 1975, Dyck et al.74 reported their own series of 53 patients and introduced the name: "chronic 
inflammatory polyradiculoneuropathy'' (CIP). Typical features of CIP were described which 
included: muscle weakness (distal slightly more than proximal), distal sensory disturbances 
(numbness far more frequently than pain), hyporeflexia or areflexia, elevated CSF protein, 
slowed motor and sensory nerve conduction velocity (NCV) mostly marked in the proximal part 
of the nerve, and an associated disease must be excluded. They found a pure motor CIP in 9% 
and a pure sensory CIP in 6% of the cases. 
Later, the name varied again: Prineas and McLeod246 (1976) used the name "chronic relapsing 
polyneuritis", Oh226 (1978) named it "subacute demyelinating polyneuropathy responding to 
corticosteroid treatment" whereas Dalakas and Engel62 (1981) used "chronic relapsing 
( dysimmune) polyneuropathy. In 1982, Dyck et al.77 reported their prednisone trial in patients 
with a "chronic inflammatory demyelinating polyradiculoneuropathy' (CIDP), since then, CIDP 
is the most widely used name. In 1987, McCombe et al.198 reviewed 92 patients and in 1989, 
Barohn et al.23 reviewed 60 patients with a CIDP. Barohn et al. concluded that CIDP is still an 
heterogenous disorder and proposed diagnostic criteria that allow for the heterogeneity. 
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DIAGNOSIS 
There are no specific clinical signs and symptoms or laboratory tests that prove. the diagnosis 
of CIDP. Therefore the diagnosis is descriptive referring to clinical signs and laboratory data. 
Signs and symptoms . 
The onset of CIDP can be in any decade of life.16.23•74•19•198,246 There appears to be a slight male 
predominance. Generally the patients have symptoms of muscle weakness and sensory 
disturbances, especially paresthesias and numbness (Table 1). 
Table 1. CIDP characteristics 
author N male female onset re· fo II ow· s/m m 
Pat. % % age lapse up % % 
. (years) % (years) 
Austin16 32 69 31 23 100 8 
D y c k 74 53 66 34 50 34 7. 5 84 10 
P r i n e a s246 2 3 61 39 32 82 3 70 30 
McComb e198 92 62 38 35 65 10 72 22 
Barohn23 60 58 42 48 47 2. 8 86 14 
* = 16% of the patients had a progressive phase shorter than 4 weeks 
s = pure sensory polyneuropathy 
m = pure motor polyneuropathy 
sfm = combined sensorimotor polyneuropathy 
CSF = cerebrospinal fluid 
prot = protein 
- = not mentioned 
s cranial CSF minimal 
% nerve increased progressive 
invo I ve· prot ce II s phase 
ment % % % (weeks) 
34 87 13 21 
6 10 91 11 26 
0 43 87 13 3 
6 16 ,. 
0 17 95 3 8 
Pain is reported as relatively infrequent19 but was observed in other studies198 in 20% of the , 
patients. Tremor is occasionally found, 198.246 however it was reported by Dalakas and Engel in 
44% of the CIDP patient.62 Tremor is neither related to weakness nor to severe proprioceptive 
loss. Dysautonomia is rare. A pure or almost pure motor polyneuropathy occurs in a minority 
(10-30% 4 of the patients, whereas a pure sensory polyneuropathy is relatively rare (0-
6%).23'74' •198•246 Usually the symptoms are s)'.lllmetrical and the patients both have proximal and 
distal muscle weakness.23'19 Prineas et al.246 described even a predominance of proximal over 
distal limb muscle weakness. Weakness is more frequently in the limbs than in the trunk.19 
Cranial nerve involvement is observed in 10-43% of the patients (Table 1).23•74•19•198•246 A hypo-
or areflexia is found in all patients. 23•74•19•198.246 Papilledema may occur and has been attributed 
to the elevated CSF protein concentration. 
Course 
Dyck et al.19 concluded that the neurological symptoms in CIDP develop slowly and that 
maximal deficit is reached in many months or years. In his study only patients were included 
with a progressive phase of at least 6 m6nths?4 However, the minimal duration of progressive 
disease before a patient can be diagnosed to have a CIDP is arbitrary. It varies in different 
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studies: Prineas et al.246 (3 weeks), McCombe et al.198 (16% within 4 weeks), Barohn et al.23 (2 
months) and Austin16 ( 5 months). Generally, a progression of symptoms of more than 4-6 weeks 
seems to be a safe interval to separate CIDP from the Guillain-Barre syndrome (GBS). 
CIDP may have a course with recurrences, which was essential for the diagnosis in the study 
of Austin.16 In large studies,23•74•198.246 the percentage of patients with remitting disease varies 
between 34-82% (Table 1). McCombe et al.198 found that a relapsing course was significantly 
associated with earlier age of onset and that there was a significant increase in the number of 
relapses during pregnancy and 3 months postpartum. 
Dyck et al.74 distinguished 4 different courses in 52 patients: a gradually progressive (15% ), 
stepwise progressive (35%), recurrent (35%) and a monophasic (15%) course. 
Laboratory examinations 
The CSF protein is increased in 87-95% of the patients23•74•79.246 and especially so during 
relapses.246 A CSF pleocytosis is found in only 3-13% of the patients23•74•79.24 (Table 1). 
According to Dyck et al.,74'79 it is a characteristic - although not invariable - finding that the 
nerve conduction velocities (NCV) of both motor and sensory fibers are slowed. Some 
authors23•198.246 included in their studies only patients with a motor NCV below 60-75% of normal 
values. The amplitude of the action potentials is generally reduced in motor and sensory 
nerves.79 Nerve conduction blocks cause a fall iu. compound muscle action potentials (CMAPS's), 
but this has to be distin~hed from dispersion and loss of motor units. Distal motor latencies 
are generally delayed. Electrodiagnostic criteria of demyelination in CIDP were recently 
described by Albers and Kelly? 
Nerve biopsies may show a mononuclear, often pericapillary, epi-, peri- or endoneurinal cell 
infiltrate without evidence of vasculitis. Furthermore there may be some edema, segmental 
demyelination and remyelination or signs of hypertrophic neuropathy.79 Stripping of myelin by 
invading macrophages was observed by electron microscopy in nerve biopsies from 5 CIDP 
patients.29.245 Krendel et al.157 investigated sural nerve biopsies in 14 CIDP patients and found 
endoneurinal pericapillary cellular infiltration in 4, onion bulbs in 5 and predominant 
demyelination in 7 patients. These findings are not specific features of CIDP. Barohn et al.23 
investigated sural nerve biopsies in 56 CIDP patients and found predominantly demyelinating 
changes in 27 ( 48% ), axonal ch~ges in 12 (21% ), :mixed axonal and demyelinating features in 
7 (13%), whereas 10 (18%) biopsies were normal. 
The value of nerve biopsies in CIDP patients is questionable. However, in difficult cases it might 
contribute to the diagnosis, especially by excluding vasculitis and amyloid deposits. 
Absence of associated disorders 
Dyck et al.74'79 proposed that the diagnosis of CIDP can only be made in the absence of an 
inherited polyneuropathy, intoxication or demonstrable systemic disease. This opinion has been 
challenged by Barohn et al.23 since clinical and laboratory features indistinguishable from CIDP 
may occur in association with some systemic disorders. 
GBS is associated with disorders as Hodgkin's disease, chronic hepatitis and in.fJ.ammatory bowel 
disease.14 Other autoimmune disorders like myasthenia gravis may occur in combination with 
rheumatoid arthritis, SLE and Graves' disease.228 Therefore, it's not surprising that CIDP, a 
disorder of presumed autoimmune pathogenesis, occurs in the setting of other immune-
mediated conditions. This means that the presence of an other disorder does not always exclude 
the diagnosis of CIDP.23,43,54,ss,139'151'198 
6 
Chapter I 
McCombe et al.198 found an associated disease with possible allergic or autoimmune aetiology 
in 9 of 92 CIDP patients: thyrotoxicosis ( 4), psoriasis (2), urticaria (1), iritis (1) and eczema (1). 
Barohn et al.23 included 8 patients who had a concurrent condition in a series of 60 patients with 
CIDP: Hodgkin's disease (1), benign monoclonal gammopathy (5), inflammatory bowel disease 
(1) and chronic hepatitis (1). 
Furthermore in some patients with CIDP, clinical features and magnetic resonance im~:§ 
(MRI) signs of central nervous system demyelination have been demonstrated.23•79,93,20S,227,26l .3 
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Table 2-
Proposed Diagnostic Criteria* 
Mandatory Inclusion Criteria: All patients must have these features 
1. Progression of muscle weakness (steady, stepwise or relapsing) for 2 months 
2. Symmetrical _proximal and distal weakriess in upper or lower extremities 
3. Areflexia or liyporeflexia 
Mandatory Exclusion Criteria: Patients must be devoid of these features 
1. Glinical featt¥es~ inclpding pure se~ory ~europathy, mutilation of hands or. feet, retinitis 
ptgmento~ahtchtnyosiS, orange tollSils, history of exposure to drugs or toxms known to 
cause penp eral neuropathy 
2. Laboratory findipgs of low serum cholesterol levels, abnormal Qorphyrin metabolite values, 
fasting glucose levels of > 7.6 mmoljL). low ScPrum vitamin B12 levels, hypothyroidism, 
heavy metal intoxication, CSF WBC > ::>0 x 10 /L 
3. Nerve biOP.SY SP.ecimen with features of vasculitis, neurofilamentous swollen axollS, 
intramyefuiic blebsl amyloid deposits, Schwann cells with evidence of storage materialS 
typical for Fabry's disease, adrenal _leukodystrophy, metachromatic leukodystrophy, globoid 
cell leukodystrophy, or Refsum disease 
4. Electrodiagnoshc features of neuromuscular transmission defect, myopathy, or anterior 
hom cell disease 
Major Laboratory Criteria 
1. Nerve biopsy specimellS with predominant features of demyelination that include segmental 
~emyelination, remyelination, loss of nerve fibers, onion-bulb formation, and perivascular 
inflammat10n 
2. Nerve conduction studies with features of demY.elination, including slowing of conduction 
velocities in at least 2 motor nerves to < 70% of lower liinit of normal (2 nerves required 
to avoid inclusion of_patients with focal compression neuropathy) 
3. CSF protein level > U:45 g/L 
DiaP.ostic Categories 
Depntte 
1. Mandatory inclusion criteria 
2. Mandatory exclusion criteria 
3. All3 major laboratory criteria 
Probable 
1. Mandatory inclusion criteria 
2. Mandatory exclusion criteria 
3. 2 of 3 laboratory criteria 
Possible 
1. Mandatory inclusion criteria 
2. Mandatory exclusion criteria 
3. 1 of 3 laboratory criteria 
Concurrent illness 
Patients in this ~oup have an acquired demyelinating polyneuroi>_ill_!J_y accompanying another 
disorder; conditions so far described include thyrotoXIcosis, HlV infection, monoclonal 
gamJ!!qpaJ:hy, hereditary motor ~d sellSory nyurop~thy, CNS demyelination, chronic active 
liepatltJS, inflammatory bowel disease, Hodgkin's disease 
• CSF indicates cerebrospinal fluid; WBC, white blood cell count; HIV, human immunodeficiency 
virus; and CNS, centraf nervous system 
- Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations 
for diagnostic criteria. Arch Neurol 1989;46:878-884. Copyright 1989, American Medical Association. 
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It has even been suggested that CIDP may develoR in patients with a hereditary neuropathy, 
which responds to steroids and plasma exchange?7• 11 
All these diverse findings indicate that CIDP is not one condition but a syndrome, which may 
be the result of different causes with common immunopathogenic mechanisms.23 
Barohn et al.23 recently concluded that CIDP is not in that regard different from GBS, a 
condition for which diagnostic criteria have been established. 
In the following sections the new criteria proposed by Barohn et al.23 (Table 2) will be discussed. 
Mandatory Inclusion Criteria: All patients must have the following features (Table 2): 
1. Progression of muscle weakness for 2 months which is probably included to separate CIDP 
from the acute form, the Guillain-Barre syndrome (GBS).14 Patients with GBS usually have 
a monophasic course with a rapid onset and a progressive phase over 1-4 weeks. After a 
plateau phase, the majority of the patients partially or completely recover in weeks or 
months. 
Some CIDP patients initially have a typical course of GBS. However, subsequently they have 
a relapse of muscle weakness or a chronic progressive course without a tendency to 
spontaneous recovery.23•198•246.337 This does not mean that all GBS patients with a relapse in 
fact have CIDP. For instance a biphasic course after plasma exchange has been reported by 
Osterman et al.230 in 5 of 23 GBS patients, 2 to 4 weeks after initial improvement and by 
Ropper et al.253 in 10 of 94 GBS patients, 1 to 6 weeks after improvement. 
Deterioration after plasma exchange may be explained by persistence of a pathogenic 
neurotoxic factor and indicates that the treatment was simply too short in these GBS patients. 
A group of patients difficult to classify are those who com:Eletely recovered but who had an 
acute relapse several months or even up to 36 years later. 7 Because of the recurrence they 
may be classified as CIDP but they can also be considered as patients with a second bout of 
GBS. 
2. Symmetrical weakness in upper and lower extremities. Most patients with CIDP have this 
pattern of weakness, but in some patients there is asymmetry. This has also been described 
in patients with GBS.14 However, asymmetry is imsEortant in the distinction of CIDP from 
other neuropathies such as vasculitic neuropathy, .214 multifocal demyelinating neuropathy 
with persistent conduction block176 and multifocal motor neuropathy.236 
In patients with systemic vasculitis and neuropathy,30'41,209,266,333 distinction from CIDP is usually 
not difficult, but it is, if the vasculitis is confined to the peripheral nervous system and the 
neuropathy is not of the mononeuritis multiplex type. Kissel et al.147 and Herati et al.128 more 
frequently found a distal symmetric sensorimotor polyneuropathy than a mononeuritis 
multiplex in patients with non-systemic vasculitic neuropathy. Dyck et al82 investigated 20 such 
patients. Multiple mononeuropathy was seen in 13 patients, asymmetric neuropathy in 4, 
distal polyneuropathy in 3, and sensory polyneuropathy in 1 patient. The symptoms included 
weakness, atrophy, paresthesias, pain and sensory deficits. In an affected nerve in patients 
with multiple neuropathy (most frequent were the ulnar, peroneal or median nerve), the 
symptoms generally reached a maximum in hours or days. The site of the lesion is usually 
not a common site of compression or entrapment.82 There is evidence of axonal degeneration 
and segmental demyelination/28 but axonal degeneration predominates.82 CSF protein is 
generally not elevated.82'128 It was found that patients with increased CSF protein had a better 
response to immunosuppressive agents.128 
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In multifocal demyelinating neuropathy with persistent conduction block/76 there is a subacute 
onset with a slow progression of sensorimotor symptoms involving one or two nerves in the 
arms, usually the median or ulnar nerve. Arms are always more affected than legs and tendon 
reflexes are generally absent in the arms but preserved in the legs. The sensory disturbances 
seem to involve primarily large-fibre modalities (vibration, position and touch). These patients 
have normal motor latencies and there are focal conduction blocks in the nerves which may 
persist at the same site for months or years. These patients may respond to corticosteroids. 
Multifocal motor neuropathy resembles multifocal demyelinating neuropathy but is confined 
to motor nerves.236 These patients have asymmetrical weakness, which develops in one arm 
and progresses over 2 - 3 years to the other arm, legs and trunk. Initially this polyneuropathy 
resemble lower motor neuron disease. However, later in the course of the disease multifocal 
conduction blocks compatible with patchy selective demyelination can be demonstrated in 
motor but not sensory fibres. In these patients, upper motor neuron and bulbar signs were 
not seen but reflexes were sometimes relatively brisk in areas of weakness. The patients 
sometimes had paresthesias but sensory examinations remained normal. Antibodies to GM1 
and other gangliosides can be demonstrated in these patients. Pestronk et al.236 reported 
that these patients may respond to cyclophosphamide and not to treatment with 
corticosteroids or plasma exchange. However, antibodies to GM1 are not a specific feature 
of this disorder since they have been demonstrated in patients with other neuropathies 
(approximately 20% of patients with GBS or CIDP) and in patients with myasthenia gravis, 
amyotrophic lateral sclerosis (ALS),280 polymyositis, systemic lupus (SLE) and rheumatoid 
arthritis. The question is whether these multifocal neuropathies are variants of the 
inflammatory neuropathies or are other neuropathies for instance vasculitic neuropathies. 
3. Areflexia of all tendon reflexes occurs in most patients with CIDP. However, in mild cases 
or shortly after onset of disease, total areflexia is not obligatory. 
Mandatory Exclusion Criteria: 
1. Patients must be devoid of the following clinical features (Table 2) 
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- Pure sensory neuropathy. Some other studies reported a sensory neuropathy in 0-6% of 
patients with CIDP (Table ll. A pure sensory neuropathy may occur in diabetes mellitus, 
vasculitis, Sjogren syndrome, 1 primary biliary cirrhosis,44 amyloidosis, pyridoxine abuse, after 
the use of antibiotics, 288 folate deficiency, HIV infection, 56•85 and in some hereditary sensory 
neuropathies. Also a paraneoplastic polyneuropathy or a neuropathy induced by 
chemotherapeutic drugs may be of a pure sensory type. In Fabry's disease, pain is the 
predominant symptom. In plasmacell dyscrasia's initially there may be only sensory 
disturbances. Therefore, all these disorders should be considered before the diagnosis pure 
sensory form of CIDP is made. A neuropathy which resembles the pure sensory form of 
CIDP is chronic idiopathic ataxic neuropathy or ClAN. CIAN,63 presents with distal 
paresthesias and sensory ataxia with slow progression, areflexia, normal strength and a 
profound loss of proprioceptive and kinesthetic sensation extending up to the most proximal 
joints. Motor NCV's are normal, but sensory potentials are absent. Some patients have serum 
monoclonal or polyclonal gammopathy, but only few patients have elevated CSF protein. 
Immunosuppressive agents or plasma exchange were not effective. During a follow-up period 
of 17 years, patients continued to worsen, but no signs of systemic illness or malignancy were 
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found. ClAN has also been referred to as "progressive sensory neuropathy in patients without 
carcinoma" .144 
- Mutilation of hands or feet; which is not a feature of patients with CIDP but occurs 
especially in neuropathies with marked impairment of sensation, such as the hereditary 
sensory neuropathies, but also occurs in patients with diabetic sensory neuropathy, alcoholic 
neuropathy or sensory neuropathy in carcinoma. 
- Retinitis pigmentosa; which can be found in different storage- and degenerative diseases 
and in disorders associated with inborn errors of metabolism such as phytanic acid storage 
(Refsum) disease;252 a rare autosomal recessive disorder due to storage of phytanic acid in 
the peripheral and central nervous system. Symptoms develop between the ages of 10-30 year, 
but occasionally later. The course may be relapsing. Clinical features are a chronic distal 
demyelinating sensorimotor polyneuropathy and usually cerebellar ataxia with pigmentary 
retinal degeneration. The peripheral nerves may be thickened and NCV's are sometimes, but 
not always, markedly reduced. 
- Ichthyosis; which may occur in patients with phytanic acid storage disease, but also in 
patients with abetalipoproteinemia (Bassen-Kornzweig), an autosomal recessive disorder with 
onset of neurological symptoms nearly always by the age of20.129 There is ataxia, dysarthria, 
areflexia, proprioceptive loss, muscle weakness, pes cavus and scoliosis. These patients have 
low serum cholesterol, phospholipids, free fatty acids and chylomicrons in the absence of low 
density lipoproteins. The neurological complications may be secondary to vitamin E 
deficiency.167 
- Orange tonsils; which have been described in patients with hereditary high density 
lipoprotein (HDL) deficiency (Tangier's diseaseV29 
- Drugs and toxins; that may cause a polyneuropathy. Most of these ( acrylamide, carbon 
disulfide or organophosphates) cause mainly axonal neuropathies.12 Some drugs and toxins 
may cause a neuropathy which may mimic CIDP, for instance amiodarone, a drug to treat 
cardiac arrhythmias. Amiodarone may cause a severe chronic sensorimotor polyneuropathy 
after 6 months to 3 years of treatment. The CSF cell count is usually normal, the CSF protein 
is slightly or moderately increased and the NCV is generally severely decreased. Nerve 
biopsies show segmental demyelination,98.234 but there are also signs of axonal degeneration.234 
Electron microscopy may reveal Schwarm cells with numerous lipid containing lysosomal 
inclusions in Schwarm cells. After discontinuing the drug, slow but usually complete recovery 
occurs. Perhexilene, used in the treatment of angina pectoris, may result in a gradual 
sensorimotor polyneuropathy with slow motor nerve conduction velocity and a raised CSF 
protein. Segmental demyelination and a variable degree of axonal degeneration is found in 
sural nerve biopsies together with the presence of lipid body inclusions. Gold, used in the 
treatment of rheumatoid arthritis may induce a sensorimotor or purely motor polyneuropathy. 
Whether the polyneuropathy was caused by the drug or occurs as complication of the disease 
can often not be established. The NCV can be severely slowed and the CSF protein is 
increased in 50% of the patients. Both evidence of demyelinating and axonal disturbances 
have been found in nerve biopsies. Dapsone, used in the treatment of leprosy and in various 
dermatologic disorders, may induce a predominantly motor polyneuropathy with reduction 
of the NCV. 
Alcohol abuse may result in a chronic, sensorimotor polyneuropathy with a distal 
predominance. The motor NCV is normal or mildly slowed but the amplitude is frequently 
reduced. 
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In hexacarbon polyneuropathy, secondary demyelination and considerable reduction in nerve 
conduction velocity has been found. Hexacarbon solvents, are used in industrial and domestic 
agents e.g. in glue. 
2. Patients must be devoided of the following laboratory findings: 
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- Low cholesterol levels; in patients with a neuropathy this may indicate Tangier's disease. 
- Abnormal porphyrin metabolite values. Porphyrin metabolites are often measured in 
patients with polyneuropathy but porphyria is rare, the onset is usually acute and peripheral 
neuropathy seldom occurs in patients without previous abdominal or mental disturbances. 
- Fasting glucose levels of > 7.6 mmoljl; which can be found in patients with diabetes 
mellitus. Usually, axonal disturbances predominate.166 CSF protein is increased in two thirds 
of the diabetes patients with a polyneuropathy.189 Generally, the distinction between CIDP 
and diabetic polyneuropathy is not difficult, but sometimes diabetes patients may present with 
a predominantly motor neuropathy, slowed NCV and increased CSF protein. 
- Low Vitamin B12levels. Vitamin B12levels are usually measured together with vitamin 
B1 and B6. Vitamin B1 is important in patients with malnutrition and vitamin B6 deficiency 
in patients treated with Isoniazid (INH). Intoxication with vitamin B6 may also cause 
neuropathy. Neuropathy in patients with vitamin Bl2 deficiency is usually not difficult to 
distinguish from CIDP, but sometimes a sensorimotor polyneuropathy with a remitting or 
stepwise progressive course may occur. 
- Hypothyroidism; but this condition rare~ presents with a sensorimotor polyneuropathy, 
slowed NCV and increased CSF protein.165 9 
- Heavy metal intoxication. Screens for heavy metals are expensive and very rarely necessary. 
Segmental demyelination169 has been found in experimental lead neuropathy, but these 
features have not been described in human nerves after lead exposure. Other metals mainly 
cause an axonal neuropathy. 
- CSF white blood count > 50 x 106• In CIDP, the number of CSF cells is usually within 
normal limits, but it may be slightly increased. If the number of CSF cells is > 50 x 106/1, 
another diagnosis should be considered, for instance Lyme borreliosis. 
In patients with Lyme borreliosis the neuropathy is often very painful and the type is that of 
a mononeuritis (multiplex) or a sensorimotor polyneuropathy. The patients usually have a 
rapid progression of muscle weakness, but a more protracted course during several months 
has been described.231 The patients may have areflexia and the CSF protein is often increased. 
In these patients, there is evidence of both demyelinatin~06.289 and axonal184 disturbances. 
Peripheral nerve vasculitis has also been reported in patients with Lyme borreliosis.40 
Improvement of NCV was found after penicillin treatment.114 For the diagnosis, detection of 
Borrelia burgdorferi antibodies is important but a negative test does not exclude the 
diagnosis.273 The demonstration of these antibodies is dependent on the duration of the 
disease, prior antibiotic treatment, the fresence of HLA-DR2 antigen344 and the technique 
used to demonstrate these antibodies.11 
Other neuropathies which may sometimes resemble CIDP and which are associated with an 
increased CSF cell count are neuropathies in malignancy e.g. (non-)Hodgkin's disease, or 
those associated with vasculitis, sarcoidosis, cytomegalovirus (CMV), herpes zoster and HIV 
infections.54•65•171 
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3. Patients must be devoided of the following features in nerve biopsies: 
- vasculitis or neurofilamentous swollen axons; which argue against the diagnosis of CIDP. 
These neurofilamentous swollen axons have been found in ALS, in giant axonal neuropathy 
and after intoxication with acrylamide, aluminum chloride, and vincristine. 
- Intramyelinic blebs; which can be found in GBS but may also be an artefact. 
- Amyloid deposits which are not present in biopsies of CIDP patients. 
- Storage materials in Schwann cells; which can be seen in neuropathies other than CIDP 
and usually can be distinguished from CIDP on clinical criteria without the need of a nerve 
biopsy. Storage material is present in: 
Fabry's disease, an X-linked recessive disorder which develops in childhood or adolescence. 
Pain is the major feature and may be the presenting symptom. Characteristic are 
telangiectatic skin lesions. 
Adrenoleucodystrophy (ALD), an X-linked recessive disorder, the age of onset is usually in 
childhood. Polyneuropathy, dementia, tetraplegia, seizures, blindness and adrenal insufficiency 
are features of this disease. An increased ratio of C26 to C22 fatty acids can be demonstrated 
in patients and carriers. 
Adrenomyeloneuropathy, which is characterized by spastic paraplegia, distal muscle weakness 
and sensory loss. The features develop in adolescence or adult life. 
Metachromatic leukodystrophy (MLD), a heterogenous disorder with at least five distinct 
autosomal recessive forms. The cause of this storage disease is deficiency of arylsulphatase. 
The motor NCV is reduced and the amplitude of sensory nerve action potentials is reduced 
or absent. The tendon reflexes are depressed or absent. The disease is a mixture of cerebellar 
and pyramidal signs, dementia, optic atrophy and polyneuropathy. The onset is usually before 
the age of 2, sometimes between 3-20 years and occasionally there may be a adult onset form 
of MLD. Therefore, this diagnosis should be considered in any adult with a combination of 
dementia and polyneuropathy. 
Globoid eel/leukodystrophy (Krabbe's disease), a rare autosomal recessive disease caused by 
a deficiency of galactosylceramide beta-galactosidase. The onset of this multisystem 
degenerative fatal demyelinating disease is between 3 and 6 months. It is not difficult to 
distinguish the disease from CIDP. 
Refsum's disease, which is discussed on page 11. 
4. Patients should be devoid of the following electrodiagnostic features indicating: 
neuromuscular transmission defect (myasthenia gravis or Eaton-Lambert syndrome) or 
myopathy, which are not a feature of CIDP. However, fasciculations may be found in patients 
with CIDP. 
Major laboratory criteria (Table 2) 
1. In nerve biopsies of patients with the clinical diagnosis of CIDP, the classical predominant 
features should be demyelination, remyelination, loss of nerve fibers, onion-bulb formation, 
and perivascular inflammation, but these are not always present. Barohn et al.23 found that 
18% of 56 CIDP patients had no abnormalities in their sural nerve biopsy, 21% had evidence 
of axonopathy, whereas 13% had mixed demyelinating and axonal changes. 
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2. The nerve conduction velocities are usually moderately or severely slowed. However, especially 
shortly after onset of CIDP or in mildly disabled patients, the NCV may be only slightly 
decreased. 
3. The CSF protein is usually increased, especially so during relapses,246 but is normal in 5-
13% of the patients.23'74'79.246 
According to Barohn et al.23 the diagnosis of CIDP can be made using the presented criteria 
(Table 2): 
Diagnostic Categories 
Definite 
1. Mandatory inclusion criteria 
2. Mandatory exclusion criteria 
3. A113 major laboratory criteria 
Probable 
1. Mandatory inclusion criteria 
2. Mandatory exclusion criteria 
3. 2 of 3 laboratory criteria 
Possible 
1. Mandatory inclusion criteria 
2. Mandatory exclusion criteria 
3. 1 of 3 laboratory criteria 
Concurrent illness 
Patients in this group have an acquired demyelinating polyneuropathy accompanying another 
disorder; conditions so far described include thyrotoxicosis, mv infection, monoclonal 
gammopathy, hereditary motor and sensory neuropathy, CNS demyelination, chronic active 
hepatitis, inflammatory bowel disease, Hodgkin's disease 
The presence of some other associated disorders does not always exclude the diagnosis of CIDP. 
This has been discussed on page 6. 
Other disorders which may cause a chronic, mainly demyelinating polyneuropathy and which 
should be included in the differential diagnosis of CIDP are: 
1. Plasmacell dyscrasias such as lytic multiple myeloma (Kahler's disease), Waldenstrom 
macroglobulinemia, 162.201 sclerotic myeloma, POEMS syndrome (polyneuropathy, 
organomegaly, endocrinopathy, monoclonal protein and skin changes),22 B cell lymphoma of 
the peripheral nerve138 and cryoglobulinemia.182,219 These disorders will be identified if in all 
patients with unexplained neuropathy immuno-electrophoresis or immunofixation is carried 
out.350 
2. Chronic polyneuropathy of undetermined cause (McLeod neuropathy). McLeod et al.202 
described 67 patients with a chronic symmetrical polyneuropathy which was slowly progressive 
over many years and in which the cause remained undiagnosed. The mean age of onset was 
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50 years, total areflexia was uncommon, the mean CSF protein was 0.73 g/1 and the NCV 
in most cases was only mildly slowed. Generally, these patients were only mildly disabled. 
Distinction from CIDP may be difficult, especially if these patients are seen late in the course 
of the disease when axonal loss of fast conducting fibres suggest a demyelinating disorder. 
TREATMENT Table 3. Corticosteroid treatment in CIDP patients 
uncontrolled studies 
Corticosteroids 
Austin16 presented a historical Author 
Thomas303 
DeVivo64 
Matt h ews 196 
Do lman68 
Dyck74 
Griggs109 
Prineas246 
Oh226 
Da I akas"'62 
Sladky283 
McComb e198 
Barohn23 
year 
1969 
1970 
1970 
1973 
1975 
1976 
1976 
1978 
1981 
1986 
1987 
1989 
N 
patients 
5 
1 
3 
1 
38 
1 
21 
10 
25 
6 
76 
59 
treatment 
pos neg 
2 
1 
3 
15 
1 
14 
10 
>12 
6 
49 
56 
23 
5 
27 
3 
response 
dubious 
3 
2 
overview, but also a N = 1 trial in a 
CIDP patient who had 20 relapses -
spontaneously or induced by drug 
withdrawal - during a period of 5 
years. This patient responded 
dramatically and repeatedly to 
corticosteroids. Since then, many 
uncontrolled studies of corticosteroid 
treatment in CIDP patients were 
published (Table 3). The time lapse 
between initiation of prednisone 
treatment until onset of clinical 
improvement varied up to 3.5 months.64 
In an uncontrolled study Dyck et al?4 
treated 38 CIDP patients with different 
• prednisone was "successful in the majority" of patients 
dosages of corticosteroids during variable periods. It was concluded that some patients initially 
responded favorably to prednisone treatment, but this benefit was often not apparent over 
protracted periods and there were severe complications such as gastric hemorrhage and 
perforation, activation of tuberculosis and bronchopneumonia. 
Dalakas and Engel62 reported that in a series of 25 patients with CIDP, daily high-single-dose 
prednisone (1.5-2 mg/kg body weight), slowly tapered of to an alternated-day program, was very 
successful in the "majority'' of the patients. Side effects which occasionally were seen included: 
hyperglycemia, hypertension, avascular necrosis of femoral or humeral head, osteoporosis and 
cataract. Unfortunately no exact percentages or duration of treatment were mentioned. 
McCombe et al.198 treated 76 CIDP patients with corticosteroids, 49 (65%) improved. Of 12 
patients who did not respond to steroids, 7 were treated with azathioprine and improved, the 
other patients were successfully treated with cyclophosphamide. 
Barohn et al.23 reviewed their 10 year experience with 60 CIDP patients. All but one patient 
received "high-dose" prednisone and 95% initially improved. The mean time to the first signs 
of improvement was rather long (1.9 months) and maximal improvement was reached not 
earlier than after 6.6 months. After discontinuing steroids, 59% of the patients with a 
monophasic course and 18% of the patients with a relapsing course were in remission. An 
overall complete remission was observed in 30% of the patients. Side effects of treatment were 
not mentioned. It was concluded that the majority of patients initially showed a beneficial 
response to steroids, but that relapses will occur in 70% of the patients after discontinuation 
of steroids. 
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A controlled clinical trial was performed in 28 CIDP patients by Dyck et al.77 Prednisone was 
shown to cause a small but significant improvement over no treatment accessed by a 
neurological disability scale. No difference in response was found between patients with a 
progressive course or those with a recurrent one. 
The percentage of patients responding to steroids varies in the reported studies, probably 
because the selection of patients and the evaluation of treatment is different. Unfortunately 
assessment of treatment effects are not always based on clinically relevant features and the side 
effects of long term steroid treatment in CIDP and its effect on the disability of these patients 
has hardly been investigated. 
Recently in an editorial on the treatment of CIDP, Dyck83 emphasized that prolonged 
corticosteroid use is not safe; mentioned side effects were: weight gain, hypertrichosis, altered 
appearance, hyperglycemic hyperosmolar coma, psychosis, gastric ulcer, infection, cataract, 
osteoporosis and aseptic necrosis of hips or shoulders. 
Immunosuppressive drugs 
No clinical trials are 
available on the therapeutic 
effect of azathioprine, 
cyclophosphamide or 
cyclosporin A (Table 4). 
Case reports showed 
promising results, however 
follow-up was usually short 
and side effects of long 
term treatment may be 
serious. 
In 1985 Dyck et a1.80 
published a non-blinded, 
randomized trial in 30 
CIDP patients who were 
treated with alternate day 
decremental prednisone 
therapy alone or combined 
with 2mg/kg azathioprine 
for 9 months. Three 
patients were withdrawn 
from the study because of a 
change in diagnosis. No 
statistically significant 
Table 4. Treatment of CIDP with different immunosuppressive agents 
uncontrolled studies 
Author 
Heathfield125 
Yuill 346 
Cendrowsk i42 
Prus i nsk i2A7 
Wa Ike r330 
Dalakas63 
Pentland235 
McComb e198 
Prineas2A6 
Rosen255 
Dalakas63 
McCombe198 
K0lkin150 
J ongen142 
Tindall 307 
Engel 86 
Rosenberg257 
year 
1970 
1970 
1977 
1978 
1979 
1981 
1982 
1987 
1976 
1976 
1981 
1987 
1986 
1988 
1988 
1978 
1985 
treatment N 
patients 
aza 1 
aza 1 
aza 2 
aza 1 
aza 2 
aza 4 
aza 5 
aza 7 
cyclophos 4 
cyclophos 3 
cyclophos 1 
cyclophos 5 
cyclosp A 1 
cyclosp A 2 
cyclosp A 10 
poly·ICLC 4 
lymphoid irr 4 
treatment 
pas 
1 
1 
2 
3 
5 
4 
4 
3 
1 
4 
1 
2 
6 
2 
3 
neg 
4 
2 
1 
response 
dubious 
aza =azathioprine; cyclophos =cyclophosphamide; cyclosp A= cyclosporin A; 
poly-ICLC=polyinosinic-polycytidylic acid; lymphoid irr=lymphoid irradiation 
differences were demonstrated between the 2 groups. Treatment with the anti-lymphocytic drug 
polyinosinic-polycytidylic acid (poly-ICLC) has been reported to be successful in 2 of 4 CIDP 
patients86 and one study in 4 CIDP patients showed beneficial effects of total lymphoid 
irradiation after other treatments had failed.= 
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Table 5. Plasma exchange (PE) in patients with CIDP Plasma exchange (PE) 
There are several studies on the effects 
of PE in patients with CIDP (Table 5). Author 
PE is often not the first choice of 
treatment and is usually applied if side 
effects of other treatments had occurred, 
or after unresponsiveness or loss of 
response to treatment with 
corticosteroids, azathioprine or 
cyclophosphamide. In the different series, 
both patients with remitting and 
progressive course improved. Some 
patients needed regular PE to maintain 
the improved clinical condition; in other 
patients, addition of immunosuppressive 
drugs was necessary. Some patients do 
not respond to PE but respond after 
prednisone, azathioprine or 
cyclophosphamide. 
In 1986 Dyck et al. reported the results 
of the only controlled PE study.81 In a 
double-blind trial, 15 patients were 
randomized to PE and 14 patients to 
sham exchange for three weeks. Plasma 
was replaced by albumin. A neurological 
disability score, showed no significant 
Fowler96 
L e vy17S 
Serve r275 
Cook49 
Mark191 
Server276 
To yk a310 
Dalakas62 
Gross111 
Con no r46 
Gross110 
Tindall 306 
Toyka311 
Vede I er325 
Feasby92 
Po II ard239 
Va I bones i316 
Tandon298 
Burke37 
Po II ard240 
McComb e199 
Kunze 158 
year 
1979 
1979 
1979 
1980 
1980 
1980 
1980 
1981 
1981 
1982 
1982 
1982 
1982 
1982 
1983 
1983 
1983 
1983 
1985 
1985 
1987 
1988 
N 
patients 
1 
1 
1 
3 
1 
2 
1 
3 
6 
2 
2 
14 
1 
7 
5 
5 
4 
11 
9 
8 
13 
11 
Treatment 
pos neg 
1 
1 
1 
1 
1 
2 
1 
1 
2 
2 
2 
6 
1 
5 
5 
2 
4 
5 
7 
6 
10 
9 
2 
4 
8 
2 
2 
6 
2 
2 
3 
2 
response 
dubious 
2 
differences between the two groups. However, it was concluded that PE had a beneficial effect 
on some manifestations of CIDP. Five patients (33%) receiving PE had an improvement in their 
scores at three weeks, as compared with base-line scores, that exceeded the largest improvement 
attained by any patient receiving sham exchange. This conclusion was based on the finding of 
improvement in scores on weakness, deep tendon reflexes and nerve conduction velocities. 
Improvement was observed both in patients with slowly progressive disease and those with a 
remitting course. Thirteen of 14 patients who initially had sham PE subsequently received 
therapeutical PE, 4 patients (31 %) improved. In this controlled study, only the initial effects of 
PE were investigated and not the effects of long-term treatment. The beneficial effects of PE 
began to fade 10 to 14 days after treatment. 
Intravenous immunoglobulin 
High-dose polyspecific immunoglobulin for intravenous use (IVIg) might be an alternative 
treatment in patients with CIDP. Several uncontrolled studies have been published. Busch et 
al.38 ~1982) described the favorable effect of fresh frozen plasma in 2 CIDP patients. Vermeulen 
et al. 28 (1985) reported the effect of infusion of fresh frozen plasma (FFP) and IVIg (0.4 gfkg 
body weight for 5 consecutive days) in 17 patients with CIDP. The first signs of improvement 
were seen within 8 days from onset of treatment and no serious side effects were observed. 
Improvement was short-lasting in most patients, but none of the patients became refractory for 
further IVIg treatment. Of the 13 patients who improved, 5 patients were treated with 
cyclophosphamide and two improved, 3 patients were treated with azathioprine and two 
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Table 6. Intravenous immunoglobulin (IVIg) treatment in CIDP 
patients 
improved. One patient had PE and 
improved. Of the 4 non-responders, 2 
patients were treated with 
cyclophosphamide and one improved. Author 
Albama et al.6 (1987), Cook et al.50.s1 
(1987), Curro Dossi et al.59 (1987) 
and recently Faed et al.87 found 
similar effects of IVIg. All 9 patients 
described by Faed et al.87 responded 
after treatment with a dosage of 0.4 g 
IVIg/kg body weight for 3 
consecutive days, which indicates that 
Ve rmeu I en328 
Cook50,51 
Albama6 
Cur ro·Doss i 59 
Fa e d87 
year N 
patients 
1985 
1987/8 
1987 
1987 
1989 
17 
5 
1 
4 
9 
Treatment 
pos 
13 
5 
1 
4 
9 
response 
neg 
4 
the initial treatment dosage is arbitrary. Results of studies on IVIg treatment are shown in 
Table 6. 
Comparison of different treatments in CIDP 
The percentage of CIDP patients responding to the various treatments is difficult to estimate. 
The definition of improvement and the selection of patients vary considerably. In general, most 
patients initially improve after treatment with corticosteroids, but a stable remission, off therapy, 
may occur in only 30% of the patients. The results of PE and IVIg treatment are yet not 
systematically evaluated during long-term follow-up. Variations in response may partially be 
explained by differences in the selection of patients. The clinical effectiveness of azathioprine, 
cyclophosphamide, lymphoid irradiation and Poly-ICLC treatment is difficult to estimate 
because only non-randomized studies in less than 10 patients have been reported. In a 
randomized study it was shown that addition of azathioprine to prednisone treatment did not 
result in a superior response or allowing a lower maintenance prednisone dosage. Some patients 
improve after one type of treatment and not after another treatment. The time-lapse between 
onset of corticosteroids, PE or IVIg treatment and the beginning of improvement varies 
considerably. Other factors important in the choice of treatment are the side-effects, 
convenience of maintenance therapy and costs of long-term treatment. 
Clinical follow up 
The majority of CIDP patients has no tendency for a spontaneous good recovery. Dyck et al.74 
evaluated 53 patients with CIDP with an average follow up of 7.5 years. Complete recovery 
occurred only infrequently; about 60% of the patients were able to remain ambulatory and to 
work, 25% became confined to a wheelchair or bedridden, and approximately 10% died from 
their disease. Of thirty-eight patients who were treated with different dosages of corticosteroids, 
3% recovered, 63% had varying neurologic deficits but were ambulatory, and 34% were in a 
wheelchair or bedridden. McCombe et al.198 surveyed 92 patients with a CIDP; in 87 patients 
the follow up was approximately 10 years. Seventy-three percent had made a good recovery and 
were independent; 12% died, half of them from the disease. Barohn et al.23 followed 60 CIDP 
patients for on average 34 months. Twenty-four patients(40%) reached partial or complete 
remission without continuation of medication, 2 patients (3%) died from complications of the 
disease and 3 (5%) did not respond to treatment. 
These studies indicate that maintenance treatment can not be discontinued in most CIDP 
patients and that the majority of the patients do not reach complete clinical remission despite 
immunosuppressive therapy. 
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IDGH-DOSE INTRAVENOUS 
IMMUNOGLOBULIN TREATMENT 
IN CHRONIC INFLAMMATORY 
DEMYELINATING POLYNEUROPATHY 
A double-blind placebo-controlled crossover study 
INTRODUCTION 
Chronic inflammatory demyelinating polyneuropathy (CIDP) differs in course and prognosis 
from the Guillain-Barre syndrome (GBS). The course of CIDP may be a continuous or stepwise 
worsening with fluctuations in severity or a prolonged monophasic deterioration over many 
months or years. The prognosis of CIDP is worse than of GBS; in a group of 53 patients with 
CIDP followed for an average of 7.4 years only 2 recovered, 36 had mild to moderately neuro-
logical disability, 6 were confined to wheelchair, 6 were dead from the disease, and 3 died from 
other cause?4 Patients with CIDP may respond to treatment with corticosteroids77 or 
plasmapheresis.81 The results of non-controlled studies suggest a beneficial effect of high-dose 
intravenous immunoglobulin treatment (IVIg).50,59,S7,32B 
We studied the effect of IVIg in a double-blind placebo-controlled crossover study in patients 
with CIDP, who we considered to be dependent on regular IVIg treatment. 
PATIENTS AND METHODS 
Criteria for eligibility 
Patients with signs and symptoms of CIDP79 who had, according to their physician, responded 
to IVIg and needed this treatment at regular intervals to prevent relapse. The patients were not 
on corticosteroids, other immunosuppressive drugs, or plasmapheresis and showed signs of 
deterioration after discontinuation of Mg treatment. 
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Randomization 
Regular IVIg treatment was discontinued in 7 patients. Using a sealed envelope technique, 
patients were randomized, after informed consent, to placebo or IVIg treatment. All patients 
received once placebo (albumin) and once IVIg. The two treatments could not be distinguished. 
The first trial treatment was given when the patients' condition had deteriorated and the 2nd 
trial treatment when on day 8 after the onset of the 1st treatment the clinical condition had 
further deteriorated. If the patients' clinical condition had not changed, the second treatment 
was postponed until further deterioration occurred. If the patients' condition had improved after 
the first treatment, the second treatment started when the patients' condition again deteriorated. 
The trial code was broken after the results of all patients had been recorded. 
The ethics committee of our hospital approved the study. 
Treatment 
The dosage was approximately 0.4 g/kg bodyweight/day for 5 consecutive days and was 
administered intravenously. The total dosage of freeze dried IVIg was divided in 50 ml bottles, 
each containing 3 g immunoglobulin. If the treatment was placebo the same number of 50 ml 
bottles was given each containing 3 g albumin. The daily dose was infused within 2 hours. The 
immunoglobulin CLB (prepared in the Central Laboratory of the Dutch Red Cross Blood 
Transfusion Service) is produced from plasma of more than 3.000 Dutch blooddonors by ethanol 
cryoprecipitation (Cohn fraction IT). The resulting product is then treated at pH 4 with traces 
of pepsin to make it suitable for intravenous use. It's characteristics are similar to those of the 
immunoglobulin described by Skavari1.282 It contain:s 99% IgG, 1% IgA and traces of IgM 
(protein content 60g/l). IgG subclasses are distributed as follows: IgG157,5%, IgG2 28%, IgG3 
9%, IgG4 5,5%. At least 85% of the IgG is monomeric, less than 7% dimeric and less than 3% 
polymeric. 
Placebo was prepared from 20% human albumin solution in which no IgG could be detected 
(less than 0,1% ). After pasteurization (10 hours at 60°C), the albumin solution was diluted to 
4% and freeze dried. 
Assessment of treatment response 
After discontinuation of IVIg treatment, the patients were seen at regular intervals by two 
investigators of this study. Treatment responses were assessed with the modified Rankin scale.319 
This scale is shown in Table 1. When they detected at least one point deterioration on the 
Rankin scale, the 1st trial treatment was started and the investigators recorded the time lapse 
since the last IVIg treatment. Clinical examination was repeated at day 8 after the onset of 
treatment. The two investigators together had to record whether the patient had improved (at 
least one point improvement on the Rankin scale), was unchanged or had deteriorated (at least 
one point deterioration on the Rankin scale). This was repeated after the 2nd trial treatment. 
Electrophysiological investigations ' 
Using a Disa 15-c-01 electromyograph, the nerve conduction of the right motor median nerve 
was measured with disk surface electrodes in the tendon belly montage on the right abductor 
pollicis brevis muscle and after supramaximal stimulation at the wrist and elbow. Care was taken 
to place the active electrode at the optimal site for a maximal biphasic compound muscle action 
potential. The compound muscle action potentials (CMAP's) were recorded after both 
stimulations. These measurements were carried out on day 1 and day 8 of each trial treatment 
course. 
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Statistical analysis 
Assuming that all the patients would respond to IVIg and none to albumin, it was calculated 
that 7 patients would be sufficient for this study. The treatment responses were analyzed with 
the sign test. 
Table 1. Patients characteristics at initial diagnosis 
study age I NCV motor CSF CSF duration Rankin Score"' 
number (years) median protein, c e I Is IVIg before after 
nerve (m/s) (mg/100ml) (x106/l) treatment in it i a I IVIg 
before trial IVIg (before 
onset (months) treatment start 
tria I) 
1 63 49 341 20 ' 14 3 0 
2 46 37 
' 
265 8 19 3 0 
3 10 22 80 1 52 5 1 
4 54 34 251 0 4 5 1 
5 31 19 246 12 52 4 0 
6 56 6 80 6 11 4 1 
7 7 43 55 3 36 3 1 
NCV = nerve conduction velocity (under limit of nonnal:Sl mfs) 
CSF = cerebrospinal fluid (upper limit of nonnal: children 40 mg/100 ml, adults 50 mg/100 mi 
Rankin scale* 
0 = asymptomatic 
1 = non-disabling symptoms which do not interfere with lifestyle 
2 = minor disability symptoms which lead to some restriction of lifestyle, but do not interfere 
with the patients capacity to look after themselves 
3 = moderate disability symptoms which significantly interfere with lifestyle or prevent totally 
independent existence 
4 = moderately severe disability symptoms which clearly prevent independent existence, 
although patient does not need constant attention day and night 
5 = severely disabled, totally dependent requiring constant attention day and night 
RESULTS 
The characteristics at initial diagnosis of the 7 patients ( 4 women and 3 men) are shown in 
Table 1. All patients had weakness of at least both legs, hypo- or areflexia, slowed nerve 
conduction velocities and elevated CSF protein level. There were no signs of systemic disease 
and no kinship history of neuropathy. The disability expressed by the Rankin scale319 before the 
initial IVIg treatment and the optimal score after several courses of IVIg are shown in Table 
2. All 7 patients were on IVIg treatment at regular intervals to maintain the improved condition 
(mean treatment duration 27 months, mean treatment interval2 weeks, mean IVIg dose 0.4g/kg 
bodyweight/2 weeks). The mean of the time lapses since discontinuation of the regular IVIg 
treatment until deterioration was 11 weeks (range 4-24). IVIg was the 1st trial treatment in 3 
patients and the 2nd in 4. 
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After IVIg, all 7 patients had improved on day 8 after the onset of 
treatment. After placebo, none of the patients had improved; the 
condition had deteriorated in 2 and was unchanged in 5 patients. 
Three of these 5 patients further deteriorated after 1 week and 2 after 
3 weeks. The time lapses since day 8 of the trial treatment until 
deterioration are shown in Table 2. The mean of the time lapses was 
6.4 weeks after IVIg trial treatment and 1.3 weeks after placebo 
treatment. The time lapses were longer in each patient after IVIg 
treatment than after placebo treatment. These results show that as a 
group the IVIg treated patients did better than placebo (sign test 
p=0.02). 
Since none of the patients had side effects of treatment, the blinding 
was not violated. 
Electrophysiological measurements 
The mean of the nerve conduction velocity slightly increased from 32 
Table 2. Time-lapse until 
clinical deterioration in 
weeks 
study After After 
number IVIg Placebo 
1 4 0 
2 6 1 
3 8 3 
4 11 1 
5 4 0 
6 9 3 
7 3 1 
Mean 6. 4 1.3 
m/s to 37m/sin the IVIg treatment group and did not change in the placebo group (31 m/s). 
The mean CMAP after stimulation at the wrist increased (from 5.7 mV to 11.1 mV) in the IVIg 
group and decreased (from 9.5 mV to 7.8 mV) in the placebo group. The mean CMAP after 
stimulation of the elbow increased more in the IVIg group (from 4.5 m V to 6.8 m V) than in 
the placebo group (from 5.2 m V to 5.6 m V) (Figure 1) 
The changes in NCV or CMAP's after treatment did not reach statistical significance (Wilcoxon 
matched-pairs signed-ranks test). 
DISCUSSION 
All 7 CIDP patients had deteriorated after discontinuation of maintenance IVIg treatment. 
Thereafter none of the patients responded to placebo infusion whereas all the patients had a 
beneficial response to IVIg treatment. The mean time lapse between the end of the trial 
treatment and the occurrence of deterioration was 6.4 weeks after treatment with IVIg and 1.3 
weeks after treatment with placebo. 
One may argue that the assessment of the investigators was influenced since they knew that 1 
of the treatments was placebo and the other the assumed effective treatment However, the 
study was double-blind and the blinding was not violated by side effects. If the investigators had 
judged the condition of a patient to have improved after 1 treatment and not improved after the 
other treatment, the probability of finding a treatment response to IVIg by chance is 0.5. 
However, the probability of finding, by chance, a treatment response to IVIg in 7 consecutive 
patients is very low: 0.008. 
We did not expect the nerve conduction velocity to change within 8 days of treatment. The mean 
of the nerve conduction velocity in the treatment group slightly increased and did not change 
in the placebo group. The mean of the CMAP's in the treatment group increased after 
stimulation at the wrist and decreased in the placebo group. The mean of the CMAP's after 
stimulation at the elbow increased more in the treatment group than in the placebo group, but 
all these differences did not reach statistical significance. Changes of the CMAP's were not 
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always correlated with the clinical 
condition. This might be explained by 
fluctuations in dispersion of the 
conduction velocities, resulting in 
alterations of the form of the CMAP. 
Another cause could be the rapid 
changes in excitability of the nerves 
which we observed in these patients 
and which is presently under 
investigation. The explanation may 
also be that we only investigated a 
distal segment of one nerve instead of 
looking for a conduction block at a 
more proximal location of the nerve. 
In the complete assessment of a 
treatment, it is not sufficient to 
demonstrate that the treatment is 
effective. We need to know whether 
the effect of treatment has an 
important clinical effect on disability. 
We did not investigate this, but a 
suggestion of how effective this 
treatment can be, is shown in Table 
1. All the studied patients were 
severely disabled before initial IVIg 
treatment. After several courses of 
IVIg treatment, the clinical condition 
of all these patients had considerably 
improved. The patients were reluctant 
to discontinue the treatment and to 
deteriorate to pretreatment condition. 
Therefore they gave us permission to 
carry out this study, provided we 
started treatment as soon as 
deterioration became apparent. This 
prevented us from studying the extent 
that IVIg treatment may improve 
disability. 
IVIg prepared according to the 
method described has no serious side 
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Figure 1. Compound muscle action potential of median 
nerve, before and after Mg or placebo treatment. 
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effects.27'170.264 The major drawback of IVIg treatment is its expense. Compared to plasma 
exchange, IVIg is more convenient to the patient and not more expensive. Corticosteroids are 
less expensive than IVIg, easier to administer, but the potentiallongterm side effects must be 
considered. 228 
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~VENOUS~OGLOBULIN 
TREATMENT IN PATIENTS WITH 
CHRONIC INFLAMMATORY 
DEMYELINATING POLYNEUROPATHY 
Clinical and laboratory characteristics associated with improvement 
INTRODUCTION 
Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) may respond to 
corticosteroids77 and to plasma exchange81 which was shown in controlled studies. Improvement 
has also been regorted after administration of azathioprine,62'235 cyclophosphamide62•96 and 
cyclosporin A.142'1 ;307 Recently, several uncontrolled studies described a beneficial response to 
intravenous immunoglobulin (IVIg) treatment.6,so,59,S7;32B The beneficial effect of IVIg treatment 
in patients with CIDP was supported by the results of a double blind placebo controlled cross-
over study.322 
In this report we present our experience with IVIg treatment in 52 patients who were judged 
to have a CIDP. The aims of this study were to investigate what the proportion of CIDP 
patients is that improved after IVIg treatment, what the effect of IVIg is on the disability of 
these patients and which clinical and routine laboratory factors are associated with improvement. 
PATIENTS AND METHODS 
Patients 
Clinical and laboratory records were reviewed for all patients who were judged to have a CIDP 
and who were treated with IVIg. 
All patients included in this study fulfilled the criteria outlined by Dyck et al?4: (1) the course 
of the disease may be steadily progressive, chronic monophasic, or recurrent; (2) nerve 
conduction may be normal in motor and afferent fibres, but more commonly (though not 
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mandatory) it is slowed; (3) cyto-albuminologic dissociation is usually seen at some time during 
the course of the disease and most of our patients ( 4) had a tendency to symmetric involvement 
and to involvement of proximal as well as distal limb muscles. 
We tried to exclude patients with the Guillain-Barre syndrome,15 therefore all patients had the 
clinical features of a polyneuropathy with a progression of weakness of at least 2 months. 
, Patients with known systemic disease were excluded in our series, except 4 patients with diabetes 
mellitus and 2 patients with a benign monoclonal gammopathy, type IgG-kappa and IgG-
lambda, respectively. 
Clinical assessment 
Muscle strength was tested manually using the Medical Research Council (MRC) scale.204 At 
least 6 muscle groups were tested on each side. These were muscles for: shoulder abduction, 
elbow flexion, wrist extension, hipflexion, knee extension and ankle dorsiflexion. Asymmetric 
weakness between left and right was defined as a difference of 2 or more grades on the MRC 
scale between at least 1 of the same muscle groups. Discrepancy in weakness between arms and 
legs, was defined as a difference in muscle strength of 2 or more grades on the MRC scale 
between ankle dorsiflexion and wrist extension. 
The disability of the patients was assessed using the Rankin scale.319 This scale estimates 
functional disability or handicap. Improvement was defined as an increase of at least 1 step on 
the Rankin disability scale. 
Treatment 
All 52 CIDP patients were treated with high-dose intravenous immunoglobulin (Central 
Laboratory of the Dutch Red Cross Blood Transfusion Service) in a dosage of 0.4 gjkg body 
weight/ day for 5 consecutive days. If necessary, treatment was repeated. The 52 patients did not 
receive corticosteroids or other immunosuppressive treatment within the 2 months before, or 
together with IVIg treatment. 
Statistical analysis 
We investigated the association between treatment response and the following characteristics: 
sex, age less than 50 years, disease duration less than 1 year, absence of asymmetric weakness, 
absence of discrepancy in weakness between arms and legs, areflexia legs, areflexia arms, 
progression of weakness until4 weeks or less before onset of treatment, remitting or progressive 
course of the disease, CSF protein more than 0.5 g/1 in adults or more than 0.4 in children, CSF 
cell count 10.106/1 or less and slowed nerve conduction velocity (NCV) of the motor median 
nerve. The NCV of the median nerve was measured over the forearm with standard techniques, 
slowed NCV was defined as a NCV of less than 80% of the lower limit of normal. The lower 
limit of normal was 51 m/s. 
For analysis of the association between each of the above mentioned characteristics and 
treatment response, the two-sided Fisher exact probability test was used. A logistic regression 
analysis was used for analyzing simultaneously the predictive value of all those characteristics 
which were significantly related with improvement. 
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RESULTS 
Fifty two patients (33 men and 19 women) were diagnosed as having CIDP over a study period 
of 8 years. The age ranged from 5 to 82 years (mean 48 years) at onset of CIDP in the group 
of patients who improved and from 10 to 76 years (mean 46 years) in the group of patients who 
did not improve. 
The mean follow-up in the group of patients who improved was 4.1 years, median 3.1 years 
(range 8-251 months). The mean follow-up in the group of patients who did not improve was 
5.7 years, median 3.6 years (range 16-295 months). Before IVIg was started, 9 of 52 patients 
(17%) had remissions and exacerbations. The mean and median time between onset of CIDP 
and IVIg treatment in the patients with a remitting course was 9 months (range 4-18 months). 
The mean time between onset of CIDP and IVIg treatment in the patients with the progressive 
form was 25 months, median time 6 months (range 2-247 months). The group of patients with 
a remitting course has a mean age of 36 years, median 31 years (range 10-64 years). The patient 
group with the progressive form has a mean age of 49 years, median 54 years (range 5-82 
years). 
Follow-up revealed lungcancer in 2 patients; in one patient 6 months, in the other patient 2 
years after the diagnosis of CIDP was made and IVIg was started. The second patient died. 
One patient died from mesothelioma after 6 years of IVIg treatment. Two patients died after 
a myocardial infarction and one patient died from complications after abdominal surgery; these 
3 patients received IVIg for a period of 2-3 years. All 6 patients had improved after IVIg, one 
had a remission after one treatment course, the other five needed repeated infusions to maintain 
the improved condition. 
Treatment response 
Thirty two ( 62%) of the 52 patients improved after IVIg. The improved condition could be 
maintained in 30 (94%) of these patients for a mean follow-up period of 4 years. There was 
no correlation between the course of CIDP (remitting or progressive) and improvement after 
IVIg. The mean time after onset of IVIg treatment to the initial signs of improvement was 5 
days (range 3-8 days). The mean time to reach maximal improvement was 5 weeks (range 2-
16 weeks). 
The disability before treatment and the maximal score after treatment was measured with the 
Rankin score (Table 1). Four patients improved 1 grade, 10 patients improved 2 grades, 8 
patients improved 3 grades and 10 patients improved 4 grades on the Rankin scale. 
Twenty one of the 32 patients who improved (40% of all patients) needed intermittent IVIg 
treatment to maintain the maximal level of improvement. Initially, most of these patients 
received 0.4 g IVIgjkg bodyweight every other week. In 9 of these 21 patients the dosage of 
IVIg could gradually be tapered off to an average dosage of 0.25 g IVIg/kg body weight every 
other week, without clinical signs of relapse. This maintenance therapy of IVIg was 
administrated within 1.5 hours at an outpatient department. 
In 2 of 32 patients, there was a shortlasting improvement ( ± 3 weeks) and subsequent IVIg 
infusion had no effect. Nine of the 32 patients who improved reached complete remission (17% 
of all patients). The median follow-up in patients in remission was 24 months (range 6-68 
months). The only differences between patients who reached complete remission and the other 
patients who improved was the disease duration before treatment. The median time from the 
first signs of CIDP to the onset of IVIg in the patients who reached complete remission was 
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Table 1. Minimal and maximal clinical grade in 32 CIDP who improved 
after IVIg treatment 
Rankin Score 
0 =asymptomatic 
1 = non- d i sa b I i n g symptoms wh i c h do not 
interfere with I ifestyle 
2 =minor disabi I ity symptoms which lead 
to some restriction of lifestyle, but 
do not interfere with the patients 
capacity to look after themselves 
Before After 
IVIg IVIg 
treatment treatment 
no. no. 
7 
18 
4 
3 =moderate disabi I ity symptoms which 12 3 
significantly interfere with lifestyle 
or prevent totally independent 
existence 
4 =moderately severe disabi I ity symptoms 13 
which clearly prevent independent 
existence, although patient does not 
need constant attention day and night 
5 =severely disabled, totally dependent 7 
requiring constant attention day and 
night 
3 months (range 2-8 months), whereas the median time was 7 months (range 2-220 months) in 
the group of patients who improved but who needed intermittent IVIg treatment. 
Side effects of Mg treatment 
Minor side effects such as headache nausea and fatigue were sometimes observed, mainly 
related to the speed of infusion. None of the patients developed hepatitis. Ten patients who had 
intermittent IVIg infusions for at least 2 years were tested for HIV; all were negative. 
Laboratory data 
The mean conduction velocity of the motor median nerve was 27 m/s (range 6-58 mjs) in the 
group of patients who improved and 44 m/s (range 11-61 m/s) in patients without improvement. 
The mean CSF protein was 1.08 g/1 (range 0.35-3.41) in the group with improvement and 1.10 
gjl (range 0.33-3.44) in the group without improvement. The mean number of cells in the CSF 
in both groups was 5xl06 /1, the range in the group with improvement varied between 0-
20x106/l, in the group without improvement it varied between 0-27x106/l. 
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Table 2. Clinical and laboratory characteristics associated with improvement 
after IVIg treatment in 52 CIDP patients 
imQroved after IVIg P value"' 
YES NO 
N=32 N=32 
no (%) no (%) 
Sex: male 20 (63%) 13 (65%) ns 
female 12 (37%) 7 (35%) ns 
Age <50 years 12 (38%) 11 (55%) ns 
Disease duration <1 year 28 (88%) 8 (40%) 0. 0005 
Progression of weakness unti I 32 (100%) 14 (70%) 0. 002 
<4 weeks before onset of 
treatment 
Remitting course 6 (19%) (15%) ns 
Absence asymmetric weakness 30 (94%) 16 (80%) ns 
Absence discrepancy weakness 30 (94%) 8 (40%) 0. 0001 
between arms and legs 
Areflexia arms 27 (84%) 6 (30%) 0. 0001 
Areflexia legs 28 (88%) 14 (70%) ns 
NCV motor median nerve 27 (84%) 8 (40%) 0. 002 
<80% of normal 
CSF protein >0. 50 g/1 30 (94%) 18 (90%) ns 
CSF ce II s <10. 106/ I 27 (84%) 19 (95%) ns 
* Fisher's exact probability test, 2 sided 
Factors associated with improvement 
Table 2 shows that 5 factors were significantly associated with improvement; disease duration 
< 1 year, progression of weakness until <4 weeks before onset of treatment, absence of 
discrepancy in weakness between arms and legs, areflexia of the arms and slowed NCV of the 
motor median nerve over the forearm. 
Since the factor "progression of weakness until onset of treatment" was required for 
improvement, we excluded this factor from further analysis. 
Using logistic regression, the other 4 factors significantly associated with improvement were 
analyzed and the predictive value of these factors combined was calculated (Table 3). This 
Table shows that if the factors "absence of discrepancy in weakness between arms and legs, 
disease duration less than 1 year, areflexia of the arms and slowed NCV over the motor median 
nerve" are present, the estimated probability of improvement is 93%. If none of these factors 
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Table 3. Logistic regression model for chance of improvement after IVIg 
Factor Odds Logistic P-
ratio coefficient value 
Absence of discrepancy in 
weakness between arms and legs (a) 6. 664 1. 897 
Disease duration less than 
one year (b) 6. 234 1. 830 
Areflexia arms (c) 4. 138 1. 420 
NCV motor median nerve 
< 80% of normal (d) 3. 284 1. 189 
Probability of improving after IVIg if factors a, b, c and d are all 
present = 1 / (1 + e·Y) = 0.93 
y = C 0 + Ca + C1, + Cc + Cd = 2556 Co = constant term = -3.780 
Ca,b,c,d are the logistic coefficients of factors a,b,c, and d 
0. 076 
0. 041 
0. 102 
0. 199 
is present, the estimated probability is 2%. 
The first 2 factors are the strongest predictive factors, but the last one "slowed motor median 
NCV" still has a clinically relevant contribution to the probability of improvement, since the 
Odds ratio is 3.284. 
Patients without improvement 
Twenty (38%) of 52 CIDP patients did not improve after IVIg treatment. Fifteen of these 20 
patients were treated with prednisone, and 5 improved. After tapering off prednisone, one of 
these 5 patients was treated with Azathioprine which was followed by improvement. Five 
patients were not treated with prednisone; one patient showed a slow spontaneous improvement 
without further treatment and the 4 other patients were not treated with prednisone because 
of fear of side effects. One of the 2 patients with short lasting improvement after IVIg had a 
favorable response to prednisone. The second patient did not respond to prednisone, 
azathioprine or cyclophosphamide. This patient improved after plasma exchange and treatment 
with cyclosporin A After two years, this patient is in Rankin scale 3. 
We reviewed the case records and the follow-up information of the 20 patients who had not 
improved after IVIg, and tried to find a diagnosis other than CIDP. Two patients might have 
had a polyneuropathy of the type as described by McLeod,202 and 1 patient might have vasculitis 
limited to the peripheral nervous system.82 In 2 patients the polyneuropathy was associated 
with mild diabetes mellitus and in 1 patient with alcohol abuse. 
Three patients had a polyneuropathy which could have been initially a neuropathy as described 
by Pestronk;236 in sera of these 3 patients high titers of anti-GM1 antibodies were demonstrated. 
In one patient a hereditary polyneuropathy was likely. In the 10 other patients, no diagnosis 
other than CIDP could be established. 
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DISCUSSION 
This study shows that 38% of patients judged to have a CIDP did not improve after treatment 
with IVIg. A further 4% had a shortlasting improvement and subsequent infusions had no 
effect. A complete remission was reached in 17% which might have been caused by treatment 
but spontaneous remissions do occur and because some patients may have had a GBS like 
course even after progression of more than 8 weeks. Especially in this group of patients it is 
difficult to decide whether or not these patients had responded to treatment. A beneficial 
treatment response is more likely in the patients ( 40%) who improved after IVIg and who 
needed intermittent infusions to maintain the improved condition. 
IVIg treatment was not accompanied by serious side effects. None of the patients developed 
hepatitis. In 10 patients who had been treated at regular intervals for at least two years, illY 
antibodies could not be demonstrated. 
One of the major advantages of treatment with IVIg in comparison with prednisone is that 
improvement begins immediately. This is clearly demonstrated when we compare our results 
with that of a study in 60 patients23 treated with 100 mg prednisone daily for 2 to 4 weeks 
followed by an alternate-day single-dose of 100 mg until the clinical improvement reached a 
plateau phase. In that study the mean time for initial improvement was 1.9 months (after IVIg 
5 days) and the mean time to reach a clinical plateau was 6.6 months (after IVIg 5 weeks). 
To maintain the improved condition, 40% of the patients needed intermittent IVIg infusions 
every other week. We tried various schedules to reduce the IVIg dosage. We had more 
favorable results with tapering off the infusion dosage than with increasing the interval between 
the infusions. In 9 of 21 patients, the dosage could be reduced to 0.25 g IVIg/kg body weight 
every other week. 
Maintenance treatment with IVIg is expensive. This treatment has to be compared with plasma 
exchange and to prednisone which is the standard treatment in CIDP. There is no study which 
shows what the maintenance dosage of prednisone usually is and what the side effects are of 
long term prednisone treatment in CIDP. It is reasonable to assume that the side effects of 
prednisone treatment in myasthenia gravis are not much different from CIDP. It has been 
estimated that approximately 25% of patients with myasthenia gravis develop serious side effects 
within 4 years of treatment with prednisone.228 
Prolonged plasma exchange has not been associated with any complications except anaemia,82 
is about as expensive as IVIg treatment, but is inconvenient for the patient. 
CIDP, according to the criteria outlined by Dyck et al,74 is difficult to distinguish from some 
other neuropathies. The first neuropathy to consider has been described by McLeod et al.202 
This neuropathy is a slowly progressive axonal degeneration of undetermined cause. The 
characteristic history is that of a gradual onset of numbness, tingling, coldness or burning 
sensation in the feet and hands, weakness of the legs and less commonly weakness of the hands. 
Neurological examination may demonstrate distal muscle wasting and weakness in the lower 
limbs which may be quite pronounced. In McLeods' series of patients one third had areflexia 
of the legs, but total areflexia was less common. The CSF protein was often slightly elevated and 
the NCV's were slightly reduced and sometimes reached values which suggested a demyelinating 
neuropathy. If these patients are seen late in the course of the disease, distinction from CIDP 
may be difficult. 
A second neuropathy that may be difficult to distinguish from CIDP is the non-systemic 
vasculitic neuropathy.82 The course in these patients may be stepwise progressive and thereafter 
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static for a time. These patients may have severely affected legs and no or slight involvement 
of the arms. 
Finally, CIDP may be confused with multifocal motor neuropathy. In the patients described by 
Pestronk et al236 asymmetrical weakness developed in one arm and progressed over 2 to 3 years 
to involve the other arm, legs and trunk. High titers of antibodies to GMl ganglioside were 
demonstrated in these patients. These patients do not necessarily have areflexia of the arms or 
slowed NCV of the motor median nerve over the forearms. Three of our patients had initially 
a similar course and in sera withdrawn at the beginning of the disease we could demonstrate 
high titers of antibodies to GMl. These three patients did not respond to IVIg. 
We conclude that several factors which can be taken together as a progressive neuropathy of 
relatively short duration with clearly affected arms, are associated with improvement after IVIg 
treatment and that the presence of these factors may have consequences for the choice of 
treatment in patients with CIDP. 
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IMMUNOPATHOGENESIS OF CIDP 
INTRODUCTION 
It is likely that the inflammatory demyelinating polyneuropathies are precipitated by antecedent 
illnesses. 
In CIDP, the rate of antecedent infectious diseases is generally reported to be lower than in 
GBS.14'79 However, Prineas et al.246 reported various illnesses within a month before onset of 
neurological symptoms in 15 of 23 (65%) CIDP patients: non-specific upper respiratory tract 
infections in 11, varicella in 1 and flu-like symptoms in 3 patients. McCombe et al.198 recently 
reported that 29 of 92 (32%) CIDP patients had a history of various preceding infectious 
diseases in the six weeks before onset of neuropathy. In this study a cytomegalovirus (CMV) 
IgG antibody titer > 1:4 was found on 19 of 39 (49%) patients with CIDP, in 11 of 22 (50%) 
patients with GBS and in 2 of 25 (8%) healthy controls. The mean height of the CMV antibody 
titer was also found to be significantly increased in CIDP and GBS patients compared with 
controls. However, high titers of CMV antibodies can also be the result of (endogenous) 
reactivation or of polyclonal B cell activation elicited by another infection. Other antecedent 
events re~orted in CIDP patients are: hepatitis B virus,139 HIV,54 rubella,226 and vaccinations with 
influenza 6 and tetanus toxoid.110 
It has been investigated if HLA-linked genetic factors may influence susceptibility to CIDP or 
GBS. Immunogenetic studies have not demonstrated a human leucocyte antigen (HLA) 
association in GBS patients,4'143'164,342 but in two series with a total number of 36 CIDP patients, 
an association with the HLA-A30/31,B8,DR3 haplotype was found.5.29° Recently Feeney et al.94 
found increased frequencies of HLA-A3 and B7 in a group of 71 CIDP patients. In 56 CIDP 
patients, who were typed for DR and DQ they found that HLA-DR2 was increased. Although 
none of these fmdings reached statistical significance after correction, it was suggested that 
CIDP might be associated with HLA-DR2. The linkage between HLA-B7 and DR2 appeared 
much greater in patients with CIDP than in healthy controls.94 
An association with other immune-mediated diseases or immune-compromised conditions is 
observed in both CIDP and GBS patients and has been discussed in Chapter 1. 
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Controlled studies showed that both CIDP81 and GBS patients100'108.302 can improve after plasma 
exchange, which suggests a pathogenic role for circulating antibodies. In different assays, 
circulating anti-neural tissue antibodies have been demonstrated. Animal models showed that 
clinical and laboratory symptoms resembling CIDP and GBS can be induced by both cellular 
and humoral transfer experiments. 
As there is a limited understanding of the underlying events at the molecular level in 
neuropathy, the definite roles of antibodies and cellular immunity have not been established. 
Immunohistopathology 
The percentage of nerve biopsies showing inflammatory cell infiltrates is low (11-29%).23'157 
Usually, these small mononuclear cell infiltrates are perivascular located in either epi-, peri- or 
endoneurium. A non-perivascular, predominantly endoneurinallocated inflammatory infiltrate 
may be present in CIDP. These infiltrates however should preferentially be located in the region 
of the nerve roots242 and are therefore not often found in sural nerve biopsies. 
In nerve biopsies from 6 CIDP patients, it was found that HLA class II antigens were expressed 
within nerve fascicles and the perineurium,241 even in the absence of an inflammatory infiltrate 
in the perineurium.242 Schwann cells forming onion bulbs were clearly HLA class II positive, 
suggesting that Schwann cells in patients with CIDP may act as antigen presenting cells. 
Immunoglobulin deposits have been shown in peripheral nerve tissue of patients with CIDP.124.= 
Using a direct-immunofluorescence assay (IFA), Dalakas and Engel60 demonstrated linear 
deposits of IgM immunoglobulin at the Schwann cell membrane of myelinated fibers in 6 of 9 
CIDP patients, IgG was present in 3 of 9 biopsies whereas 10 control biopsies did not show IgG 
or IgM deposits. The specificity of immunoglobulin deposits in peripheral nerve tissue must be 
questioned, because these have also been demonstrated in polyneuropathies associated with 
diabetes mellitus,53 carcinoma,52 vasculitis/24 IgM monoclonal gammopathy,213 and also in other 
diseases such as acute hepatitis, idiopathic liver cirrhosis,313 and in healthy controls.53•69•84•180,295 
Humoral immunity 
The presence of anti-neural tissue antibodies in patients with CIDP and GBS has been 
investigated extensively. As both neuropathies are probably different manifestations of one 
disease they were studied simultaneously in most assays. 
As the putative antigen(s) in GBS and CIDP are still unknown, whole peripheral nerve, myelin, 
Schwann cells, other neural constituents and neural equivalents as neuroblastoma cell lines have 
been used for antibody detection. 
Antibodies to peripheral/central nerve tissue 
A technique to demonstrate antibody binding to nerve tissue is an immunofluorescence assay 
(IFA). In these experiments, patients' serum is incubated with non-pathological human or 
animal peripheral nerve tissue. In most reports, GBS sera were evaluated. The technique is 
complicated by aspecific binding of immunoglobulins resulting in a high incidence of positive 
controls. 
Vedeler et al.324 who first described a mixed hemagglutination test (MHT) to demonstrate anti-
human peripheral nerve tissue antibodies, found that a positive MHT in GBS and CIDP patients 
was associated with a beneficial response to plasma exchange.325 After studying an extended 
group of patients, Osterman et al.Z29 could not confirm their initial observations. 
The results of various assays to detect anti-peripheral nerve antibodies are shown in Table 1. 
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Table 1. Antibodies in serum directed against peripheral nerve tissue 
Author year test GBS CIDP controls antigen 
normals pnp non-pnp 
N pos N pos N pos N pos N pos 
% % % % % 
Ts e313 1971 IFA 6 67 35 25 8 hi ra t/gp 
mo/rab 
Lui j ten186 1972 IFA 6 50 0 4 0 
DowliMw 1973 IFA 40 70 15 37 22 mo 
Novak 1973 IFA 6 83 5 20 mo 
Schott272 1978 IFA 20 65 23 13 h 
Swash295 1979 IFA 2 0 1 0 4 50 h 
Dalakas60 1980 IFA 7 100 1 0 1 0 h 
Nyland225 1981 IFA 4 25 4 50 h 
Toyka311 1982 I FA 1 100 h 
Hays 124 1988 IFA 2 50 4 25 93 10 2 0 h 
Nyland224 1978 GCA 40 38 4 25 40 10 22 0 h 
Vedeler3Z7 1988 Ell 90 59 36 19 63 8 42 14 105 8 h 
Vedeler324 1982 MHT 42 36 9 22 20 0 12 0 h 
Vede I er325 1982 MHT 11 55 7 71 20 0 h 
v Doorn320 1987 MHT 16 69 22 50 25 0 34 3 71 11 h 
Os t erma n229 1988 MHT 36 53 30 0 h 
assays: 
IFA= immunofluorescence assay 
GCA = anti-globulin consumption assay or Coombs' consumption test 
ELI= enzyme linked immunosorbent assay (ELISA) 
MHf= mixed hemagglutination test 
controls: 
normals=healthy controls; pnp=patients with a non-GBS/CIDP polyneuropathy; 
non-polyneuropathy= patients with various other diseases; -=not indicated 
antigen: nerve tissue from h=human; gp=guinea pig; mo=monkey; rab=rabbit 
Complement-activation 
The first complement fixation (Cf) assay using nerve tissue was described by Melnick in 1963.207 
Since then, several investigators tested for complement activation with various substrates (Table 
2). Koski et al.153(1985) used a Clq-fixation assay with peripheral nerve myelin extract and 
found a high percentage of positive reactions in sera from GBS and CIDP patients; controls 
were also often positive but they generally had lower antibody titers. Since Koski et al.153 found 
up to fifty-fold increased titers in GBS sera obtained early during the course of active disease, 
differences in results among investigators might be related to the timing of serum withdrawal. 
A terminal complement ( C5-C9) fixation assay by Koski et al.155 showed a similar high incidence 
of positive results compared with the Clq fixation assay.153 
The results of complement fixation assays in vitro seem compatible with CSF findings regarding 
com~lement activation in vivo. Consumption of C3 and C4 was not found in serum from both 
GBS ,261),309,34o and cmp269 patients. One publication reports activation of C3a and C5a in CSF 
and not in serum from GBS patients.119 Amarenco et al.9 found C3 consumption in CSF during 
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Table 2. Complement iiXation (Cf) assays 
Author year complement GBS ClOP controls antigen 
component normals pnp non-pnp 
measured N pos N pos N pos N pos N pos 
96 96 96 96 96 
Melnick207 1963 CH50 38 50 14 43 183 3 34 26 1035 6 p/c-h 
Dalakas60 1980 C3 7 86 1 0 1 0 p-h 
Latov163 1981 CH50 11 27 9 22 8 0 45 9 74 0 p-h/rab 
Nyland225 1981 C3b 5 40 3 67 10 0 p-h 
Hughes 132 1984 CH50 17 12 11 9 19 0 20 0 15 0 p-h 
17 29 19 0 20 0 15 7 p-gp 
Ryberg262 1984 CH50 18 50 c-h 
18 56 p-h 
Ryberg263 1984 CH50 19 37 12 8 50 2 c-h 
19 21 p-h 
19 42 p/c-h 
19 16 c-h 
Koski 153 1985 C1 12 92 4 75 12 50 7 43 p-h 
Koski 154 1986 C1 7 100 15 20 3 100 25 8 p-h 
Koski 155 1987 C5b-9 19 100 7 86 10 0 5 80 12 42 p-h 
Hays 124 1988 C3b 2 100 4 50 93 13 2 0 p-h 
Osterman229 1988 CHSO 36 83 50 0 p-h 
Winer340 1988 CH50 100 7 100 1 p-h 
antigen: 
p=pns; c=cns; h=human; gp=guinea pig; rab=rabbit 
the course of GBS and Sanders et al.Z7° showed that the terminal attack complex (C5b-C9) was 
activated in the CSF of GBS patients. 
These findings suggest that complement-binding antibodies are in vivo present in GBS and that 
these antibodies are likely to activate the terminal complement attack complex. 
In 1989, Koski et al.1S3 reported that Clq-fixating anti-peripheral nerve myelin antibodies are 
directed against a neutral glycolipid which can be absorbed with the Forssman antigen. This 
observation may have important implications in further research on the antigen(s) involved in 
the pathogenesis of the inflammatory demyelinating polyneuropathies. 
Antibodies to cultured cells 
Cell cultures can be used to identify more specifically the pathological events in the 
inflammatory demyelinating polyneuropathies. Since myelin of the peripheral nervous system 
is produced by Schwann cells, these cell cultures were considered as models for demyelination. 
Unfortunately Schwann cell clones or lines are not yet available and cultures are to a variable 
extend contaminated with collagen tissue or with fibroblasts. Results of studies using various 
cultured cells are shown in Table 3. 
When cultured Schwann cells, obtained from rat peripheral nerves, are incubated with sera from 
patients with various diseases, weak immunoglobulin staining of both Schwann cells and 
fibroblasts could only be observed during the first days of culture when 30-40% fibroblasts were 
present. The meaning of this finding is not clear, but it was suggested that this could be the 
result of dedifferentiation of Schwann cells, resulting in a change of the antigenic expression 
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Table 3. Antibodies and functional investigations against cultured cells 
Author year test GBS CIDP controls antigen 
normals pnp non-pnp 
N pos N pos N pos N pos N pos 
% % % % % 
Neuroblastoma cells 
Rosenberg256 1975 tox 4 100 2 100 6 16 0 mouse 
C1300 
Tindall 305 1980 tox 10 80 166 2 14 0 mouse 
C1300 
MG II e r216 1984 RIA 11 55 58 50" human 
SH-SY5Y 
v Doorn321 1988 IFA 48 42 42 43 40 0 43 7 85 5 rat-mouse 
108cc15 
Schwann cells rat nerve 
Kennedy 146 1979 IFA 5 100 4 100 3 100 6 100 sw 70% 
5 0 4 0 3 0 6 0 sw 100% 
Dorsal root ganglia 
Cook52 1971 ted 31 84 2 0 11 9 16 31 23 39 mouse 
Dubois71 1971 ted 6 83 rodent 
Hi rano 131 1971 ted 6 100 11 9 mouse 
B i r c hem28 1987 t cd 10 40 rat 
Peripheral nerve 
Arnason13 1969 ted 5 0 rat 
assays: 
tox = cytotoxicity assay 
RIA = radio-immuno assay 
IFA = immunofluorescence assay 
ted = tissue culture demyelination 
sw = Schwann cell culture (70%= 70% Schwann cells and 30% fibroblasts) 
. 
= 21/33 (64%) patients with myasthenia gravis were positive 
during culture.146 The Schwann cell cytotoxicity assay reported by Lisak et al.181 did not show 
differences between serum from GBS and controls. 
In tissue culture experiments with myelinated rodent spinal ganglia cultures, evidence of a serum 
factor was found in GBS patients showing a complement-dependent demyelination71•131 which 
diminished or disappeared with serum obtained later in the course of GBS.131 In cultures of 
mouse dorsal root ganglia, a cytotoxic effect and complement-dependent demyelination was 
found in serum from 26 of 31 GBS patients.52 However, such serum factor was not found in 2 
patients with CIDP neither was it specific for GBS as it was present in sera from patients with 
other polyneuropathies and other neurologic disorders as well.71•131 Complement dependent 
myelinotoxic activity a~ainst rat cerebellar cultures was found in serum from patients with GBS 
and multiple sclerosis. 1 
In 1987, Birchem et al.28 showed with electron microscopic studies that serum from 4 of 10 
GBS patients in the presence of complement and in the absence of mononuclear cells, caused 
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a direct myelin-related Schwann cell lysis in cultures containing pure rat Schwann cells and 
dorsal root ganglion neurons. In addition they found that serum from recovered GBS patients 
had no cytolytic activity to neurites or Schwann cells.28 Amason et al.13 found demyelination of 
rat trigeminal nerve cultures after incubation with lymphocytes derived from nerve-immunized 
rats but also with lymphocytes from 7 of 9 GBS patients, whereas lymphocytes from 5 control 
patients, sera from 5 GBS patients and sera from nerve immunized rats did not induce 
demyelination. The results of tissue culture demyelination experiments are rather confusing as 
is illustrated by Silberberg et al. 281 who found that sera from all 20 normals and even 4 
agammaglobulinemic patients induced some demyelination of mouse cerebellum cultures. 
Other cells which have been used for the detection of anti-neural tissue antibodies are 
neuroblastoma (NBL) cells. NBL is a tumor of neural crest origin. Because NBL's are 
malignant cells, they express various oncofetal antigens. Most primitive neuroblastic cells can 
still differentiate in Schwann cells and in neuronal cells. Neuroblastomas are a heterogenous 
group of neoplasms, they usually have the ability of forming neurites, they have electrically 
excitable membranes, possess neurohormone receptors and produce multiple hormones and 
enzymes.115 
Rosenberg et al.256 using a complement dependent cytotoxicity assay, found a high incidence 
of antibodies in sera from CIDP and GBS patients directed against a cholinergic and a non-
cholinergic neuroblastoma cell line, which were originally cloned from an Ajax C1300 mouse 
NBL tumor. Immunofluorescence studies showed evidence of both IgM and IgG antibodies. 
Reactivity was not found against a NBL cell line of human origin. The high incidence of 
antibodies against these mouse NBL cells was confirmed by Tindall et al.305 using an antibody 
dependent cytotoxicity assay. Miiller et al. reported that 6 of 11 (55%) of GBS patients216 and 
44 of 109 ( 40%) of patients with myasthenia gravis217 had antibodies against the human NBL 
cell line SH-SY5Y. Many different NBL cell lines - expressing various neural antigens - are 
available and apparently express antigens showing reactivity with sera from various neurological 
diseases217 (Chapter 7). 
Hybrid cell lines sometimes express certain antigens even stronger than the parental lines did. 
We used the hybrid mouse neuroblastoma/rat glioma NBL cell line 108cc15. On the ion 
excitable membrane of the 108cc15 cell line, many neural properties are expressed.115 
Clonal cell lines offer the advantage of an unlimited supply of standardized antigens, and are 
therefore a feasible tool to study the interactions with anti-NBL antibodies and IVIg. 
Antibodies to subcellular fractions of neural tissue 
Many studies have been performed regarding to antigen( s) which might be involved in the 
pathogenesis of the inflammatory demyelinating polyneuropathies (Table 4). 
The peripheral nerve contains glycoproteins and glycolipids that may act as antigenic 
determinants involved in GBS and CIDP. Three proteins P0, P1, and P2 account for 
approximately 70% of peripheral nervous system (PNS) myelin proteins. P0 is the major protein 
and is restricted to the PNS. P1 is probably identical to myelin basic protein (MBP) and is also 
found in the central nervous system (CNS), but P2 is predominantly restricted to the PNS. 
Galactocerebroside is a major part of lipid constituents of both CNS and PNS myelin.336 Other 
structures of importance are glyco(sfingo)lipids. . 
Luijten et al.187 found evidence for P2 specific antibody secreting cells in GBS patients using a 
plaque forming assay. However, antibody studies with serum from patients with CIDP or GBS 
against antigenic neural structures such as P 2188.34°,35
1 galactocerebroside, 260.34° or myelin basic 
protein (MBP)351 were found incidently positive. Antibodies against the myelin associated 
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Table 4. Antibodies against fractions of neural tissue 
Author year test GBS ClOP controls antigen 
normals pnp non-pnp 
N pos N pos N pos N pos N pos 
96 96 96 96 96 
Zwe iman351 1983 ELl 19 11 0 12 0 9 0 P2-bov 
MBP-gp 
Sato271 1986 ELl 6 50 3 33 18 0 3 67 52 27 c-MAG- h 
Wi ner340 1988 ELl 100 34 100 17 p-gal-h 
1 0 10 0 P2-h 
Luijten187 1988 ELl 20 0 - P2-h 
Luijten186 1984 PFA 5 100 2 0 3 0 - P2-h 
Nob i I e222 1985 RIA 9 0 7 0 8 0 30 43 9 0 c-MAG-h 
Ros tam i 261"' 1987 RIA 17 11 5 6 18 c/p-gal 
RIP 6 16 45 
llyas134 1988 TLC 26 19 10 0 19 0 g I yc I i p 
h nerve 
Wi ner340 1988 Cf 100 0 100 0 ga 1- h 
Koski 155 1989 Cf 12 100 25 28 11 45 Forssman 
* No difference found between GBS, CIDP and controls; percentage of positive sera is not mentioned 
assays: 
ELI= enzyme linked immunosorbent assay; PFA= plaque forming assay; RIA= radio-immune assay; 
RIP= radio-immune precipitation assay; TLC= thin layer chromatography; 
Cf = complement ftxation assay 
antigen: 
p=pns; c=cns; h=human; bov=bovine; gp=guinea pig; MBP=myelin basic protein; 
MAG= myelin associated glycoprotein; gal= galactocerebroside; glyc lip= glycolipids; 
glycoprotein (MAG) are associated with polyneuropathy in patients with paraproteinemia.163,222 
The carbohydrate-determinant of MAG cross-reacts with the leu 7-antigen (recognized by HNK-
1/L2 monoclonal antibodies) that is expressed on natural killer cells and therefore may have 
functional implications for anti-MAG antibodies in cellular immunity.67 The MAG antigen 
belongs to the immunoglobulin superfamily of which several members are expressed exclusively 
or abundantly in the nervous system and include theN-CAM (neural adhesion molecules). Anti-
MAG antibodies have been demonstrated in patients with GBS, CIDP but also in stroke 
patients and some healthy controls.200•271 The presence of anti-MAG antibodies in GBS and 
CIDP could not be confirmed by others.222 Antibodies to glycolipids248 and gangliosides134.236 are 
often observed in different neuropathies, mainly in those associated with (oligo) clonal IgM 
production but also in CIDP, as well as in other neurological diseases. Antibodies against 
gangliosides may arise as the result of (mechanical) nerve damage.36 Anti-glycosphingolipid 
antibodies can be detected with thin layer chromatography (TLC) and by Elisa.135 Using TLC, 
high levels of IgM antibodies reacting with GDla and GT1b and IgG antibodies to GD1b 
gangliosides have been found in 4 of 26 of GBS patients.135 Antibodies of the IgG and IgM 
class against GM1 and GDlb have been demonstrated in 1 of 15 CIDP patients.134.248 Anti-
GM1 antibodies have been especially found in other diseases as multifocal motor neuropathy, 
amyotrophic lateral sclerosis (in lower titer), multiple sclerosis and in systemic lupus.236,280 
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Antibodies of the IgG class to LMl ganglioside, the major ganglioside of human peripheral 
nerve myelin, was shown in 1 of 26 GBS patients.134.248 Antibodies against LM1, GD1a, GD1b 
and GT1b were neither present in 19 patients with other neurological diseases, including various 
polyneuropathies nor. in 10 normal controls.135 · 
Koski et al.156 reported that the complement fixing antibodies in GBS serum, which are directed 
against peripheral nerve myelin extract also bind a neutral glycolipid present on nerve tissue. 
These antibodies could be absorbed by Forssman glycolipid. Forssman antigen is a common 
non-specific viral and bacterial antigen. Anti-glycolipid antibodies have been demonstrated in 
many (autoimmune) diseases. Therefore, the pathogenicity of these antibodies in GBS and 
CIDP remains to be shown. 
Cardiolipin antibodies of the IgA class have been found in 23% of patients with GBS.97 It is 
suggested that antibodies to cardiolipin cross-react with myelin phospholipids.97 Anti-cardiolipin 
antibodies of the IgG and IgM class are often detected in various neurological3z.174 and other 
autoimmune diseases, 174 but may also be found in GBS.232 Anti-cardiolipin antibodies were found 
in 30% of patients with variety of uncomplicated infections. Far reaching conclusions about the 
pathogenetic significance of cardiolipin antibodies should not be drawn as the antibodies may 
be an indicator of a preceding infection. 
Immune complexes 
Circulating Immune complexes have been infrequently identified in CIDP patients320.321 and are 
analogous to cardiolipin antibodies presumably related to a triggering infectious event.43 
Passive transfer of antibodies in animals 
Passive transfer demyelination (ptd) experiments were performed with sera from GBS/CIDP 
patients, as well as with serum or lymphocytes from animals with (chronic) experimental allergic 
neuritis. 
Intraneural injection of GBS serum into rat sciatic nerve produced microscopic signs of 
demyelination.90,9l,268 A conduction block was observed after perineural,118 but not after 
intraneural injection of serum from GBS patients.53•183.34° Microscopic signs of demyelination 
were less pronounced after storage of serum/83'238,298 but even stored GBS serum showed more 
distinguished microscopic signs of demyelination than fresh control serum did.90,91,268 
Nerve conduction studies confirmed that mainly fresh serum of GBS patients obtained during 
the active phase of the disease blocked nerve conduction in contrast to frozen serum or fresh 
serum obtained during the recovery phase.118 
Only selected animals could be used to study the pathogenic role of antibody transfer 
experiments, which may be related to an~nic differences or variation of the blood-nerve 
barrier in different animals. Heiniger et al.1 investigated marmoset monkeys and found that 
intramuscular injections of immunoglobulins or purified IgG from 5 CIDP patients responding 
to PE, resulted in a 24-42% reduction of the initial sciatic motor nerve conduction velocity 
(NCV). Significant reduction of NCV, was only observed with immunoglobulins from the 5 
patients responding to PE and not with serum from a non-responding patient. After the 
injections had been stopped, reduction of NCV was partially reversible. Although NCV 
decreased, muscle weakness and ultrastructural myelin changes were very mild. 
In conclusion, passive transfer demyelination experiments show results depending on the way 
of transmission and the species studied. Several investigators could find the presence of a 
myelinotoxic factor in serum which was affected by storage. The cytotoxic effect on myelin was 
mainly observed with serum derived from GBS patients in the acute stage of the disease. 
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Transfer experiments with lymphocytes from GBS (and CIDP) were not successful in 
transmission of the disease.90 
Cellular immunity 
Cellular immunity in vitro was evaluated by lymphocyte transformation tests (LTI) upon 
stimulation with nerve extracts, myelin basic protein (MBP) or the purified myelin P 2 protein. 
After exposure to peripheral nerve protein P 2> LTI's showed fcroliferation of peripheral blood 
lymphocytes (PEL) withdrawn in the active phase of GBS3• 04.218,277 or during the course of 
CIDP.151•177 Continued activity to peripheral nerve antigen was sometimes observed even several 
years after recovery of GBS/48 but others found loss of proliferation during recovery of GBS24 
or no stimulation at all of PEL's from CIDP or GBS patients after exposure to P2 or MBP.133,351 
LIT's also showed proliferation in the presence of an extract of peripheral nerve in 19 of 30 
(63%) GBS gatients58•105,203 and only in 1 of 14 (7%) from patients with a polyneuropathy of 
other origin. 
Evidence of cell-mediated immunity is mainly derived from animal models for GBS and CIDP. 
Experimental models for CIDP 
There are several animal models for inflammatory demyelinating polyneuropathies. 
Experimental allergic neuritis (EAN) represents the features of GBS.14,291 EAN can be produced 
in a number of species by injection with whole peri~heral nerve tissue homogenates,331 myelin, 284 
P 2 protein,35,259 pe_gtides of P 2, galactocerebroside 7 or by transfer of a P 2 specific T cell line 
upon Lewis rats.1 
If myelin is injected in animals to induce EAN, the antibodies that generally arise are directed 
against galactocerebroside.36 It was found that EAN rabbits treated with plasma exchange10'112 
developed less severe disease than controls. 
Chronic EAN as a model for CIDP could be induced in Lewis rats by inoculation of whole 
bovine dorsal root with Freund's complete adjuvant.57 New Zealand white rabbits, inoculated 
with a single dose purified bovine peripheral nerve myelin and Freund's adjuvant developed a 
chronic relapsing or progressive EAN with slowed nerve conduction velocity, reduction of the 
compound muscle action potential (CMAP), and onion bulb formation with signs of active 
demyelination.120 Recently, Harvey et al.122 investigated these New Zealand white rabbits and 
showed that plasma exchange using IgG immunoabsorption columns resulted in a significant 
beneficial, but shortlasting (2 days) clinical response. Infusion of rabbit fresh frozen plasma in 
these animals also resulted in clinical improvement.123 These findings in chronic EAN suggest 
at least an additional involvement of pathogenic antibodies. 
Leucocyte associated cytokines or ion-channel blocking agents have not been studied intensively 
in GBS of CIDP. In EAN rats it was shown that the K+ channel blocker quinidine caused a 
significant reduction in weakness and neural inflammatory infiltrate if it was injected 
simultaneously with the induction of EAN. Single injections had no effect. Therefore it was 
suggested that ion channel blocking agents may exert some immunomodulatory effect.212 
Recently it was shown that tumor necrosis factor (TNF) could play a role in the proces of 
demyelination.33.274 
IVIg treatment 
IVIg is effective in many autoimmune diseases. Different immunomodulato~ actions of IVIg 
have been demonstrated which may lead to immediate and long-term effects. 1 In autoimmune 
hematocytopenia's the increase of peripheral blood cell counts is attributed to the blocking5 
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or loss159 of Fe-receptors on mononuclear-phagocytic cells. Blocking of these receptors can be 
mediated~ dimers in IVIg,300 anti-HLA class I and II antibodies,220 and by anti-monocyte 
antibodies. Monocyte functions can also be blocked by binding of antibody coated red blood 
cells.18.= 
Other immediate effects of IVIg are the neutralization of pathogenic antibodies and circulating 
immune complexes.194 This was demonstrated in vivo and in vitro for anti F VIll-e antibodies 
by Sultan et al.293.294 In addition, there is evidence of IL-l inhibition by IVIg treatment.141 In 
patients with Kawasaki disease the beneficial effect of IVIg was associated with a reduced 
release of Il-l from the patients' monocytes.173 
Longterm effects induced by IVIg may occur by modulation of the cellular and humoral immune 
response. Such mechanisms 8' ~ supported by the observation that the serum IgM 
immunoglobulin level in the majt r of ITP patients significantly but transiently increased after 
IVIg treatment.136 A suppressive erfect of IVIg by interferem. with B cells was observed in 
vitro after pokeweed stimulation to induce antibod~ produc "i6 Interaction with idiotype 
specific B cells was found in vivo by Sultan et al. who dt. .... onstrated that anti-F VIll-e 
antibody activity disappeared and anti-idiotypic antibodies against F VIII antibodies increased 
after IVIg treatment. These results demonstrate that IVIg can exert improvement in 
autoimmune diseases by interference with cellular and humoral immune mechanisms as well as 
with release of cytokines. 
CONCLUSION 
The beneficial response to plasma exchange, the demonstration of anti-neural tissue antibodies, 
the demyelinating activity of patients' serum in purified cultures of Schwarm cells and dorsal 
root ganglions, together with results of passive transfer experiments in animals, suggest that a 
primary or secondary humoral immune-mediated response, resulting in complement activation 
and possibly antibody dependent cellular cytotoxicity (ADCC) is involved in the pathogenesis 
of the inflammatory demyelinating polyneuropathy. A role for primary cellular immunity leading 
to secondary antibody formation is not excluded. 
Westfall and Bernstein334 proposed a dual infection hypothesis for post-infectious neuropathies, 
in which a neuritogenic micro-organism and an infection which produces adjuvant material must 
act simultaneously to cause nerve damage. In the light of this dual antigen theory, the recent 
finding of circulating antibodies to glycosfingolipid (GSL) antigens in patients with GBS and 
CIDP is interesting because GSL are highly expressed on neural tissue and have shared antigens 
with many micro-organisms. Additional support for a dual antigen hypothesis was obtained from 
EAN induced by bovine P z, that was enhanced when P 2 was combined with bovine 
gangliosides. m These experiments may indicate that gangliosides can serve as natural adjuvant 
for the induction of inflammatory demyelinating polyneuropathies. 
The purpose of our study was to acquire insight in the mechanism of action by which IVIg 
therapy induces improvement in patients with CIDP. The availability of a clonal cell line (NBL 
108cc15) expressing antigens reacting with sera from CIDP patients allowed us to study the 
interaction of IVIg in vitro. 
42 
Chapter 5 
CLINICAL SIGNIFICANCE OF 
ANTIBODIES AGAINST 
PERIPHERAL NERVE TISSUE IN 
INFLAMMATORY POLYNEUROPATHY 
INTRODUCTION 
At least a proportion of patients with monophasic Guillain-Barre syndrome (GBS)302 and some 
patients with chronic inflammatory demyelinating polyneuropathy (CIDP)81 show a beneficial 
response to plasmapheresis. This might indicate that a subgroup of these inflammatory 
demyelinating polyneuropathies (IDP) are antibody-mediated disorders. Using various 
techniques, antibodies against peripheral nerve tissue (PNT) have been demonstrated in sera 
from GBS mients, esgecially during the first four weeks after onset of the neurological 
symptoms.15 ,sos,s13,s26,s However, some of these antibody assays are not specific for 
inflammatory polvneuropathies, as antibody activity was also detected in patients with other 
polyneuropathies.:;2'69'107'1~'163'181 '207'272 This suggests that antibodies may also occur as the result 
of nerve tissue damage exposing immunogenic structures. Vedeler et al.325 using a Mixed 
Hemagglutination Test (MHT) found antibodies against PNT in 6 of 11 GBS and in 5 of 7 
CIDP patients. Only patients with these antibodies responded to plasmapheresis. The antibodies 
detected by this technique apparently have a pathogenic role, but this MHT has not been 
investigated in extended populations of patients. We tested the sera of patients with various 
causes of polyneuropathy, of patients with neurological disorders other than polyneuropathy, of 
patients with immune-mediated diseases without nervous system complications and of healthy 
controls. We also investigated whether antibodies detected by the MHT are exclusively directed 
against PNT. In addition, we evaluated whether a positive test result predicts a beneficial 
response to treatment with intravenous immunoglobulin (Mg) in CIDP patients. 
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PATIENTS AND METHODS 
Mixed hemagglutination test (MHT) 
The MHT, described by T6ndero8 and Portanova243 was slightly modified. The procedure was 
as follows: 
a. Tissue 
Human post-mortem sciatic nerve, brain, liver, striated muscle and renal tissue was obtained 
within twelve hours of cardiac death in patients who had no evidence of other diseases. Pieces 
were snap frozen in liquid nitrogen and stored at -70°C until cryostat tissue sections were cut. 
No fixatives were used. 
b. Indicator system (EApA) 
The following cells and reagents were used. Sheep red blood cells (SRBC or E), rabbit anti-
SRBC antibodies (A) (Sera-lab, Sussex, England) and protein-A (pA) (Pharmacia, Woerden, 
the Netherlands). All incubations and washings were carried out at room temperature (20-
250C). All dilutions were performed with phosphate buffered saline (PBS) pH 7.2.10 ml1% 
washed SRBC was incubated with 1/4 of the agglutination titer of rabbit anti-SRBC (A) for 
30 min., thereafter the EA were washed. EA 1% were incubated with an excess of pA (50 
p.g/10 ml EA 1 %) for 30 min. and thereafter washed and resuspended to 0.75% EApA. . 
c. Incubation tissue section with serum dilutions 
Before testing, sera were heat inactivated for 30 min. at 56°C. Tissue sections were incubated 
in a moist chamber for 30 min. with 25 microliter of serum dilutions and subsequently 
carefully washed three times with excess PBS. 
d. Incubation with indicator system (EApA) 
± 0.5 ml EApA 0.75% was incubated with the presensitized tissue sections for 30 min. in a 
closed chamber allowing the EApA indicator system to sediment on the tissue section. The 
closed chamber was then carefully turned upside down to allow unbound EApA to sediment 
to the bottom of the glass w·ell. Microscopic evaluation of adsorbed EApA was performed 
after 30 min. 
e. Evaluation 
Scoring was performed with a light-microscope (magnification 10 x 40). The MHT assays 
were always read without knowledge of the diagnosis and without knowledge of the treatment 
response. The MHT was considered positive, in accordance with Vedeler,325 when distinct 
agglutinates could be identified on the tissue section using serum dilutions 1:16. 
Blocking studies 
Nerve tissue sections were pre-incubated for 30 min. with dilutions of purified heat-aggregated 
IgG immune complexes or sera containing high levels of Rheumatic Factor (IgG-IgM immune 
complexes). Subsequently the sections were washed and the MHT was carried out with patient 
or control sera as described above. 10 MHT positive and 10 MHT negative sera were tested. 
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Immune complex assays 
Circulating immune complex analysis 
was carried out with the 1251 Clq-
Binding Assay,349the IgM Polyethylene 
glycol (Peg), 19 and the IgA Peg 
Assay.317 
Patients 
Using the MHT, sera from the 
following patient groups were tested 
for the presence of antibodies against 
peripheral nerve tissue: Patients with 
inflammatory polyneuropathy, 
polyneuropathy of other causes, 
neurological disorders other than 
polyneuropathy, immune complex 
and/or antibody-mediated diseases 
without neurological complications and 
blood bank donors. 
"Inflammatory demyelinating 
polyneuropathy'' was defined as a 
sensorimotor polyneuropathy in the 
absence of diabetes, uremia, 
paraproteinemia, connective tissue 
disease, porphyria, heavy metal 
intoxication and malignancy. The 
family history had to be negative for 
hereditary polyneuropathy. We 
distinguished acute monophasic 
Guillain-Barre syndrome (GBS)14•15 
from Chronic and/ or Relapsing 
Inflammatory Dem(elinating 
Polyneuropathy (CIDP)." '79 In GBS 
the progression of weakness did not 
exceed four weeks, in CIDP the 
progression of weakness exceeded four 
weeks and/ or had a relapsing course. 
Sera were withdrawn during the active 
stage of the disease and in CIDP 
patients before treatment was started. 
Intravenous immunoglobulin (IVIg) 
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Table 1. Antibodies against human sciatic nerve tissue, 
demonstrated by the Mixed Hemagglutination Test(MHT) 
N 
patients 
Diagnosis tested 
Inflammatory Polyneuropathy 
GBS 
CIDP 
Total 
Polyneuropathy of other origin 
Diabetes 
Alcoholic 
lgG-benign gammopathy 
Paraneop I ast i c (Oat ce II) 
Borre I ia burgdorferi 
Unknown 
Total 
Neurological disorders, 
other than polyneuropathy 
Multiple Sclerosis 
Myasthenia Gravis 
Lambert-Eaton Syndrome 
Viral encephalitis 
Dystrophia Myotonica 
Amyotrophic Lateral Sclerosis 
Miscellaneous (headache, arm or 
back pain) 
Total 
Immune complex and/or antibody 
mediated diseases without 
n e u r o I o g i c a I c omp I i cat i on s 
Rheumatoid Arthritis 
Felty Syndrome 
lgA vasculitis 
Systemic Lupus Erythematodus 
Type II Cryoglobulinemia 
Goodpasture 
M. Wegener 
Multiple Myeloma 
Other paraproteinemia's 
Total 
16 
22 
38 
6 
4 
2 
1 
1 
19 
34 
5 
12 
1 
1 
1 
2 
10 
32 
9 
11 
2 
2 
1 
2 
1 
4 
7 
39 
No. 
patients 
with 
antibodies 
11 (6996) 
11 (50%) 
22 (58%) 
0 
0 
0 
0 
1 
0 
(396) 
0 
2 
1 
0 
0 
0 
0 
3 (996) 
1 
4 
0 
0 
0 
0 
0 
0 
0 
5 (1396) 
treatment Blood Bank donors 25 0 
21 patients with CIDP were treated 
with IVIg (human immunoglobulin, 90% monomeric IgG, for intravenous use, Central 
Laboratory Dutch Red Cross, Amsterdam): 0.4 gjkg body weight/ day for five consecutive days. 
All patients were in a stable or deteriorating neurological condition for at least eight weeks 
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before IVIg was administered. The patients had no immunosuppressive treatment before IVIg 
infusion was started. A positive treatment response was recorded when the patient's neurological 
condition improved within three weeks after the onset of treatment and a negative response 
when there was no change or deterioration. 
RESULTS 
Table 2. MHT against various tissues using sera from 
patients with an inflammatory demyelinating 
polyneuropathy. 
The MHT on sciatic nerve tissue was 
carried out with sera from 38 patients with N 
Test results 
Sciatic 
inflammatory polyneuropathy, 34 patients patients Nerve Brain Kidney Liver Muscle 
with other polyneuropathies, 32 patients 
with neurological disorders other than GBS 
polyneuropathy,39 patients with immune 3 
complex and/ or antibody mediated diseases ~ 
without neurological complications and 25 2 
healthy blood bank donors. The results are 4 
shown in Table 1. s 
In GBS patients with a positive test, the Tot a I 16 
median duration between the onset of the 
disease and the bloodsample withdrawal CIDP 
11 time was 3 weeks (range 0,5 - 27 weeks) 11 
versus 4 weeks (range 2 - 15 weeks) in 
patients with a negative test. 
In patients with a CIDP, this median time 
Tot a I 22 
+ 
+ 
+ 
+ 
+ 
11 
+ 
11 
+ 
4 
0 
was 9 months (range 1- 120 months) in +=positive; -=negative 
+ 
+ 
+ 
+ 
8 
0 
+ 
+ 
+ 
7 
0 
+ 
+ 
5 
0 
patients with a positive test and 24 months ------------------
(range 2 - 240 months) in patients with a negative test. These differences are not significant. 
Table 2 shows the results of the same hemagglutination technique with the sera from 38 patients 
with inflammatory polyneuropathy when tested against other tissues. None of the 22 patients 
with CIDP had positive reactions against brain, liver, kidney or striated muscle, neither had the 
five patients with GBS without antibodies against sciatic nerve. In contrast, 8 of 11 GBS sera 
that showed a positive MHT with sciatic nerve also had positive reactions with one or more 
other organ tissues. 
Blocking studies 
Blocking experiments were performed to investigate whether Fe- or C3-receptors present on 
peripheral nerve tissue played a role in the positive reactions with sera from patients with 
inflammatory polyneuropathy and in the positive reactions with sera from patients with Felty 
syndrome. Preincubation of PNT with purified aggregated IgG or with sera containing high 
levels IgG-IgM immune complexes (Rheumatoid Factor) neither changed the results of 10 
MHT positive GBS or CIDP sera nor the results of 10 negative sera (not shown). 
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Immune complex assays 
One of the 16 GBS sera and none of the 22 CIDP sera had circulating immune complexes as 
detected by the solid phase C1q-Binding assay, the IgM Polyethylene glycol (Peg) and the IgA 
Peg assay. 
Relation between MHT and response to Mg 
treatment 
Table 3. Relationship between antibodies 
against PNT and clinical response to IVIg 
treatment in 21 CIDP patients 
21 of 22 CIDP patients were treated with IVIg. Eight 
of these 21 patients have been described before?28 11 c 1 i n i c a 1 
response 
Antibodies against PNT 
Total patients had a beneficial response. The relationship t 0 1 v 1 g p 0 s i t i v e Neg at i v e 
between MHT results and the response to IVIg --------------
treatment is shown in Table 3. Sera of 7 MHT Pas it i ve 8 3 11 
positive CID P patients were retested after IVIg Neg a t i v e 2 8 1 0 
treatment. In patients who responded to treatment, _r_o t_a_1 ____ 1 o ____ 1_1 ____ 21_ 
the test was negative in 5 and weaker positive in 1 Fisher's exact p = 0.045 (2 sided) patient. The MHT results were unchanged in the 
remaining, non-responding patient. A significant 
relationship could be demonstrated between MHT results and IVIg treatment using Fisher exact 
't'-test. 
DISCUSSION 
Using a mixed hemagglutination test (MHT), antibodies against human peripheral nerve tissue 
were demonstrated in sera of 50% (11/22) of CIDP and in 69% (11/16) of GBS patients. We 
found 1 positive serum among 34 patients with a polyneuropathy of various other causes. This 
patient had a polyneuropathy caused by Lyme borreliosis (Bannwarth's Syndrome).231 In this 
disorder neuropathy is probably immune-mediated.262 The negative results in 33 patients indicate 
that the antibodies detected in the MHT are not a result of nerve damage. Three sera of a 
group of 32 patients without neuropathy showed a positive reaction; two patients with 
Myasthenia Gravis and one patient with Lambert-Eaton Syndrome. Antibodies against various 
tissues have been described previously in patients with Myasthenia Gravis192.265 or Lambert-
Eaton Syndrome.172 
Sera from patients with immune-mediated diseases without nervous system involvement were 
selected for the presence of circulating IgG, IgM and IgA immune complexes, anti-DNA 
antibodies, anti-HLA antibodies and antibodies against glomerular basement membrane. Four 
patients with Felty syndrome and one patient with Rheumatoid Arthritis showed a positive 
MHT. These positive reactions may be the result of the binding of the immune complexes to 
~or Fc-receptors present on PNT. To test this assumption, we preincubated the sciatic nerve 
sections with aggregated IgG or IgG-IgM immune complexes which should bind to such 
receptors. No positive MHT results occurred and there was no interference with the positive 
reactions of sera from patients with inflammatory polyneuropathy. Therefore, ~ or Fc-receptor 
structures on the human peripheral nerve appear not to be important for antibody binding in 
this assay. The positive MHT results in Felty syndrome or in Rheumatoid Arthritis are more 
likely caused by antibodies against the connective tissue of the nerve sections. The immune 
complex assays were positive in only 1 of 38 IDP sera. Therefore, it is unlikely that circulating 
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immune complexes play a role in the MHT results. The low percentage of sera containing 
immune complexes is in contrast with the results of some other studies that showed immune 
complexes in a higher. percentage of the patients with GBS.11,53,l05,296 An explanation may be that 
the meantime between the onset of the disease and the bloodsample withdrawal time was longer 
in our group of patients than in some other studies. 
In agreement with others180,207,262,263,3l3,335 we found antibodies against various other tissues in 
sera of some GBS patients. Reactivity with other tissues was neither seen in any of the CIDP 
patients nor in GBS patients who lacked antibodies against PNT, but were present in a high 
number (8/11) of GBS patients with antibodies against PNT. This reactivity with other tissues 
is difficult to explain. It is not invariably caused by immune complexes and it is a frequent 
finding in autoimmune diseases. 
A proportion of the patients with an inflammatory demyelinating polyneuropathy showed a 
negative MHT. An explanation could be that some false-negative reactions occurred because 
protein A mainly selects for the IgG subclasses IgG1, IgG2 and IgG4, which means that it is 
certainly not an optimal assay for the detection of IgG3, IgM and IgA antibodies. Another 
explanation may be that a different pathogenic mechanism causes nerve-damage in antibody-
negative patients, which may have consequences for the choice of therapy. 
Eleven of 21 patients with CIDP responded to intravenous gammaglobulin infusion. For three 
reasons we attribute the improvement to IVIg. Firstly, signs of improvement to IVIg were 
noticed within three weeks after the onset of treatment, while patients were in a stable or 
deteriorating condition at least 2 months prior to treatment. Secondly, the rapid increase in 
muscle strength contrasted with the more gradual increase which may occur during the natural 
course. Thirdly, patients deteriorated on average three weeks after the IVIg infusion and 
improvement could be achieved by re-institution of the IVIg infusions. However, the response 
to IVIg treatment has to be confirmed in a randomized clinical trial. Such a trial is in progress. 
It is likely that the same subgroup of patients with CIDP who will improve after plasmapheresis, 
removing pathogenic antibodies, will also respond to IVIg, interfering with the binding of 
antibodies with PNT. An in vitro assay demonstrating pathogenic antibodies would be useful for 
the selection of patients, who are likely to respond to treatment. We investigated whether there 
is a relationship between the presence of antibodies against PNT and the response to treatment 
with IVIg infusion in CIDP. Patients with a positive MHT responded significantly more often 
to this treatment than patients without antibodies against PNT. Moreover, after IVIg infusion, 
in 6 CIDP patients responding to IVIg treatment, the initial positive MHT became negative 
in 5 and weakly positive in the other patient. Antibodies remained positive in a non-responsive 
patient. These results suggest that the antibodies against PNT were neutralized by the infused 
IVIg in patients who improved after treatment. The relationship with treatment response 
suggests that antibodies against peripheral nerve tissue detected by means of the MHT, play a 
pathogenic role in CIDP. 
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INFLAMMATORY DEMYEliNATING 
POLYNEUROPATHY AND LYME BORRELIOSIS 
Serological similarity in anti-neuroblastoma cell line antibodies 
INTRODUCTION 
Inflammatory demyelinating polyneuropathies (IDP) can be distinguished in the Guillain-Barre 
syndrome (GBS) and the chronic inflammatory demyelinating polyneuropathy (CIDP).14'19 The 
etiology of IDP is unknown. Both cellular and humoral immune mechanisms have been 
demonstrated in these polyneuropathies.14'19.312 At least half of the GBS patients have a 
prodromal infectious episode one to three weeks before the onset of neurological symptoms.14 
An increased frequency of infections preceding CIDP198 has also been found. Therefore, IDP 
may be considered as a post-infectious immune-mediated disease. 
The beneficial effect of plasma exchange81,3°2 favours a pathogenic role of circulating antibodies. 
Furthermore, in tissue culture experiments, demyelination has been observed with serum from 
IDP patients in the absence of inflammatory cells or lymphocytes.28 The target (auto)antigen(s) 
involved in IDP are still unknown. Some possible antigenic target structures on nerve, such as 
P 1, P 2 
351 and galactocerebroside260 have been excluded, while antibodies reactive to fosfolipids, 
such as cardiolipin97 and glycosfingolipids: Forssman related neutral glycolipids153 and 
gangliosides135 have been demonstrated in some patients with IDP. 
Anti-neural tissue antibodies have been detected using various assays, such as. complement 
fixation/54 immunofluorescence/86,313 mixed hemagglutination,320,324 and ELISA163 with native 
human or bovine peripheral nerve or nerve extracts as antigen. Equivalents for neural tissue 
have also been applied for antibody detection. In a cytotoxicity assay, antibodies against anAjax-
C1300 mouse neuroblastoma (NBL) cell line were found in serum from patients with GBS and 
CIDP.256,305 Using an immunofluorescence assay (IF A), we found antibodies against the mouse-
rat hybrid neuroblastoma cell line (NBL) 108cc15 in serum from patients with GBS and 
CIDP?21 
In this study we evaluated the use of three neuroblastoma cell lines from different species, for 
the specificity and sensitivity of antibody detection in patients with various neuropathies. We 
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found that antibody reactivity in serum from patients with GBS, CIDP and Lyme neuro-
borreliosis was similar. 
There is growing evidence that neuropathy in Lyme borreliosis can be considered as an 
immune-mediated neuropathy due to cross-reactive antibodies against antigenic determinants 
present on Borrelia burgdorferi and human tissue.2.l03,279 Similarly, anti-neural antibodies in 
patients with IDP may cross-react with shared antigenic determinants on other micro-
organisms. We investigated whether the anti-NBL antibodies in patients with Lyme disease and 
IDP recognize the same or different structures on NBL-cells. 
PATIENTS AND METHODS 
Sera 
Sera were obtained from 71 patients with GBS during acute stage of disease (median 1 week 
from onset), 57 patients with CIDP during active phase of disease and before treatment was 
started, 23 patients with Lyme neuro-borreliosis (anti-Borrelia burgdorferi IFA > 1:120), 6 
patients with erythema chronicum migrans (ECM) without neurological signs or symptoms, 68 
patients with various other polyneuropathies, 97 patients with other neurological or immune-
mediated diseases and 40 healthy individuals. All sera were stored at -30°C until tested. 
Neuroblastoma cell lines (NBL) 
The mouse neuroblastoma-rat glioma 108cc15 cell line was provided by Prof B Hamprecht, 
Physiological Chemical Institute, University Tiibingen, FRG.116 The mouse NBL cell line 
N1E115, was provided by dr H Vijverberg, dept Veterinary physiology, pharmacology and 
toxicology, State University Utrecht, the Netherlands.8 The human NBL cell line CHP 212 was 
provided by dr AE Evans, div Oncology, the Children's Hospital of Philadelphia, Pennsylvania, 
USA.347 All NBL cell lines were cultured in Dulbecco's modified Eagle's medium with 10% 
fetal calf serum at 37°C, 5% C02• 
Neuroblastoma immunofluorescence assay (NBL-IFA) 
The NBL-IFA has been described in detail previously.321 In short: 0.5 X 10mL cells were 
incubated with 50 microliter patient serum or mouse monoclonal antibodies. After washings, the 
resuspended pellet was incubated with goat anti-human-IgG or IgM FITC and with rabbit anti-
mouse Ig FITC, respectively. After washings, the NBL cells were resuspended in glycerol and 
examined on a microscope slide, using an IF microscope. Two hundred cells were counted, a 
percentage of > 20% IF stained cells was considered as a positive test result. 
Absorptions with 108cc15 and N1E115 cell lines 
One volume of serum was incubated for 1 hour at room temperature with an equal volume of 
a washed dry pellet NBL cells, while periodically resuspended. The mixture was then centrifuged 
for 10 min at 1800 x g; the supernatant was collected and stored at -30°C without addition of 
conservatives. 
Borrelia burgdorferi (Bb)-IFA 
Strain B31 was used in the Bb-IFA.286 The test was considered "positive" if immunofluorescence 
was obtained with serum diluted 1:120 or more. 
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Borrelia burgdorferi Western Blot analysis 
Western Blot anal7ssis was performed according to the protocol of Kolk et al.149 with the German 
skin-isolate PKo.3 8 The spirochetes were sonificated, centrifuged and the cell-wall fraction was 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Patients' sera were 
diluted 1:200. 
Monoclonal antibodies (MoAb) against Borrelia burgdorferi 
The MoAb H5332 and H9724 were kindly provided by DrAG Barbour, Div Infectious diseases, 
dept Medicine, University of Texas, USA. H5332 is specific for the OspA protein (30-32k~ 
of Borrelia burgdorferi, 20 but it does not react with all European Borrelia burgdorferi isolates. 
H9724 is specific for the ( 41kd) flagellin protein of all Borrelia species.21 These MoAb were 
tested in the NBL 108cc15-IFA, using rabbit anti-mouse Ig-FITC. 
Absorption with Borrelia burgdorferi 
Spirochetes were isolated from the cerebrospinal fluid of a Dutch patient with Lyme neuro-
borreliosis (strain A01CSF)?85 Serum from this patient was absorbed with her Borrelia 
bur&dorferi isolate (H9724 positive and H5332 negative) according to the protocol of Shigal et 
al. The same procedure was performed using serum from a patient with CIDP. 
Detection of antibodies against glycosfingolipids 
Round bottom polyvinyl plates were coated with 50 microliter of either a crude ganglioside 
mixture ( 40 microgram/ml) or with a mixture of neutral glycolipids (10 microgram/ml) 
containing ceramide hexoside, ceramide dehexoside, ceramide trihexoside, globoside and 
Forssman glycolipids (Biocarb) dissolved in methanol, for 2 hours at room temperature. After 
drying, the plates were incubated at room temperature for 30 min with 200 microliter· PBS 
containing 1% gelatine and washed with PBS. Serial dilutions of patient's sera were incubated 
for 2 hours at room temperature. After washings with PBS/Tween 0,02%, 50 microliter of 
optimal dilutions of peroxidase labeled rat -anti-human Ig (1:2000), IgG (1:2000) or lgM (1:1000) 
antibodies (Dakopatts) were incubated overnight at 4°C. Between each incubation step all 
washings were very extensive. The enzyme reaction was developed for 30 min. at room 
temperature using a-phenylenediamine (Sigma) as a substrate. The reaction was stopped by 
adding sodium dodecyl sulphate 10% (Sigma). The optical density was subsequently measured 
at 450nm. 
RESULTS 
The results of the NBL-IFA are shown in Table 1. Antibodies against the NBL 108cc15 cell line 
were found in 48% of the patients with an IDP, in 52% of the patients with Lyme neuro-
borreliosis, and in 7% of the patients with a polyneuropathy of other origin, other neurological 
diseases or other immunological disorders. Patients and healthy individuals with a negative test 
result had a mean percentage of 2 (0-15%) IF positive 108cc15 cells. 
The human cell line CHP 212 gave positive test results in 3/68 (4%) of patients with IDP, in 
2/5 multiple sclerosis patients and in 3/12 of myasthenia gravis patients, whereas all other sera 
were negative. 
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The large number of positive IF A 
results with both the 108cc15 and 
NlE115 cell line was similar for 
GBS, CIDP and Lyme borreliosis 
Table 1. IgG andfor IgM Antibodies against neuroblastoma (NBL) cell 
lines in serum from patients with an inflammatory demyelinating 
polyneuropathy, Lyme borreliosis and various controls 
patients. However, the number of 0 is ease Positive Test Results 
108cc15-IFA N1E115-IFA CHP212-IFA 
no./N % no./N % no./N % sera from patients with other diseases that showed positive 
Inflammatory 
demyelinating 
GBS 
ClOP 
NBL-IFA reactions was much 
higher with the NlE115 than with 
the 108cc15 cell line. Almost all 
sera showing 108cc15-IFA 
antibodies were also positive in 
h Lyme neuro-t e N1E115-IFA. borrel iosis 
Absorption experiments with 
pnp 
61/128 48 
31/71 44 
30/57 53 
12/23 52 
44/78 56 
25/43 58 
19/35 54 
15/22 68 
3/68 
1/34 
2/34 
0/22 
4 
3 
6 
0 
serum from CIDP patients 
showed that the NlE115 cell line 
absorbs the anti-108cc15 
antibodies while the 108cc15 cell 
line removes the N1E115 
PNP other origin 
diabetes, alcohol 
paraprotein 
miscellaneous 
5/68 7 
0/12 0 
2/14 14 
3/42 7 
17/44 39 
0/8 0 
5/9 56 
12/27 44 
0/30 
0/10 
0/4 
0/16 
0 
0 
0 
0 
antibodies. These cross- Other neurological disorders 
4/56 11/46 24 5/35 14 7 
absorptions were not extended to 
Non-neurological 
immune mediated 
disorders 
3/41 7 8/33 24 0/33 0 other non-polyneuropathy patient 
groups which had more 
discrepancies in NBL-IF A results 
between the two cell lines. 
All sera were tested separately Healthy individuals 0/40 0 1125 4 0/25 0 
for the presence of IgG and IgM 
anti-NBL antibodies. In all groups of patients, anti-NBL antibodies were more frequently of the 
Table 2. Anti-Borrelia burgdorferi and anti-NBL antibodies 
in serum from a Lyme and a CIDP patient before and after 
absorption with Bb and NBL. 
NBL 108cc15-IFA 
Lyme ClOP 
before 1: 4 1: 128 
absorption 
after neg 1: 4 
absorption Bb 
after neg neg 
absorption NBL 
Sorrel ia 
burgdorfer i -IF A 
Lyme ClOP 
1: 128 neg 
neg neg 
1: 128 neg 
Values are given in titers which represents the highest 
dilution that gives a positive test result 
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lgM than of the IgG immunoglobulin 
class. 
Serum from patients with Lyme neuro-
borreliosis was sampled between 1 and 39 
months from onset of disease (median 10 
months). Differences in NBL-IFA results 
were not related to time lapse from onset 
of Lyme borreliosis and serum sampling 
date. Furthermore, no relationship was 
found between severity of clinical signs 
and symptoms in patients with Lyme 
neuro-borreliosis and the presence of anti-
NBL antibodies. The pattern of NBL-
IF A reactivity in serum from patients with 
Lyme neuro-borreliosis was surprisingly 
similar to that of patients with GBS or 
CIDP. In order to evaluate whether anti-
NBL antibodies in Lyme borreliosis were 
related to the neuropathy, we included 6 
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patients with erythema chronicum migrans (ECM). Although these ECM patients did not 
develop neurological symptoms during a follow-up period of 6-18 months (median 6 months) 
from onset of disease, anti-108cc15 antibodies were found in 3 out of 6 sera. 
We subsequently investigated if the reaction of GBS and CIDP sera with the NBL 108ccis could 
be explained by the presence of anti-Borrelia burgdorferi (Bb) antibodies. Sera from twenty 
randomly chosen GBS/CIDP patients (10 with, and 10 without anti-NBL 108cc15 antibodies) 
had a negative Bb-IFA (titer <1:20). The MoAb's H5332 and H9724 were negative in the NBL 
108cc15-IFA, whereas the Bb spirochetes used for absorption experiments were H9724 positive 
and H5332 negative. 
Serum from a Lyme neuro-borreliosis patient was absorbed with Bb, this resulted in a removal 
of anti-Bb and anti-NBL antibodies (Table 2). Absorption of this serum with NBL 108cc15 
removed anti-NBL antibodies, whereas anti-Bb antibodies activity remained present both 
detected in the Bb-IFA and the Bb Western Blotting analysis. Borrelia burgdorferi also removed 
anti-NBL reactivity from the serum of a CIDP patient (Table 2). 
Figure 1. Anti-neutral glycolipid (A) and anti-ganglioside (B) antibodies in serum of a CJDP patien~ before and after 
absorption with neuroblastoma cell line (NBL) 108cc15 and Borrelia burgdorferi. 
A anti-neutral glycolipid antibodies 8 in serum of ClOP patient 
absorption at 450 nm 
anti-ganglioside antibodies 
in serum of ClOP patient 
absorption at 450 nm 
1.4,---~-------·-----, 
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0 absorption on Borrelia burgdorferi 
X absorption on neuroblastoma 108cc15 cell line 
Anti-glycosfingolipid antibodies present in the serum of this CIDP patient were removed after 
absorption with Bb and NBL 108cc15 (Figure 1, A and B). The antibodies against neutral 
53 
glycolipids were preferentially removed by absorption with NBL 108cc15 and Borrelia 
burgdorferi. 
DISCUSSION 
The pattern of antibody reactivity in sera from patients with GBS, CIDP and Lyme neuro-
borreliosis was similar for all 3 NBL cell lines tested. The NBL N1E115 cell line showed 
reactivity with sera from patients with various disorders, whereas the CHP212 mainly showed 
reactivity with sera from patients with myasthenia gravis and multiple sclerosis. The NBL 
108cc15-IFA showed a high percentage of positive reactions with sera from GBS, CIDP and 
Lyme borreliosis patients. 
Using a radio-immunoassay, Miiller et al.217 demonstrated that 44 out of109 (40%) myasthenia 
gravis patients had circulating antibodies against the human NBL cell line SH-SY5Y. The 
differences with our results are likely the result of variation in the antigen expression on the 
NBL cell lines tested. 
The reactivity patterns between the NBL-108cc15 and NIE115 cell line suggest sharing of at 
least one antigen. Cross-absorption studies with these cell lines indicate that IDP sera recognize 
the same antigen( s) on both cell lines. Whether the N1E115 cell line expresses an epitope not 
present on 108cc15 resulting in reactivity with non-IDP sera was not further investigated. 
In Lyme borreliosis, antibodies against central262,292 and peripheral2.Z79,320 nervous tissue have 
been demonstrated. The neuropathy in ~e borreliosis can be caused by axonal disturbances318 
which can be the result of vasculitis, but there are also signs of demyelination in this 
disease106,289 and improvement of peripheral nerve conduction velocity was observed following 
penicillin treatment.114 The anti-flagellin (41kd) antibody cross-reacts with axons,Z79 myelin and 
CNS tissuez.103 as well as with synovia and heart muscle cells.2 Since anti-flagellin antibodies 
can be demonstrated in nearly all patients with Lyme borreliosis, other factors must contribute 
alone or together with anti-flagellin antibodies to cause tissue damage. The negative NBL-IFA 
with the anti-flagellin Moab H9724 combined with the Bb-IFA results with serum from 20 
GBS/CIDP patients excludes the flagellin protein as the target for the cross-reactive antibodies 
in IDP and Lyme borreliosis patients. 
In Lyme borreliosis, polyclonal B cell activationZ78,339 and cellular immunity to several host 
antigens has been demonstrated.193 The NBL antibodies we encountered in both Lyme and IDP 
patients could indeed be the result of polyclonal B cell activation caused by Borrelia burgdorferi 
and by infections preceding the manifestations of IDP. However, Borrelia burgdorferi absorbed 
the anti-NBL antibodies both from serum of a Lyme neuro-borreliosis and a CIDP patient. This 
rather points towards an antigenic relationship between NBL antigens, Bb and presumed 
infectious agents preceding IDP and it argues against non-specific B cell activation. 
The finding that CIDP sera were only low-reactive in the Bb-IFA while Bb absorbed anti-
NBL activity from CIDP serum is compatible with a very low antigenic expression resulting in 
negative serology although there is still a possibility for absorption of antibodies. The 
observation that the anti-Bb antibodies were not removed by absorption with NBL 108cc15 
cells, suggests that the shared epitope may not be one of the proteins contributing to Bb-IFA 
or Bb-Western blotting. We therefore investigated whether other antigenic structures could 
explain the results. Patients with IDP but also patients with other immune-mediated diseases 
may have antibodies against glycosfingolipids (GSL).248 These GSL's are present in many- e.g. 
54 
Chapter 6 
neural - tissues and can be divided in glycolipids and in the sialic acid containing gangliosides. 
Western-blot analysis is not a proper assay for the detection of anti-GSL antibodies which may 
explain our Western-Blot results. 
The serum from the CIDP patient indeed showed antibodies to various glycosfingolipids (GSL) 
and we found that anti-GSL antibodies were absorbed by both Bb and the NBL 108cc15 cell 
line. 
Antibodies against GSL epitopes may be induced by a spectrum of micro-organisms that 
stimulate cross-reactive antibodies to host-related antigens. Whether such antibodies have any 
relationship with the pathogenesis of CIDP is unknown, but the presence of anti-NBL antibodies 
in patients with Lyme borreliosis without polyneuropathy may argue against a pathogenic role. 
We conclude that serological similarities between GBS, CIDP and Lyme borreliosis exist and 
we suggest that the neuroblastoma 108cc15-IF A may identify a group of post -infectious immune-
mediated polyneuropathies from polyneuropathies due to another origin. 
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ANTI-NEUROBLASTOMA CELL LINE 
ANTIBODIES IN INFLAMMATORY 
DEMYELINATING POLYNEUROPATHY 
Inhibition - in vitro and in vivo - by intravenous immunoglobulin 
INTRODUCTION 
The Guillain-Barre syndrome (GBS)15 and the chronic inflammatory demyelinating 
polyneuropathy (CIDPf4 are considered to be immunologically mediated disorders of the 
peripheral nervous system. The successful treatment by plasmapheresis of some patients with 
GBS or CIDP suggests that circulating anti-nerve antibodies might be of importance. Several 
assays are available to detect antibodies against neural determinants in sera from patients with 
GBS and CIDP. 
We recently studied the occurrence of antibodies in GBS and CIDP, using a mixed 
hemagglutination test (MHT) against tissue sections of sciatic nerve as originally described by 
Vedeler?24 The MHT detected antibodies in about 50% of the patients with GBS and CIDP, 
whereas positive test results were rarely observed in sera from patients with other 
polyneuropathies or other disorders.320 In CIDP patients, these antibodies disappeared or 
decreased after intravenous immunoglobulin (IVIg) treatment. Patients showing these antibodies 
in pretreatment serum samples more often improved after IVIg. These results suggest that 
antibodies detected with the MHT are of pathogenetic significance. To study the in vitro 
interaction of IVIg and antibodies atPainst nerve tissue, the MHT is not a suitable technique. 
Rosenberg et al.256 and Miiller et al.21 demonstrated antibodies against a neuroblastoma cell line 
(NBL) in sera from patients with various neurological diseases. Since a technique using cells 
instead of tissue-sections would enable us to study the interaction between IVIg and antibodies 
in sera from patients with CIDP, we investigated if antibodies against neuroblastoma cell lines 
can be detected in sera of these patients. Using an immunofluorescence assay (IFA) we found 
antibodies against three neuroblastoma cell lines (CHP 212, NlE 115 and 108cc15) in patients 
with GBS or CIDP. The 108cc15 appeared to be the most specific cell line. 
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The aims of this study were to compare NBL-IFA (108cc15) and MHT in terms of sensitivity 
and specificity and to investigate the in vivo and in vitro interaction of IVIg with antibodies 
detected by this IF A. 
PATIENTS AND METHODS 
Sera 
Sera were obtained from 48 patients with GBS and 42 patients with CIDP. The diagnosis of 
GBS15 and of CIDP74 was made by clinical criteria. Sera from patients with GBS were sampled 
within a median period of 1 week of onset of the neurological symptoms and in patients with 
CIDP during an active phase of the disease. Sera from 43 patients with a polyneuropathy of 
other or unknown causes and 46 sera from patients with various neurological diseases without 
polyneuropathy were used as controls. Finally, sera from 39 patients with non-neurological 
immune-mediated diseases (rheumatoid arthritis N = 9, Felty syndrome N = 11, vasculitis N = 1, 
SLE N =2, cryoglobulinemia N = 1, Wegener's granulomatosis N = 1, Goodpasture N =2, multiple 
myeloma N = 5, other dysproteinemia's N = 7) and 40 healthy bloodbank donors were tested. All 
sera were heat-inactivated for 30 minutes at 56°C before use. The sera were numbered and the 
technician who performed the tests did not know the diagnosis of the patients. 
The mixed hemagglutination test (MHT) 
The MHT was carried out as described before.320 
Neuroblastoma cell line (NBL) 
The rat-mouse NBL cell line 108cc15116 was kindly provided by Prof B Hamprecht, 
Physiological-chemical Institute University Tiibingen, Western Germany. The cell line is cultured 
in Dulbecco's Modified Eagles Medium (DMEM) with 10% fetal calf serum (FCS) at 37°C 5% 
C02• 
Neuroblastoma cell line immunofluorescence assay (NBL-IFA) 
0.5 x 106 NBL cells were incubated with 50 microliter serum for 90 minutes at 4°C (for the 
optimal detection of IgM-antibodies) and 60 minutes at 22°C (for the optimal detection oflgG-
antibodies). After incubation, the cells were washed two times in phosphate buffered saline 
(PBS-BSA 1%, pH 7,4) and the pellet was resuspended to a concentration of 0,5 x 106 NBL 
cells/100 microliter and incubated with goat anti-human IgG for 30 minutes at 22°C (Go-anti-
Hu IgG-FITC, Nordic, Tilburg, the Netherlands) or 45 minutes at 4°C with goat anti-human 
IgM (Go-anti- Hu IgM-FITC, Nordic). 
The antisera were diluted in PBS (anti-Hu IgG 1:7, anti-Hu IgM 1:9). After washing in PBS 
three times, the cells were mounted in glycerol and examined with a Leitz IF microscope (8x63) 
with a 495 nm excitation and a 525 nm filter. The proportion of fluorescent cells of 200 counted 
cells is determined and expressed as a percentage. A percentage of > 20% IF stained cells was 
considered as a positive test result (Figure 1). 
Absorption studies 
100 microliter serum was incubated for 5 hrs with 20 x 106 NBL 108cc15 cells at 22°C, while 
periodically resuspended, then centrifuged for 10 minutes at 1800 x g and the supernatant was 
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harvested. The supernatant was absorbed once more with 20 x 106 fresh NBL cells. After 
absorption the serum was diluted with PBS to the same protein concentration as the pre-
absorption serum. All the sera became negative in the NBL-108cc15 IF A after one or two 
absorptions. 
In vitro-incubation with intravenous immunoglobnlin 
This was assayed with a CIDP serum containing IgM-anti NBL 108cc15 antibodies. IVIg was 
diluted to a 6% solution in distilled water. Fifty microliter of different serum/Mg solution 
ratio's (range 0.1-0.9) was incubated with 1 x 106 NBL 108cc15 cells for 90 minutes at 4°C.After 
washing (2 times in PBS-BSA 1%) the 
cells were incubated for 45 minutes Table 1. Comparison of MHT and NBL 108cc15-IFA 
Goat-anti-human IgM (1:9). Then the 
cells were washed again and read as 
described above. The results are 
expressed as % IF stained NBL 
108cc15 cells. 
Incubations were also performed and 
compared to serum/PBS dilutions 
(range 0.1-0.9). 
Immnne complex assays 
Rheumatoid factor was analyzed, using 
an Elisa assay, in serum of 37 GBS or 
CIDP patients who had a positive MHT 
and/or NBL 108cc15-IFA. 
Circulating immune complex analysis 
was carried out in sera from 40 CIDP 
or GBS patients (29/40 sera showed a 
positive MHT and/or NBL-IFA) using 
the 1251 C1q-Binding Assay,349 the IgM 
Polyethylene glycol (peg)19 and the IgA 
Peg Assay.317 
RESULTS 
Sensitivity and specifity of the NBL-
IFA 
The comparison of the antibodies 
detected with two techniques, the MHT 
and the NBL-IFA, is shown in the 
MHT 
pos 
no. 
N 
Disease sera 
Inflammatory polyneuropathy 
GBS 48 23 
CJDP 42 17 
total 90 40 
Other polyneuropathies 
diabetes 6 0 
alcohol 4 0 
paraprotein 5 0 
miscellaneous 28 2 
total 43 2 
Other neurological disorders 
multiple sclerosis 6 0 
myasthenia gravis 12 2 
Lambert-Eaton 2 1 
Amyotrophic Lateral 
Sclerosis 5 0 
miscellaneous 21 0 
total 46 3 
Non-neurological, immune-mediated 
rheumatoid arthritis 
or Felty syndrome 20 
mi see II aneous 19 
total 39 
5 
0 
5 
Table 1. Antibodies against the NBL B I o o db an k donors 
cell line 108cc15 (IgG, IgM or both) 
40 0 
were present in 20/48 (42%) of the 
NBL 
JgG 
pos 
no. 
6 
8 
14 
0 
0 
0 
0 
1 
0 
0 
1 
2 
108cc15-IFA 
JgM JgG 
pos and/or 
no. I gM 
17 
12 
29 
0 
0 
0 
3 
3 
0 
1 
0 
0 
2 
3 
pos 
no. 
20 
18 
38 
0 
0 
0 
3 
3 
0 
1 
0 
0 
2 
3 
disorders 
1 
0 
1 
0 
0 
0 
0 
0 
0 
1 
0 
patients with GBS and in 18/42 (43%) of the patients with CIDP. Three of 43 patients with 
polyneuropathy of other causes showed antibodies against this NBL cell line. These were: one 
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patient with Non-Hodgkin 
Lymphoma, one patient with Systemic 
Lupus Erythematosus and one patient 
with polyneuropathy of unknown 
origin. One of the 12 patients with 
myasthenia gravis and two of 34 
patients with other neurological 
diseases showed positive reactions 
with the NBL 108cc15 cell line, these 
were a patient with amyotrophic 
plexus neuritis and one patient with 
dementia and an oatcell carcinoma. 
Of 39 patients with various immune-
mediated disorders one patient with 
Felty disease showed a positive test. 
Normal donors had a mean 
fluorescence of 4% cells (Figure 1). 
Immunoglobulin class and immune 
complexes 
The majority of the antibodies against 
the 108cc15 cell line in patients with 
GBS or CIDP were of the IgM class 
only (n=24), 3 patients with GBS and 
2 with CIDP showed both IgM and 
IgG antibodies and 3 of the patients 
with GBS and 6 of the CIDP patients 
showed IgG antibodies alone. 
There was no difference between 
GBS and CIDP patients in respect of 
the antibody class distribution. 
One of the 17 tested GBS, (14/17 
showed a positive MHT and/ or NBL-
IFA), and none of 23 tested CIDP 
sera, (15 /23 showed a positive MHT 
Figure 1. Antibodies against NBL 10&cl5 eel/line in inflammatory 
demyelinating polyneuropathy and control sera. 
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diseases 
no 39 
bloodbank 
donors 
n=40 
and/or NBL-IFA), had circulating immune complexes as detected by the solid phase C1q-
Binding assay, the IgM Peg or the IgA Peg assay. Rheumatoid factor (Rf) was analyzed in the 
37 GBS or CIDP patients with a positive MHT and/or NBL-IFA Sixteen patients had weakly 
positive (n=4) or positive (n=12) Rf activity (IgG, IgM and/or IgA). Seven patients had 
IgM.Rf, 3 IgG.Rf and 6 IgA.Rf. Of the 20 patients with IgM-NBL antibodies 4 had a positive 
IgM.Rf. 
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Relation between MHT and NBL 
techniques 
In these 90 patients with GBS or 
CIDP, 40 had a positive MHT, 38 a 
positive NBL-IF A and 23 patients 
had both a positive MHT and a 
positive NBL-IFA. To investigate if 
the NBL line expresses antigens 
present on human sciatic nerve, sera 
from 13/23 patients who had both a 
positive MHT and NBL-IFA were 
absorbed with excess NBL 108cc15 
cells. Three patients sera showed a 
negative MHT after absorption of the 
NBL antibodies with the NBL 
108cc15 cell line, 6 patients showed a 
clear decrease in agglutinates against 
the sciatic nerve compared with the 
unabsorbed serum but remained 
positive in the MHT and 4 sera 
showed an unchanged MHT before 
and after absorption with the NBL 
108cc15. 
Relation between NBL antibodies 
and clinical response to Mg 
The relation between antibodies 
Chapter 7 
Figure 2. Antibodies against NBL 108cc15 cell line (NBL-IFA) using 
different serumjiVIg ratio's. 
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against the NBL 108cc15 cell line and o . 1 o . 2 o . 3 o . 4 o . 5 o . 6 o . 7 o. 8 m 1 
the clinical response to IVIg was 
investigated in 10 CIDP patients who c 1 DP serum 
had NBL-IFA antibodies in 
pretreatment serum samples. After 8=1VIg+CIDP serum 
IVIg treatment 7/10 patients o =PBS+C I DP serum 
improved. All these 7 patients 
became NBL-IFA negative. Three patients did not improve: one became NBL-IFA antibody 
negative and 2 had persisting NBL-IF A antibodies. 
In vitro interaction between Mg and NBL-antibodies 
The in vitro interaction between IVIg and NBL 108cc15-IF A antibodies was studied with serum 
from a patient with a CIDP who responded to IVIg treatment. As can be seen (Figure 2) there 
is an optimal range of IgG-concentration showing maximal inhibition whereas despite increasing 
the concentration of IgG, the degree of inhibition is less. 
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DISCUSSION 
Using an immunofluorescence assay, antibodies against the neuroblastoma (NBL) cell line 
108cc15 were detected in 42% of sera from patients with GBS or CIDP whereas these 
antibodies were found in 5% of sera from patients with other disorders and in none of the 40 
bloodbank donors. Antibodies against peripheral nerve tissue (MHT) were detected in 44% of 
the GBS or CIDP patients, in 8% of sera from patients with other disorders and in none of the 
bloodbank donors. After absorption the NBL 108cc15 cell line removed anti-sciatic nerve 
activity from 9 of the 13 GBS or CIDP sera. 
These absorption studies and the number of concordant and discordant reactions when both 
techniques are compared suggest that there is a partial sharing of antigenic determinants 
relevant for inflammatory demyelinating polyneuropathy on the NBL 108cc15 cell line and 
human sciatic nerve. 
The MHT and the NBL 108cc15-IFA detect antibodies in 42-44% of the patients with 
inflammatory demyelinating polyneuropathy whereas 61% of the patients show antibodies in 
one of the two assays, and 26% of the patients are positive in both assays. Although both assays 
have a low percentage of positive reactions in polyneuropathies of other origin and in other 
neurological diseases, the pathogenic role of the antibodies described is still speculative and an 
epiphenomenon is not excluded. The observation that antibodies detected with both techniques 
become undetectable or considerably decrease in titer in patients improving after IVIg is 
suggestive for pathogenic antibodies. This raises the question whether patients with 
'seronegative' inflammatory polyneuropathy have antibodies of higher avidity resulting in non-
detectable free serum antibodies or have polyneuropathy due to a different pathogenesis for 
instance cell mediated immunity. 
A beneficial effect of IVIg has been reported in disorders such as autoimmune 
thrombocytopenia39•136 autoimmune leukocytopenia, 237 acquired factor Vlli deficienc~,294,34s and 
myasthenia gravis.89•102,140 These presumably antibody mediated diseases have in common a 
variable response to corticosteroids, alkylating immunosuppressive drugs and temporary 
improvement on plasma exchange. Recently a beneficial response to IVIg has also been 
observed in CIDP patients,6,so,328 which is now investigated in an randomized controlled clinical 
trial. 
The mechanism of the beneficial effect of IVIg is unknown. IVIg blocks Fc-receptor mediated 
immunological functions. This mechanism may play a role in CIDP, as macrophages have been 
demonstrated in nerve biopsies of these patients. Blockade of these cells might prevent the 
cytopathological effect of anti-neural antibodies mediated by macrophages. The decrease of the 
anti-NBL antibodies after IVIg treatment suggests a different mechanism. In chronic idiopathic 
thrombocytopenic pur&ura it has been shown that after IVIg, con A induced antibody 
production diminishes. Although such an effect could explain the decrease of antibodies in 
CIDP patients improving after IVIg, an alternative mechanism is that IgG binds to and 
neutralizes auto-antibodies. This was demonstrated by Sultan et al.294 for acquired anti-F Vlli 
antibodies. In in vitro experiments, they demonstrated that there was an optimal range for the 
inhibition of anti-F Vlli antibodies by IVIg. 
In this study the in vitro effect of IVIg was investigated with serum from a CIDP patient with 
high titred IgM-anti NBL antibodies. These antibodies were significantly inhibited when a 
certain amount of IVIg was added. The prozone effect in these in vitro experiments, which 
was also found by Sultan et al.294 suggests that it is an interaction between antibodies. Further 
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studies are needed to test the hypothesis that IVIg contains anti-idiotypic antibodies reacting 
with pathogenic auto-antibodies in patients with inflammatory demyelinating polyneuropathy. 
In these studies an immunofluorescence assay to demonstrate NBL 108cc15 antibodies, which 
are rather specific for this polyneuropathy and which disappear in patients improving after IVIg, 
may be a useful technique. 
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Chapter 8 
HLA ANTIGENS IN PATIENTS WITH 
CHRONIC INFLAMMATORY 
DEMYELINATING POLYNEUROPATHY 
INTRODUCTION 
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a clinically heterogenous 
disorder.23 Clinical trials have shown that patients with CIDP can be treated successfully with 
prednisone,77 plasma exchange81 and intravenous immunoglobulin (IVIg)?22 However, not all 
of the patients respond to one of these different methods of treatment. The variability in clinical 
response may have a genetic component. HLA typing in patients with Guillain-Barre syndrome 
(GBS) did not reveal any si~cant differences between HLA antigen frequencies in GBS 
patients and in controls.4'164' 43.342,290 However, Winer et al.342 reported that HLA-DR2 was 
significantly increased in 12 GBS patients with most profound muscle weakness compared with 
77 other GBS patients studied. 
Stewart et al.29 tested 16 patients with a chronic relapsing polyneuropathy and 8 patients with 
a subacute polyneuropathy (which could be distinguished from GBS) and found an association 
with HLA-A30/31 and also with HLA-B8 and DR3. Adams et al.4 suggested an association 
with HLA-A1, B8 and DR3 by testing 14 CIDP patients. 
Recently Feeney et al.94 found increased frequencies of HLA-A3 and B7 in a group of 71 CIDP 
patients. In the 56 CIDP patients who were typed for HLA-DR, they found that HLA-DR2 was 
increased. Although none of these findings reached statistical significance after correction for 
the number of tested antigens, it was suggested that CIDP might be associated with the HLA-
DR2 antigen. 
The aims of our study concerning a group of 52 CIDP patients were to investigate firstly, 
whether there are significant associations with any of the HLA-A, B, C, DR or DO antigens 
and if so, do they confirm the results of other studies; secondly, if there is a relationship 
between improvement after high-dose IVIg and HLA antigens; and thirdly, if the presence of 
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anti-neural tissue antibodies is associated with certain HLA antigens or with improvement after 
IVIg. 
PATIENTS AND METHODS 
Patients 
All of the 52 patients included in this stud~ were judged to have a CIDP and fulfilled the 
diagnostic criteria outlined by Dyck et al.: (1) the course of the disease may be steadily 
progressive, chronic monophasic, or recurrent; (2) nerve conduction may be normal in motor 
and afferent fibres, but more commonly (though not mandatory) it is slowed; (3) cyto-
albuminologic dissociation is usually seen at some time during the course of the disease and ( 4) 
there is a tendency to symmetric involvement of proximal as well as distal limb muscles. To 
exclude patients with the Guillain-Barre syndrome, all patients had the clinical features of a 
polyneuropathy with a progression of weakness of at least 2 months. 
IVIg treatment 
All 52 CIDP patients were treated with high-dose intravenous immunoglobulin (IVIg) in a 
dosage of 0.4 gjkg body weight/ day for 5 consecutive days. IVIg was obtained from the Central 
Laboratory of the Dutch Red Cross Blood Transfusion Service. 
Clinical assessment 
The disability of the patients before and several times after IVIg treatment was assessed by 
using the modified Rankin scale.S19 This scale estimates functional disability or handicap. 
Improvement is defined as an increase of at least 1 step on the Rankin disability scale. 
Anti-neural tissue antibody assays 
Serum from all 52 patients was investigated for the presence of anti-human sciatic nerve tissue 
antibodies by means of a mixed hemagglutination assay (MHT) and by the rat-mouse 
neuroblastoma cell line 108cc15 immunofluorescence assay (NBL-IFA). Both assays have been 
described before.320.321 
HLA typing 
Typing for the HLA-A, B and C (Class I antigens) was performed with the standard NIH 
lymphocytotoxity test, and typing for HLA-DR and DO (Class II antigens) with the two-color 
fluorescence tesf23 using sets of well characterized and highly selected allo-antisera and 
monoclonal antibodies. 
Statistical analysis 
Differences between groups were tested with a chi-square test. Significant p values were 
corrected for the 44 broad antigens in the HLA-A, B, C, DR and DO loci. Controls consisted 
of 504 unrelated healthy Dutch blood donors. Antigenic splits were not analyzed because of the 
relatively small numbers of cases. Relative risks (RR) were calculated using the formulae 
suggested by W oolf'45 and Haldane.113 
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Table 1. HIA phenotypes, neural antibodies and improvement after Mg treatment in 52 CIDP patients 
improvement 
Pat Sex HLA-A HLA-8 HLA-C HLA-DR HLA-DRw52/53 HLA-DQ after IVIg N8L-IFA MHT 
I M 28, 31 35, - w2, w4 w13, w15 w52 w6,- + + 
2 F 1' 3 87, W57 w6,w7 1' 7 w53 w5,w9 + + + 
3 M 3, 25 7, 35 w4,w7 w13, w15 w52 w6,- + + + 
4 F 11, 29 51, w5 5 w3,- wl5, - w6,- + 
5 F 2,w33 44, w58 w3,w5 3, 7 w52,w53 w2,w9 
6 F 3, 30 13, 18 w6,w7 7, wlO w53 w2,w5 + 
7 F 28, 11 51, 8 w7,- 3, 7 w52,w53 w2,w9 
8 M 2,23 w50,- w6, - 4, wl3 w52,w53 w6,w8 + 
9 M 2, 3 7, 44 w7,- 3, wl3 w52 w2,w6 + + 
10 M 2,28 7, - w7,- wl5, - w6, - + 
11 F 29, 30 44, 13 w6,- 4, 7 w53. w2,w7 + + 
12 M 2,28 51' 7 w2,- 4, - w53 w7,- + + + 
13 M 2, 3 44, 35 w4,- 4, 7 w53 w2,w7 + + 
14 t 2, 31 51, w60 w3,- w15, - w6,- + + 
15 F 2, - 7, 27 w2,w7 4, w13 w52,w53 w6, w8 + + + 
16 M 1' 24 51,27 w2,- w15, w11 w52 w6,w7 + 
17 M 1' 2 51, 8 w4,w7 3, w14 w52 w5,w2 + + + 
18 F 23, 24 39,w60 w3,- 4, w8 w52, w53 w8,- + + + 
19 F 26, 11 8, 38 w3,w7 3, wll w52 w2,w7 + 
20 M 2, 11 7, w62 w3,w7 w13, 9 w52,w53 w6, w9 + + 
21 F 3, 24 51, 35 w4,- 4, w11 w52,w53 w7,- + 
22 M 1' 3 8, 35 w4,w7 1, 3 w52 w5, w2 + + + 
23 F 3, 31 35, w60 w3, w4 1' - w5,-
24 M 1' 2 8, 39 w7,- 3, w8 w52 w2,w4 + 
25 F 1, 29 44, 13 w5,w6 w15, 7 w53 w2,w6 + + 
26 M 2, 24 18, - w7, - w11, w14 w52 w5,w7 + + 
27 M 2, 11 8,44 w7, - 1, 7 w53 w2,w5 .+ 
28 M 1, 29 44, 38 -
' 
- w13, 7 w52,w53 w2,w6 + + 
29 M 2, - 7, 39 w7,- 4, w12 w52,w53 w7, w8 + 
30 F 1, 2 8, w57 w6,w7 3, 7 w52,w53 w2,w9 + 
31 M 1, 2 38, w60 w3,- w13,w8 w52 w6, w4 + + 
32 M 2, 3 38, w60 w3,- wl3, - w52 w6,- + + 
33 M 3,24 w62, 27 w2,w3 1, w11 w52 w5,w7 + 
34 M 3, - 7,27 w2,w7 4, wl3 w52,w53 w6,w7 + 
35 M 3, - 51, 7 w7,- w15,w11 w52 w6,w7 + 
36 M 2, - 8,w60 w3,w7 w15, 3 w52 w6,w2 + + 
37 F 2, 3 w62,- w3,- 4, w13 w52, w53 w6,w8 
38 M 1, 2 8, w62 w3,w7 w15, 3 w52 w6, w2 + 
39 M 3, 24 7, 8 w3,w7 w15, - w6,w5 + 
40 M 2, - 44, w62 w2,w3 w16, 4 w53 w5,w8 
41 F 2, 3 38, w55 w3,- w15, 4 w53 w6,- + + 
42 M 2, 3 44,w56 w1, w4 7, - w53 w6,w5 
43 F 2, 3 7, - w7,- w15, w8 w52 w6,w4 + + 
44 F 3, 32 39, w56, 
' 
w15, 4 w53 w6,w8 + 
45 M 3, - 7, 35 w4,w7 1, w15 w5,w6 + 
46 M 1' 2 44,w57 w6,- 7, - w53 w2,w9 + + 
47 F 1' 3 51, 8 w2,w7 3, 7 w52,w53 w2,- + 
48 M 2, 3 w55,27 w2,w3 4' - w53 w7, w8 + 
49 F 2, - 7, w62 w3,w7 wl5, - w6,w5 + 
50 M 3, 30 8, 18 w5, w7 3, - w52 w2,- + 51 M 2, - 44, - w5,- 4, w6 w52,w53 w7, - + + + 
52 M 1' 2 51,w62, w3,- 1, 4 w53 w5,w8 + + 
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RESULTS 
The results of the HLA typings in the group of 52 CIDP patients, together with the clinical 
course after Mg treatment and the results of the anti-neural antibody assays are shown in 
Table 1. 
When the 52 CIDP patients were compared to controls, significantly different frequencies were 
found for the HLA antigens B5, B16 and Cw2 (Table 2). No significant values were found for 
HLA-A, DR and DQ antigens . 
Table 2. Significantly different HLA antigen frequencies in a group of 52 CIDP patients typed 
for HIA-A, B, C, DR and DQ antigens 
HLA antigen Patients Controls RR chi p p 
N positive N positive square corrected* 
no. % no. % 
CIDP patients 
85 52 10 19 504 53 11 2. 085 4. 002 0. 043 ns 
816 52 9 17 504 36 7 2. 797 6. 966 0. 008 ns 
Cw2 52 9 17 504 45 9 2. 138 3. 937 0. 045 ns 
Improvement after IVIg 
85 32 7 22 504 53 11 2. 482 4. 487 0. 032 ns 
816 32 7 22 504 36 7 3. 767 9. 132 0. 003 ns 
Cw2 32 6 19 504 45 9 2.402 3. 765 0. 049 ns 
No improvement after IVIg 
A1 20 2 10 504 170 34 0. 265 4. 464 0. 033 ns 
A3 20 11 55 504 162 32 2. 551 4. 560 0. 031 ns 
8w22 20 3 15 504 25 5 3. 989 5. 4 78 0. 018 ns 
*pis corrected for 44 antigens tested in HLA-A, B, C, DR and DQ loci 
All 52 CIDP patients were treated with Mg, of which 32 (62%) improved and 20 (38%) 
patients did not. Sex and age were equally distributed among CIDP patients who improved after 
Mg (N=32) and those who did not (N=20). 
Because there might be a difference in HLA antigen frequency between these two groups, both 
were compared to the control group of healthy donors and they were tested against each other. 
The group of 32 CIDP patients who improved after Mg treatment showed significantly 
different frequencies for the HLA antigens B5, B16 and Cw2. The group of 20 CIDP patients 
who did not improve had significantly different frequencies for the HLA antigens A1, A3, and 
Bw22. 
However, after correction for al144 tested antigens in the HLA-A, B, C, DR and DQ loci, the 
results were no longer significant. The group of CIDP patients who improved after IVIg and 
the patients who did not improve were also compared to each other. HLA-All was found in 
4 of 20 (20%) patients who did not improve and only in 1 of 32 (3%) patients who improved, 
HLA-DRw6 was found in 12 of 32 (38%) patients who improved and only in 2 of 18 (10%) 
patients who did not improve after IVIg treatment. The phenotype frequency in the control 
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group of 504 donors for HLA-All is 12%, and 31% for HLA-DRw6. However, no statistically 
different p values were found after correction. · 
Of 52 CIDP patients, 22 (42%) had a positive MHT, 24 (46%) a positive NBL-IFA and 36 
(69%) a positive MHT and/or NBL-IFA (Table 1). 
The presence of a positive MHT or NBL-IFA was not significantly associated with improvement 
after IVIg treatment. The MHT results were not significantly correlated with any of the HLA 
antigens tested for. HLA-DRw8 was more frequently (p=0.008) observed in patients with anti-
NBL antibodies ( 4/24) than in patients without anti-NBL antibodies (0/28), but this again is not 
significant after correction. 
DISCUSSION 
This study shows that the HLA antigens B5, B16 and Cw2 are more frequently found in patients 
with CIDP than in the normal population. Nevertheless, we hesitate to suggest an association 
between CIDP and genetic factors, since when the p values are corrected for the number of 
antigens tested in the different HLA loci, the results were no longer significant. 
Adams et al.4 investigated 14 patients with recurrent or chronic relapsing inflammatory 
polyneuropathy. This HLA typing included recognition of the DR1-DRw8 antigens. The 
frequency of HLA-B8 was found to be increased, however the p value was not corrected. 
Stewart et al.290 performed HLA typing in 22 CIDP patients, whereas typing for HLA-DR 
antigens was only performed for DR1, DR2 and DR3. They found a significant association with 
HLA-A30/31 after correction for the number of tested antigens, but the "probable" association 
with HLA-B8 and DR3 was not s~cant. 
The recent study by Feeney et al. included the CIDP patients which had been described by 
Stewart et al.290 and revealed increased frequencies of the HLA-A3, B7 and DR2 antigens, 
both in patients with a chronic progressive and a chronic relapsing course of disease. A 
decreased frequency was found for the HLA-B44 and DR7 antigens. However none of these 
findings reached statistical significance. Feeney et al.94 found that the joint occurrence of HLA-
B7 and DR2 was much greater than would be seen normally. In our group of 52 patients, 50% . 
of HLA-B7 positive patients are DR2 positive and 29% of the HLA-DR2 positive patients are 
B7 positive, indicating that the frequencies were not increased as compared to controls. 
Therefore we have no arguments for an HLA-DR2 association in patients with CIDP as was 
suggested by Feeney et al.94 
A comparison between increased frequencies of certain HLA antigens as reported in other 
studies and the results in our group of CIDP patients is shown in Table 3. 
We could not demonstrate a significant HLA association between the group of CIDP patients 
improving after IVIg or those who did not. 
The presence of MHT or anti-NBL antibodies was not associated with improvement, being in 
contrast to an earlier study20 in which we found an association between the presence of anti-
peripheral nerve antibodies as demonstrated by a MHT, and the improvement after IVIg in a 
smaller series of patients. Our present MHT results are compatible with findings by Osterman 
et al.229 who could not demonstrate an association between the presence ofMHT antibodies and 
a favourable response to plasma exchange in 36 GBS patients, although such an association 
initially was reported by the same group in a series of 7 CIDP and 11 GBS patients?25 
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Table 3. HLA typing for Class I and II antigens in CIDP patients performed by different groups. 
Increased HLA freguencl 
Adams Stewart Feeney vDoorn 
88, DR31 A30/312 (88, DR3)3 (A3, 87,844, (85, 816, Cw2)3 
DR2, DR7) 4 
patients controls patients controls patients controls patients controls 
HLA N = 14 N = 571 N = 22 N = 322 N= 71/56 N = 1058 N = 52 N = 504 
antigen pos 96 96 pos pos 96 96 pos pos 96 96 pos pos 96 96 pos 
A3 7 50 29 3 23 29 24 34 27 22 42 32 
A30/31 1 7 3 7 32 5 8 11 9 6 11 8 
85 2 14 8 2 23 10 10 14 10 10 19 11 
87 3 21 24 6 27 26 25 35 27 14 27 29 
88 7 50 25 9 41 26 18 25 27 12 23 23 
844 1 7 nd nd nd 13 18 29 11 21 22 
816 0 0 7 1 5 1 4 6 6 9 17 7 
Cw2 1 14* nd nd nd nd nd nd 9 17 9 
DR2 1 8 21 5/18 28 21 23 32 29 17 33 28 
DR3 7 50 17 8/18 44 14 23 32 29 12 23 24 
DR7 3 23 27 nd nd nd 10 14 26 13 25 22 
1 
= significant p values, not corrected 
2 
= significant p values after correction 
3 
= significant p values before, but not after correction 
4 
= "increased, but non-significant p values after correction" 
* = presumably 7 patients tested, population frequency not known 
nd = not tested 
In conclusion, in this study we could not detect nor confirm any significant associations between 
CIDP and HLA-A, B, C, DR and DQ antigens, nor did we find any significant HLA association 
with the presence of neural antibodies nor with the improvement after IVIg treatment. 
However, it must be emphasized that all the HLA studies in CIDP patients concern relatively 
small numbers of cases. 
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ON THE MECHANISM OF 
IDGH-DOSE INTRAVENOUS 
IMMUNOGLOBULIN TREATMENT OF 
PATIENTS WITH CHRONIC INFLAMMATORY 
DEMYELINATING POLYNEUROPATHY 
INTRODUCTION 
Acute inflammatory demyelinating polyneuropathy or Guillain-Barre syndrome (GBS) is 
preceded in over half of the cases by an infectious illness14 and is self-limiting.15 Randomized 
clinical studies demonstrated that the extent and duration of paralysis is favourably influenced 
by plasma exchange.100.302 Patients with chronic inflammatory demyelinating polyneuropathy 
(CIDP),79'78 may also benefit from plasma exchange, although only transient clinical 
improvement has been seen with this treatment.81 In several uncontrolled studies a beneficial 
response to normal polyspecific immunoglobulins (IVIg) in CIDP was found.6.S0.54.59.B7.328 A 
double-blind crossover study in seven CIDP patients, who were considered to be dependent on 
IVIg, showed that all patients responded to IVIg and none to placebo infusions.322 Although the 
immune mechanism and the antigens involved in CIDP are not yet determined, there is growing 
evidence that anti-neural antibodies contribute to the demyelination process in GBS and 
CIDP.28.sz.126•154•153,287,320,3Zl We previously found that the sera of about half of the patients with 
GBS and CIDP show antibodies against human sciatic nerve.320 These antibodies cross-react 
with a membrane antigen expressed by the 108cc15 neuroblastoma cell line (NBL) allowing their 
detection by an indirect immunofluorescence assay. The anti-NBL antibodies are often of the 
IgM -class and decreased or disappeared in patients retested after improvement following IVIg?21 
In vitro studies showed that IVIg inhibits the reaction between serum from a CIDP patient and 
the NBL cell line. 
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The aims of the present study were to investigate whether this inhibitory effect can also be 
obtained with F( ab')2 fragments of IVIg, which would support the suggestion that inhibition of 
anti-neural tissue antibodies is due to neutralization by specific antibodies present in IVIg. 
Secondly, we investigated if the IgG fraction of postrecovery GBS serum inhibits anti-NBL 
activity in autologous prerecovery serum which would suggest that GBS is selflimiting by 
suppression of auto-antibodies. Thirdly the degree of cross-reactivity between various individuals 
including recovered GBS patients and healthy donors against a particular anti-NBL antibody 
from a CIDP patient was evaluated. 
Figure 1. The course of the neurological sum-score in a patient with CIDP upon treatment with plasma-exchange, infusions 
of FFP and infusions of IVIg. The sum-score is the total MRC score of the following muscles on either side of the body: 
deltoideus, biceps, extensors of the hand, iliopsoas, quadriceps and tibialis anterior. 
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PATIENTS AND METHODS 
CIDP patient (A) 
A 14 year old boy presented in 1980 with slowly progressive ~alysis over a period of two 
months. He had total paralysis of the legs and arms (MRC 0). Nerve conduction velocities 
(NCV) of the right motor median and peroneal nerve were decreased and H-reflexes were 
absent. CSF protein concentration was increased (0.97 g/L). A sural nerve biopsy showed 
widening of the subperineural space and signs of demyelination. There was no systemic disease, 
intoxication or family history of hereditary polyneuropathy. The patient did not respond to a 3 
months course of prednisone and azathioprine. Plasmapheresis ( 4 litre exchanges weekly) 
resulted in rapid, always transient improvement but had to be discontinued after a few months 
as recurrent shunt-thrombosis caused problems in vascular access. The patient was subsequently 
treated with transfusions of cryo-supernatant plasma (100 ml/kg body weight weekly) which was 
as effective as plasmapheresis. When plasma treatment was discontinued clinical deterioration 
occurred within 2-4 weeks. A similar beneficial effect was observed after IVIg infusion. IVIg 0.4 
g/kg bodyweight for 5 consecutive days resulted in maximal improvement after 8 days. There-
after the patient's condition remained stable for about 2 weeks when subjective and objective 
signs of muscular weakness reappeared. A regular IVIg treatment regimen with empirically 
established dosages was continued for 6 years with several unsuccessful attempts to taper off 
(Figure 1). At the present time the patient receives 21 g IVIg weekly (0.3 g/kg body weight). 
Currently, pre-infusion serum immunoglobulin concentrations are 14.3 g/L for IgG; 3 g/L for 
IgM, and 2 g/L for IgA. Liver function tests are normal. There are no subjective and objective 
side effects of IVIg infusions. This CIDP patient is still able to perform normal daily activities. 
GBS patient (B) 
A 35 year old man developed sensory disturbances and progressive muscle weakness over a 
period of three weeks, resulting in paralysis of the legs (MRC 0) and paresis of the arms 
(MRC 3). Four weeks from onset of weakness improvement started and resulted in complete 
recovery after three months. 
Anti-nenroblastoma cell line (NBL) antibodies 
The neuroblastoma (NBL) l08cc15 cell line was kindly provided by Prof B Hamprecht 
(Physiological-Chemical Institute, University of Tiibingen, FRG). The cells were cultured in 
Dulbecco's Modified Eagles Medium supplemented with 10% heated fetal calf serum in a 
humidified atmosphere containinlf 5% C02 at 37°C. The indirect immunofluorescence assay 
(IFA) was previously described?2 The number of fluorescent cells of 200 counted cells was 
determined and expressed as a percentage. Forty normal blood bank donors showed a mean of 
4% (range 0-15%) positive NBL cells. A percentage of fluorescent cells above 20% was consi-
dered positive. The titer of a positive serum was defined as the last dilution step which gave a 
positive (>20%) NBL-IFA. In the active phase of the disease, patient A (CIDP) had positive 
anti-NBL antibodies. These antibodies were of the IgM-class and were present in a titer of 1/64. 
During therapeutically induced remission with IVIg the antibody titer varied between 0 and 1/2. 
From patient B (GBS) on day 6 after onset of muscle weakness, serum was withdrawn. Anti-
NBL antibodies of the IgM class were present in a titer of 1/32. One year after uneventful 
recovery, serum contained no anti-NBL antibodies of the IgM or IgG-class. 
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Sera and immunoglobulin preparations 
Serum samples were also obtained from 25 other GBS patients who had recovered since 
maximally 5 years. Serum samples from 26 donors from the Leiden Red Cross Blood Trans-
fusion Service were obtained after consent. All sera were stored at -20°C. Plasma was clotted 
with CaC~ and subsequently stored at -20°C. 
Normal polyspecific immunoglobulin for intravenous use, derived from a large pool of donor 
plasma (IVIg) was obtained from the Central Laboratory of the Dutch Red Cross Blood 
Transfusion Service. 
The IgM fraction of the CIDP patient's (A) pretreatment serum was prepared by euglobulin-
-precipitation, and chromatography on Sepharose G200. The high molecular weight fractions 
containing IgM and no detectable IgG in immunodiffusion were pooled and concentrated with 
polyethylene glycoll5-20,000 MW to 1.74 mgjml. IgG fractions from the serum of one of the 
26 Blood bank donors and post-recovery serum from the GBS patient (B') were prepared by 
ammonium sulphate precipitation and chromatography on DE-52 cellulose (Whatman). IgG and 
IgM concentrations were measured by radial immunodiffusion using monospecific rabbit anti-
human IgG and IgM antibodies (Behringwerke, Marburg, FRG). 
F(ab')2 fragments were prepared from IVIg and from the post-recovery IgG from the GBS 
patient by pepsin-digestion (2%, w jw) and chromatography on protein-A sepharose 
(Pharmacia). 
Polyvalent IVIg, postrecovery GBS serum and control serum were checked for rheumatoid 
factor activity and anti-Ig allotype antibodies.258 
Inhibition of NBL-IFA antibodies 
NBL-antibodies: serum of patient A derived during the active phase of the disease was used for 
inhibition studies in a titer of 1:4 (calculated IgM-level in this dilution step was 0.3 mgjml). 
The percentage fluorescent NBL cells with serum from patient A was 87% in a dilution of 1:4 
and 78% in a dilution of 1:8. The IgM-fraction of this serum used for inhibition studies 
contained 0.87 mgjml. Prerecovery serum of patient B was tested in a dilution 1:1 (calculated 
IgM level in this dilution step was 2.02 mg/ml). The percentage immunofluorescent NBL cells 
with prerecovery serum from patient B was 82% in a dilution of 1:1 and 88% in a dilution of 
1:2. 
Inhibitors: serum from patient B from the prerecovery phase was absorbed on NBL-cells until 
the NBL-IFA was negative. From serum, of patient B obtained one year after uneventful 
recovery (B'), IgG and F( ab )2 fragments were prepared. Sera from 25 recovered GBS patients, 
derived within 5 years after recovery and 26 blood bank donors were tested as inhibitors. 
Polyvalent IVIg was tested as such and after preparation of F( ab )2 fragments. 
Inhibition assay: for inhibition experiments, the inhibitor serum, IgG or F( ab')2 fragments were 
titrated in phosphate buffered saline (PBS) pH 7.4. 
One volume (50 microliter) of the antibody containing sera or immunoglobulin-fractions of 
patient A or B was mixed with one volume of PBS containing various concentrations of 
inhibitor. The mixture was immediately incubated with 0,5 x 106 NBL cells and further processed 
for NBL-IFA. For each mixture, the percentage of inhibition of the NBL-IFA and the 
corresponding molar ratio is calculated. The molar ratio is defmed as the amount of the 
patients' prerecovery IgM divided by the amount of inhibitory IgG or F( ab')2 and is expressed 
in mol/mol. 
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RESULTS 
Incubation of pretreatment serum from the CIDP 
patient (A) with various concentrations of IVIg and 
F( ab')2 fragments of IVIg in vitro resulted in dose 
dependent inhibition of the binding of anti-NBL anti-
bodies to the NBL 108cc15 cells of which an example is 
shown in Figure 2. 
Figure 2. In vitro inhibition of the binding to 
NBL 1 08cc15 cells of IgM-anti-NBL antibodies 
from the serum of a patient with CIDP by IVIg 
(-) and F( ab')2 fragments prepared from IVIg (- -). 
100 
Maximal inhibition occurred with intact IVIg and < 1s 
F( ab')2 fragments of IVIg at a calculated molar ratio of ~ 
patient's IgM to IVIg and patient's IgM to IVIg-F(ab')2 iil 
of about 0,003; the inhibition curves showed a prozone. : 
Similar results were obtained when inhibition of anti- ~ so 
NBL activity was assessed with the IgM fraction of the ~ 
serum from patient A (Table 1). .s::. c: 
Thus F( ab')2 fragments of IVIg contains antibody ., 2s 
specificities which interact with the anti-NBL antibodies 
in the patient's serum. Since anti-NBL antibodies are 
found in the serum of patients with CIDP and in 
patients with the self-limiting GBS, we examined 
whether the serum from patients who recovered from 2s so 7s 
GBS contained antibodies which could inhibit anti- patient's lgM/IVIg or F(ab)2 IVIg 
(moles/moles) XI 0-4 
NBL activity in CIDP serum. Table 2 shows that anti- . 
NBL activity in the CIDP patient's (A) serum was inhibited by IgG and F(ab')2 fragments from 
postrecovery serum from a patient with GBS (B'). The prerecovery GBS serum (B) did not 
inhibit patients' A anti-NBL antibodies. This prerecovery serum was tested after absorption on 
NBL cells to remove anti-NBL activity. The IgG fraction and F(ab')2 fragments from post-
Table 1. Inhibition of anti-NBL activity in serum and in the IgM-fraction from a patient 
with CIDP (A) by Mg and F(ab')2 fragments of Mg. 
Serum lgM fraction 
96 inhibition'" molar ratio""" 96 inhibition'" molar rat i o""" 
IVIg 86 ± 3 0. 0047 81 ± 15 0.0021 
(0. 0003·0. 036) (0. 0005-0. 01) 
F(ab')z IVIg 78 ± 9 0. 0044 82 ± 6 0. 0011 
(0. 0003·0. 016) (0. 0005·0. 01) 
Maximal inhibition (mean value ± SD from at least three experiments) of anti-
NBL activity obtained by mixing patient's serum or IgM fraction with Mg or 
F(ab')2 of Mg. 
Indicated are molar ratio's between patient's lgM and Mg or F(ab')z fragments 
of IVIg with which maximal inhibition was obtained. 
Parentheses indicate the range of molar ratio's that were tested. 
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Table 2. Inhibition of anti-NBL antibodies from a patient with CIDP (A) and a patient with 
GBS (B) by postrecovery (B') GBS-IgG and F(ab')2 fragments, and IgG from a normal donor 
CIDP serum (A2 GBS serum (B2 
% inhibition* molar rat i o % inhibition"' molar rat i o 
Post recovery B' 69** 0. 036 100 0. 75 
GBS·IgG (0. 0071·3. 652) (0. 032-16. 43) 
Postrecovery B' 65 0. 02 100 0. 28 
GBS F(ab') 2-lgG (0. 0048 ·0. 064) (0. 0088-4. 493) 
Normal Donor 20 ± 2 0. 005 nd 
lgG (0. 0025-0. 65) 
nd=not done 
* indicated is the maximal inhibition that was obtained and the molar ratio between 
patient's IgM and inhibitory IgG or F(ab')z fragments at which maximal inhibition was 
achieved. 
** Results are expressed as mean inhibition ( ± SD, when at least three experiments were 
performed), parentheses indicate the range of molar ratio's tested. Due to shortage of 
prerecovery GBS serum (B) only a few experiments could be performed. 
recovery serum of the GBS patient also inhibited anti-NBL activity in autologous prerecovery 
serum. In all instances, inhibition was dose dependent with an optimum at a specific molar ratio 
of patients' IgM to inhibitor IgG or F( ab')2 fragments. IgG and F( ab')2 fragments from GBS 
postrecovery serum (B') were 25 fold more effective in inhibiting autologous prerecovery anti-
-NBL antibodies compared to the inhibition of the anti-NBL antibodies of the CIDP patient. 
Inhibition of anti-NBL activity was also found in other postrecovery GBS sera and blood bank 
donor sera upon incubation with the serum of the CIDP patient. The dilution in which normal 
donor and post recovery GBS sera were still able to cause 75% inhibition of the CIDP anti-
NBL-IFA is shown in Figure 3 (left side). The calculated molar ratio's are shown on the right 
side of Figure 3. The mean molar ratio of the CIDP patients' (A) IgM to IgG in the inhibi-
tory serum was 0,0589 in normal individuals and 0,2517 in postrecovery sera, this difference did 
not reach statistical significance. GBS sera obtained within 3 years of recovery were more 
effective in inhibiting anti-NBL activity than those obtained more than 3 years after recovery. 
Five out of 12 sera from recovered GBS patients obtained within 3 years after recovery, 
inhibited anti-NBL antibodies in a dilution > 1/64 corresponding with a calculated molar ratio 
of >0.1. Two out of 25 blood donor sera showed a similar strong inhibition. Mg and post-
recovery GBS sera contained no anti-NBL antibodies, no rheumatoid factor activity and no 
detectable anti-allotype antibodies against the G1m(1) Glm(3), G1m(4), Glm(17) and Km(1) 
allotypes expressed in the heavy and light chain regions of human IgG. 
DISCUSSION 
A 14 year old patient with severe chronic inflammatory demyelinating polyneuropathy (CIDP) 
responded to plasmapheresis, infusions of fresh frozen plasma and infusions of Mg. The 
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Figure 3. Inhibition of anti-NBL activity in the serum from a patient with CIDP by postrecovery sera from patients with 
GBS and sera from normal individuals. The left side presents the lowest dilution of serum able to result in at least 75% 
inhibition of NBL-immzmofluorescence. The right side shows the calculated molar ratios between IgM in the serum of the 
patient with CIDP and IgG in the inhibitory sera. Normal individuals (e), sera obtained less than 3 years postrecovery 
from GBS (.A), and sera obtained more than 3 years postrecovery from GBS (D). 
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duration of the clinical response did not exceed 4 weeks following a single infusion of IVIg. The 
serum from this CIDP patient (A) contained anti-neuroblastoma 108cc15 (NBL) antibodies of 
the IgM-class in a titer of 1/64 as assessed by immunofluorescence. Anti-NBL activity in 
patient's sera decreased after infusions of IVIg, and reappeared in association with weakness. 
Incubation of the patient's pretreatment IgM fraction with intact IVIg or with F( ab')2 fragments 
from IVIg in vitro resulted in a dose dependent inhibition of anti-NBL activity that reached in 
various assays 80-100% at specific molar ratios between patient's IgM and competitor IgG. The 
prozone pattern of the inhibition curve was similar to that which had previously been observed 
with other auto-antibodies neutralized by IVIg.145'293 Since the inhibitory effect was observed 
with F(ab')2 fragments from IVIg and since rheumatoid factor activity, anti-Ig allotype anti-
bodies and anti-NBL antibodies, could not be demonstrated in IVIg, these observations suggest 
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that IVIg contains antibodies against idiotypic determinants expressed on anti-NBL antibodies. 
Thus the beneficial effect of IVIg in the CIDP patient may be dependent on IVIg mediated 
suppression of auto-antibodies in a similar fashion to anti-idiotypic suppression of auto-
antibodies observed with IVIg in patients with anti-Factor VIll:c auto-antibodies293.294 and in a 
patient with autoimmune pure red cell aplasia.197 
Anti-NBL activity in CIDP patients' serum was inhibited both by IgG and F(ab')z-fragments 
from IgG of a patient who recovered from GBS (B'). The prerecovery serum from patient B 
contained - after absorption of the specific NBL antibodies on NBL cell line cells - no inhibitory 
activity against the CIDP patients' anti-NBL antibodies. Post -recovery IgG from this patient with 
GBS also inhibited anti-NBL activity in autologous prerecovery serum suggesting that recovery 
from GBS is associated with the generation of anti-idiotypic antibodies. Spontaneously occurring 
anti-idiotypes have been found in the serum of patients with SLE in remission, 1 myasthenia 
gravis, 72 and in the serum of a patient who spontaneously recovered from auto-antibodies to 
factor VIII.294 Our observations suggest that anti-idiotypic IgG antibodies against auto-
antibodies develop during recovery from GBS and that these anti-idiotypic antibodies cross-
react with antibodies in a CIDP patient. The higher ability of the postrecovery serum from the 
GBS patient (B') to inhibit anti-NBL in his own prerecovery serum (B) points into the direction 
of higher affinity of the private compared to the cross-reactive idiotypic determinants. To inves-
tigate the incidence of the presence of private and cross-reactive anti-idiotypic antibodies, more 
autologous versus allogeneic combinations must be compared, as we tested only two patients 
and made only one pre- and postrecovery comparison. 
Sera from 5 /U patients recovered within 3 years from GBS but also 2/25 sera from healthy 
individuals showed strong (>75%) inhibitory anti-NBL activity against the CIDP serum. The 
remaining sera from recovered GBS and random blood donors showed equal inhibitory activity 
of the anti NBL antibodies of this particular CIDP patient tested. 
Although the mechanism of action of IVIg in antibody-mediated organ-specific autoimmune 
diseases is still the subject of hypothesis and research, 215 evidence has been provided for IVIg 
mediated anti-idiotypic suppression in patients with anti-FVIII antibodies and anti BFU-c anti-
bodies.197.293 It has however not yet been established whether anti-NBL antibodies present in 
the sera from patients with GBS and CIDP represent pathogenic auto-antibodies.256 When anti-
NBL antibodies are present in CIDP patients, they decrease or disappear in association with 
rapid clinical improvement after IVIg suggesting that they have in individual patients a 
pathogenic role. 
Our experiments were limited to the anti-NBL antibodies of one CIDP patient and one GBS 
patient in the acute phase of their disease and need to be extended to confirm the presence as 
well as the degree of cross-reactivity between GBS and CIDP antibodies. The beneficial effect 
of IVIg in patients with CIDP and the self-limiting character of GBS, in association with the 
development of novel anti-NBL antibody-inhibitory activity, may represent additional examples 
of therapeutic and spontaneous anti-idiotypic suppression of auto-antibodies in human 
autoimmune diseases. 
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GENERAL DISCUSSION 
Inflammatory demyelinating polyneuropathies have been divided into an acute and a chronic 
variety because of their difference in onset, course and prognosis. Criteria have been developed 
for the diagnosis of the acute form15 and Barohn et al.23 suggested that there is a need for 
criteria for the chronic form as well. Recently this view has been challenged by Dyck83 who 
commented that such consensus criteria have a tendency to be thought of as truth, and that if 
criteria are developed prematurely they may inhibit needed thought and study. He concluded 
that for the present, patients with a chronic symmetrical polyradiculoneuropathy with low nerve 
conduction velocity and raised CSF protein without associated monoclonal gammopathy or 
disease association should be separated from those associated with these disorders. 
After intravenous immunoglobulin (IVIg) treatment, 62% of the patients who had been judged 
to have chronic inflammatory demyelinating polyneuropathy (CIDP) improved (Chapter 3). The 
first question is whether these patients really responded to this treatment. In a crossover study 
in IVIg responders it was shown that patients responded to IVIg and not to placebo (Chapter 
2), therefore at least some CIDP patients respond to Mg. The second question is why not all 
patients improve. One explanation could be that patients who did not improve have a different 
neuropathy and this seems a likely explanation in some patients. Another explanation could be 
that at least some of the non-responders did not had an active form of the disease but actually 
had fixed neurological deficit. Analysis of clinical features which were associated with treatment 
response showed that patients with CIDP had a chance of over 90% to improve after Mg if 
the following factors were present: 1) disease duration of at least 1 year, 2) progression of 
weakness until treatment, 3) absence of discrepancy between weakness of arms and legs, 4) 
areflexia of the arms and 5) slowed nerve conduction velocity of the motor median nerve. 
Patients without all these factors have a low chance of improving after Mg treatment and may 
have a different neuropathy. The most important other neuropathies to consider are the chronic 
axonal neuropathy of undetermined cause, vasculitic neuropathy without systemic vasculitis, 
multifocal demyelinating neuropathy with persistent conduction block and multifocal motor 
neuropathy. These neuropathies have been described in the introduction (Chapter 1). The onset 
of the chronic axonal polyneuropathy of undetermined cause is usually not exactly known and 
is in many cases thought to be more recent than it actually was. When the neuropathy exists for 
many years the conduction velocity especially in the legs may have slowed considerably and the 
CSF protein may have increased over the years. Therefore this neuropathy may be difficult to 
distinguish from CID P. A long history of the disease, a very slowly progressive course and slight 
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involvement of the arms should raise the suspicion of this mysterious neuropathy which 
unfortunately does not respond to any treatment. If there is a clear difference between weakness 
of arms and legs, especially if there was asymmetry at onset, vasculitic neuropathy and the 
multifocal neuropathies should be considered. Until now, IVIg treatment in these patients was 
disappointing. 
Recently it has been reported that patients with IgM monoclonal gammopathy of unknown 
significance (MGUS) may respond to IVIg treatment.48 No reports are available on IVIg 
treatment in patients with clinical features of CIDP accompanied by another disease such as 
inflammatory bowel disease, chronic active h~atitis, thyrotoxicosis, IDV infection, Hodgkin 
disease and CNS demyelination. Barohn et al. stressed that the neuropathy in these patients 
may be indistinguishable from CIDP without another disorder and suggested that CIDP should 
be considered as a syndrome with diverse causes. It would be interesting to investigate IVIg 
treatment response in those CIDP patients who have an accompanying disorder and to see if 
there is any difference compared to CIDP patients without an associated disease. 
Should patients with CIDP be treated with IVIg? The crossover study in selected patients with 
CIDP showed that these patients may benefit from this treatment. If this can be confirmed by 
the results of a randomized double blind placebo controlled study, IVIg treatment has to be 
preferred in comparison with other treatments (prednisone and plasma exchange) that were 
shown to be effective in clinical trials.81'76 IVIg treatment is safe in contrast to prednisone. 
There is no need for a trial comparing IVIg and prednisone; if a patient responds to IVIg this 
treatment can be continued, if not, plasma exchange or prednisone treatment has to be 
considered. In this decision the inconvenience of regular plasma exchange treatment has to be 
weighed against the side effects of prednisone. In the treatment of the Guillain-Barre syndrome 
the situation is completely different because in this disorder the most effective treatment has 
to be given at once and there is no chance to try a second treatment if the first has failed. 
The main advantages of IVIg treatment are that clinical response starts much earlier than after 
prednisone treatment and that it is without serious side effects, but maintenance treatment 
generally requires IVIg i.nD.lSion every week or every other week which is very expensive and 
which takes about two hours. To develop preparations which are cheaper and which can be 
administered in smaller volume we need to know more about the pathogenesis of CIDP and 
about the mechanism of nhprovement after IVIg. 
The therapeutic mechanism of IVIg in CIDP is unknown. This mechanism was investigated in 
vitro in two CIDP patients producing IgM and IgG antibodies respectively against the 
neuroblastoma cell line (NBL) 108ccl5. IgG and F(ab)2 fragments of IgG from the IVIg pool 
neutralized the purified IgM anti-NBL antibodies of the first patient as well as the IgG or 
F(ab)2 fragments of the anti-NBL antibodies of the second patient.185 Neutralizing antibodies 
were also present in sera from healthy individuals and in sera from patients who recovered from 
the GBS. Sera from recovered GBS patients which were obtained within three years from onset 
of GBS had a stronger neutralizing capacity than sera that were obtained after this period of 
time. In the one GBS patient tested, neutralizing antibodies were present only in the recovery 
phase and not in the active phase of the disease. The antibodies present during recovery 
effectively neutralized autologous anti-NBL antibodies (Chapter 9). 
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These findings suggest that autologous and therapeutic recovery from GBS and CIDP 
respectively, occurs by anti-idiotypic antibodies which neutralize pathogenic anti-neural 
antibodies. Several aspects must be further investigated to establish this hypothesis and to 
improve the present therapeutical approach. An important aspect is the degree of cross-
reactivity between the various anti-idiotypic antibodies especially in relation to inhibition of 
antibodies from responding and non-responding patients to IVIg treatment. Possibly, non-
responders have auto-antibodies that express no cross-reactive idiotypes neutralized by anti-
idiotypic antibodies present in IVIg derived from a ·large donor pool. Studies on this cross-
reactivity may subsequently lead to the pretreatment selection of IVIg responding patients. The 
question is whether or not antibodies of responding patients express a single or multiple cross-
reacting idiotypes. In case of a single or limited cross-reacting idiotype, an IVIg preparation with 
increased effectivity can be prepared from plasma of one or a few individuals with a high titer 
of neutralizing antibodies against NBL-antibodies. Ultimately when the degree of cross-
reactivity is established, it can be decided whether it is justified to prepare human monoclonal 
anti-idiotypic antibodies for the treatment of CIDP, since such an approach is not feasible when 
a particular patient needs a unique anti-idiotypic monoclonal antibody. 
Other intriguing observations are that 9 of 52 (17%) CIDP patients recovered after one or more 
IVIg treatment courses and that in some patients the duration of clinical improvement exceeded 
three half-life periods of IVIg. Permanent remission after IVIg treatment has also been 
observed in patients with autoimmune thrombocytopenia (ITP). This was mainly described in 
children, 136 in which it is particularly difficult to distinguish between a therapeutical response 
and a spontaneous course of ITP. A definite IVIg treatment response however has also been 
reported in patients with chronic ITP .137 Similarly, spontaneous remissions in CID P patients may 
be difficult to distinguish from remissions induced by IVIg, especially since CIDP patients may 
even have a rapid spontaneous improvement after a progression of muscle weakness over 
several months. 
Prolonged improvement in CIDP and ITP patients might also be the result of inhibition of 
auto-antibody production due to interaction between IVIg and antibody presenting- or antibody 
producing cells. This is presumably not a specific inhibition of particular auto-antibodies, since 
inhibition of pokeweed induced antibody groduction in vitro was observed in studies on B cells 
derived from patients treated with IVIg. Furthermore, in one preliminary study, the clinical 
effectiveness of IVIg in ITP patients was associated with an increase in the T helper-suppressor 
subset. 66.314 
A crucial question is whether the anti-NBL antibodies in CIDP and GBS patients have a 
pathogenic role. It was suggested that anti-nerve antibodies could be the result from nerve 
damage exposing immunogenic structures.53 This is unlikely for the anti-NBL 108cc15 antibodies 
since they were rarely found in patients with other neuropathies and since they were also 
present in patients with Lyme borreliosis who had no clinical signs of nerve damage. 
The anti-NBL antibodies were shown to cross-react with human peripheral nerve tissue, but also 
with Borrelia burgdorferi, which led to the hypothesis that CIDP and GBS are preceded by 
infections with various micro-organisms sharing antigenic epitopes with nerve tissue. 
The reason why not all patients with circulating anti-NBL antibodies develop a neuropathy is 
not known. Careful investigations regarding the antibody titer, the immunoglobulin (sub )classes 
and the ability of complement activation may be helpful to answer this question. Another 
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possibility to consider is that anti-NBL antibodies itself are non-pathogenic, but that they need 
another co-factor to cause nerve damage. 
Patients with CIDP have in 50% of the cases no anti-NBL antibodies. This may be explained 
by the insensitivity of the antibody demonstrating technique, another possibility is that in 
patients without demonstrable anti-NBL antibodies, a neural antigen is involved that is not 
expressed on the NBL 108cc15 cell line. Clinical differences or a different treatment response 
between patients with or without anti-NBL antibodies could not be demonstrated. This is in 
agreement with results in patients with idiopathic thrombocytopenic purpura (ITP), in which 
circulating auto-antibodies can not be detected in all patients and even the presence of 
detectable auto-antibodies against platelets is not significantly associated with treatment 
response. 
In conclusion, patients with CIDP may improve after treatment with IVIg. The possible 
mechanism of action of IVIg was studied by investigating the interactions between IVIg and 
anti-NBL antibodies. In vitro and in vivo observations suggest that improvement after IVIg 
treatment occurs by inhibition of auto-antibodies reacting with NBL cells. However, other 
biological effects ofiVIg such as blocking and modulation ofFc-gamma-receptors, enhancement 
of removal of persisting micro-organisms and immune complexes, and the interference with the 
production of cytokines cannot be excluded and may act synergistic with the neutralizing 
antibodies in IVIg. 
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Summary 
SUMMARY 
The inflammatory demyelinating polyneuropathies can be distinguished in the Guillain-Barre 
syndrome (GBS) and in the chronic variety CIDP. 
The subject of this thesis is high-dose intravenous immunoglobulin (IVIg) treatment in CIDP. 
In Chapter 1, clinical and laboratory features of CIDP were described. A remitting inflammatory 
polyneuropathy was already reported at the end of the last century. The name of the disease 
varied several times, currently the most frequently used name is "chronic inflammatory 
demyelinating poly(radiculo)neuropathy''. CIDP generally consists of a sensorimotor 
polyneuropathy resulting in symmetrical muscle weakness and sensory disturbances with a hypo-
or areflexia. Usually the protein in the CSF is increased and nerve conduction velocities. are 
slowed. There is no definite test for the diagnosis of CIDP. Recently Barohn et al.23 proposed 
diagnostic criteria for CIDP which were discussed in Chapter 1. 
Controlled studies showed that CIDP patients may improve after plasma exchange81 and 
prednisone treatment?6 The observation that CIDP patients may also improve after treatment 
with IVIg was investigated in a double-blind placebo-controlled crossover study (Chapter 2). In 
this study, regular IVIg treatment was discontinued after informed consent in 7 patients with 
CIDP who seemed to have responded to IVIg. After discontinuation of IVIg, all patients 
deteriorated. Subsequently the patients were randomized to IVIg or placebo (albumin) infusions. 
The clinical condition of all patients improved after IVIg and did not improve after placebo 
treatment (p=0.02). The mean time lapse from the end of trial treatment to the occurrence of 
deterioration was 6.4 weeks after treatment with IVIg and 1.3 weeks after treatment with 
placebo. This selected group of CIDP patients had a beneficial response to IVIg. 
In Chapter 3, clinical and laboratory data are presented of a study in 52 patients who were 
judged to have a CIDP. All patients were treated with IVIg, 20 (38%) patients did not improve 
after IVIg treatment, 2 ( 4%) patients had a short lasting improvement and subsequent infusions 
had no effect, 9 (17%) patients reached a spontaneously or therapeutically induced complete 
remission and 21 ( 40%) patients needed intermittent infusions to maintain improvement. All 
patients who improved initially had symptoms which at least significantly interfered with lifestyle. 
After IVIg treatment, 90% of these patients were independent in their daily activities. 
Significantly associated with improvement were: disease duration ofless than 1 year, progression 
of weakness until treatment, absence of discrepancy in weakness between arms and legs, 
areflexia of the arms and slowed nerve conduction velocity of the motor median nerve. The 
probability of improvement after IVIg treatment if all these features are present is 93%. 
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In Chapter 4, immunohistopathology, humoral and cellular immunity, various neural antigens, 
experimental models and IVIg treatment mechanism in relation to the inflammatory 
demyelinating polyneuropathies are discussed. An interesting hypothesis is that inflammatory 
neuropathies may be caused by a dual infection in which one of the micro-organisms is 
neurotropic and another micro-organism provides adjuvants. Both infections must act 
simultaneously to cause nerve damage. In the light of this hypothesis it is interesting that 
antibodies to glycosfingolipids have been demonstrated in GBS and CIDP patients. These 
antigens are highly expressed on neural tissue and also on micro-organisms. Furthermore, in 
animal experiments it has been shown that gangliosides may act as adjuvant material. 
Using a mixed hemagglutination test (MHT) circulating anti-human peripheral nerve tissue 
antibodies could be demonstrated in 22 of 38 (58%) patients with GBS or CIDP (Chapter 5). 
These antibodies were found in only 1 of 34 (3%) patients with polyneuropathy of other origin 
and in 3 of 32 (9%) patients without polyneuropathy. The presence of these antibodies was 
related with improvement after IVIg, but this could not be confirmed in a larger number of 
patients (Chapter 6). 
Subsequently the results of a neuroblastoma immunofluorescence assay (NBL-IFA) were 
presented (Chapter 6). Three neuroblastoma cell lines (NBL) from different species were 
evaluated for the detection of antibodies in patients with various polyneuropathies. The pattern 
of antibody reactivity in GBS, CIDP and in patients with Lyme neuro-borreliosis was similar for 
all3 NBL cell lines. The NBL N1Ell5-IFA showed reactivity with sera from patients with many 
different groups of disorders, whereas the NBL CHP 212-IFA generally gave negative results. 
The NBL 108cc15-IFA more exclusively gave positive reactions in CIDP, GBS and Lyme 
borreliosis patients. In Lyme borreliosis, the presence of these antibodies was not related with 
neuropathy. Analysis of antibody specificity revealed that absorption of CIDP patients' serum 
on both NBL 108cc15 and Borrelia burgdorferi (the infective agent in Lyme disease) removed 
anti-glycosfmgolipid (GSL) antibodies. It was hypothesized that anti-NBL antibodies may be the 
result of various infections that induce cross-reacting antibodies against shared auto-antigenic 
related structures. 
The antibodies against the NBL 108cc15 in patients with inflammatory demyelinating 
polyneuropathy were mainly of the IgM immunoglobulin class; they disappeared in all seven 
CIDP patients retested after improvement following IVIg. Absorption studies showed partial 
homology between the NBL 108cc15 and human sciatic nerve tissue. In vitro studies showed that 
IgG from normal donors (IVIg) inhibits the reaction between serum from a CIDP patient and 
the NBL cell line. This inhibition may be due to neutralization of auto-antibodies against 
nervous tissue by anti-idiotypic antibodies in IVIg (Chapter 7). 
The development of CIDP, the presence of anti-NBL antibodies and the treatment response to 
IVIg may be dependent on immunogenetic factors. In the literature an association between 
CIDP and the HLA-Al, B7, DR3 haplotype and recently with the HLA-DR2 antigen was 
suggested. HLA typing was carried out in the group of 52 CIDP patients who were all treated 
with IVIg (Chapter 8). We could neither demonstrate a statistical significant HLA association 
in CIDP patients, nor in the subgroup of patients improving or not improving after IVIg 
treatment. No significant HLA association was found between patients with or without anti-
neural antibodies. 
Finally, further studies on the mechanism of IVIg in CIDP were described in Chapter 9. 
Purified IgM anti-NBL 108cc15 antibodies from a CIDP patient were inhibited by F(ab)2 
fragments of IVIg and by F( ab )2 of IgG of a patient recovered from GBS. Inhibition of anti-
NBL antibodies was also found among sera from patients recovered from GBS and among sera 
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Summary 
from normal individuals. The inhibition of anti-neural antibodies niay be mediated by anti-
idiotypes present in sera from recovered GBS patients and in the sera from the normal donor 
population contributing to IVIg. These fmdings suggest that the self-limiting character of GBS 
and the therapeutic effect of IVIg in CIDP are dependent on inhibition of auto-antibodies. 
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SAMENV ATfiNG 
De inflammatoire demyeliniserende polyneuropathien kunnen worden onderscheiden in het 
Guillain-Barre syndroom (GBS) en in de chronische variant CIDP. 
Het onderwerp van dit proefschrift is de behandeling van patienten met een CIDP met hoge 
dosering intraveneus immunoglobuline (IVIg). 
In hoofdstuk 1 worden zowel de klinische verschijnselen als het laboratorium onderzoek bij de 
CIDP beschreven. De remitterende inflammatoire polyneuropathie werd reeds aan het eind van 
de vorige eeuw beschreven. De naam van de ziekte veranderde menigmaal, momenteel is de 
meest gebruikte naam "chronisch inflammatoire demyeliniserende poly(radiculo )neuropathie". 
De CIDP is meestal een gemengd motorisch-sensibele polyneuropathie die wordt gekenmerkt 
door een relatief symmetrische spierzwakte, gevoelsstoornissen en verlaagde of afwezige 
reflexen. Het liquor eiwit is meestal verhoogd en de zenuwgeleidingssnelheid is in het algemeen 
vertraagd. Er is geen definitieve test voor de diagnose CIDP. Barohn et al.23 stelde onlangs 
diagnostische criteria voor, welke worden besproken in hoofdstuk 1. Gecontroleerde studies 
toonden aan dat CIDP patienten kunnen verbeteren na plasmaferese81 en na behandeling met 
prednison?6 De observatie dat CIDP patienten kunnen verbeteren na toediening van IVIg werd 
onderzocht in een dubbel-blinde, placebo gecontroleerde 'crossover' studie (hoofdstuk 2). In 
deze studie werd na verkregen toestemming bij 7 CIDP patienten die waarschijnlijk hadden 
gereageerd op IVIg, de onderhoudsbehandeling met IVIg gestopt. Na deze onderbreking van 
de IVIg behandeling gingen aile patienten achteruit. Vervolgens werden de patienten 
gerandomiseerd voor IVIg of placebo ( albumine) infusies. De klinische conditie van aile 
patienten verbeterde na IVIg, maar de patienten verbeterden niet na toediening van placebo 
(p= 0.02). De gemiddelde tijdsduur tussen het einde van de trial medicatie en het begin van 
verslechtering was 6.4 weken na IVIg behandeling en 1.3 weken na placebo toediening. Deze 
geselecteerde groep patienten met een CIDP hadden een gunstige reaktie op IVIg. 
In hoofdstuk 3, worden klinische en laboratorium parameters besproken van 52 patienten die 
voldeden aan de CIDP criteria. Alle patienten werden met IVIg behandeld, 20 (38%) patienten 
verbeterden niet na IVIg toediening, 2 ( 4%) patienten verbeterden kortdurend en bij hen 
hadden de volgende infusies geen effect, 9 (17%) patienten bereikten een spontane of 
therapeutisch geiilduceerde complete remissie en 21 (40%) patienten hadden geregelde infusies 
nodig om deze verbetering te behouden. Aanvankelijk hadden aile patienten die verbeterden 
symptomen die duidelijk interfereerden met hun dagelijkse bezigheden. Na behandeling met 
IVIg werd 90% van deze patienten onafhankelijk wat betreft hun dagelijkse aktiviteiten. 
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Significant geassocieerd met een verbetering na IVIg behandeling waren: ziektedurir korter dan 
1 jaar, progressie van de ziekte tot aan de behandeling, afwezigheid van een discrepantie tussen 
spierzwakte in armen en benen, areflexie van de armen en een vertraagde 
zenuwgeleidingssnelheid van de motore nervus medianus in de onderarm. De kans om te 
verbeteren na IVIg behandeling indien al deze factoren aanwezig zijn is 93%. 
In hoofdstuk 4, worden de immunohistopathologie, de humorale en cellulaire immun:iteit, 
verschillende antigenen, de diermodellen en het mechan:isme van IVIg behandeling besproken 
in relatie tot de inflammatoire demyeliniserende polyneuropathieen. Een interessante hypothese 
is dat inflammatoire neuropathieen veroorzaakt zouden worden door een "dubbel-infectie", 
waarbij een van de micro-organ:ismen neurotroop is en de andere het adjuvants !evert. Beide 
infecties moeten samenwerken om zenuwbeschadiging te veroorzaken. In het Iicht van deze 
hypothese is het interessant dat antilichamen tegen glycosfingolipiden (GSL) zijn aangetoond 
bij GBS en CIDP patienten. Deze antigenen zijn in hoge mate aanwezig op zenuwweefsel maar 
oak op verscheidene micro-organ:ismen. Bovendien is er in diermodellen aangetoond dat 
gangliosiden als adjuvants kunnen werken. 
Voordat het mechan:isme van IVIg behandeling werd onderzocht, werden test en ontwikkeld voor 
het aantonen van anti-perifeer zenuwweefsel antilichamen. 
Met een hemagglutinatie test (MHT) konden antistoffen tegen humaan perifeer zenuwweefsel 
worden aangetoond in 22 van de 38 (58%) sera van patienten met CIDP of GBS (hoofdstuk 5). 
Deze antilichamen werden slechts bij 1 van de 34 (3%) patienten met een andere 
polyneuropathie en bij 3 van de 32 (9%) patienten zonder polyneuropathie gevonden. De 
aanwezigheid van deze antistoffen was gecorreleerd met verbetering op IVIg therapie, maar dit 
kon n:iet worden bevestigd in een grotere groep CIDP patienten (hoofdstuk 6). 
Vervolgens worden in hoofdstuk 6 de resultaten beschreven van een neuroblastoma 
immunofluorescentie test (NBL-IFA). Drie NBL cellijnen van verschillende species werden 
onderzocht op het aantonen van antilichamen bij patienten met uiteenlopende 
polyneuropathieen. Het patroon van antilichaam reactiviteit met de drie cellijnen was 
overeen:komstig voor patienten met CIDP, GBS en Lyme neuroborreliose. De NBL NlE115-
IF A toonde reactiviteit met sera van patient en met vele verschillende aandoen:ingen, terwijl de 
NBL CHP212-IFA vrijwel alleen negatieve resultaten gaf. De NBL 108cc15-IFA gaf vrijwel 
uitsluitend positieve resultaten met sera van patienten met CIDP, GBS en Lyme borreliose. Bij 
patienten met Lyme borreliose was de aanwezigheid van deze anti-NBL antistoffen n:iet 
gerelateerd aan de aanwezigheid van een neuropathie. Absorptie experimenten toonden aan dat 
zowel de NBL 108cc15 als de Borrelia burgdorferi (de verwekker van de ziekte van Lyme) 
antistoffen tegen glycosfingolipiden (GSL) verwijderden nit het serum van een patient met 
CIDP. Dit leverde de hypothese op dat de anti-NBL 108cc15 antilichamen kunnen ontstaan door 
infecties met verscheidene micro-organ:ismen en dat deze antilichamen kunnen kruisreageren 
met antigenen op zenuwweefsel. 
De antilichamen tegen de NBL 108cc15 bij patienten met een inflammatoire demyelin:iserende 
polyneuropathie waren voornamelijk van de IgM immunoglobuline klasse, zij verdwenen bij de 
7 geteste CIDP patienten die verbeterden na IVIg therapie. Absorptie experimenten gaven 
aanwijzingen voor partiele homologie tussen de NBL 108cc15 en humaan ischiadicus 
zenuwweefsel. In in vitro experimenten werd aangetoond dat IgG van normale donoren (Mg) 
de reactie tussen het serum van een CIDP patient en de NBL cellijn inhibeerde. De inhibitie 
van deze autoantilichamen tegen zenuwweefsel zou veroorzaakt kunnen worden door 
neutralisatie door antilichamen aanwezig in IVIg (hoofdstuk 7). 
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Samenvatting 
Het ontstaan van CIDP, de aanwezigheid van anti-NBL antistoffen en de respons na 
behandeling met IVIg kan afhankelijk zijn van immunogenetische factoren. In de literatuur 
wordt er bij CIDP patienten een associatie verondersteld met het HLA-Al, B7, DR3 haplotype 
en recent met het HLA-DR2 antigeen. In hoofdstuk 8, worden de resultaten beschreven van de 
HLA typering bij de 52 CIDP patienten, die met IVIg werden behandeld. Geen statistisch 
significante verschillen werden gevonden in de totale groep CIDP patienten, noch in de 
subgroep die wel, of juist niet, verbeterde na IVIg therapie. Evenmin werd een significante HLA 
associatie gevonden met de aan- of afwezigheid van anti-zenuwweefsel antistoffen bij CIDP 
patient en. 
Tenslotte wordt nader onderzoek naar het werkingsmechanisme van IVIg bij CIDP beschreven 
in hoofdstuk 9. Gezuiverde IgM anti-NBL antilichamen van een CIDP patient werden 
geinhibeerd door F( ab )2 fragment en van IVIg en door F( ab )2 fragment en van IgG van een 
patient die hersteld was van het GBS. Inhibitie van anti-NBL antilichamen werd ook gevonden 
met sera van sommige herstelde GBS patienten en met sera van enkele bloedbank donoren. De 
remming van anti-neurale antilichamen zou kunnen worden veroorzaakt door de aanwezigheid 
van anti-idiotypische antilichamen in het serum van herstelde GBS patienten en in het serum 
van individuele donoren die bijdragen tot de plasmapool waaruit IVIg wordt gemaakt. Deze 
bevindingen suggereren dat het 'self-limiting' karakter van het GBS en het therapeutisch effect 
van IVIg bij patienten met een CIDP wordt veroorzaakt door remming van autoantilichamen. 
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